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Abstract 
Synthetic cannabinoid receptor agonists or more commonly known as synthetic 
cannabinoids (SCs) were originally created to obtain the medicinal value of THC 
but they are an emerging social problem. SCs are mostly produced coated on 
herbal materials or in powder form and marketed under a variety of brand 
names, e.g. “Spice”, “K2”. Despite many SCs becoming controlled under drug 
legislation, many of them remain legal in some countries around the world. In 
Scotland, SCs are controlled under the Misuse of Drugs Act 1971 and 
Psychoactive Substances Act 2016 that only cover a few early SCs. In Saudi 
Arabia, even fewer are controlled. The picture of the SCs-problem in Scotland is 
vague due to insufficient prevalence data, particularly that using biological 
samples. Whilst there is evidence of increasing use of SCs throughout the world, 
in Saudi Arabia, there is currently no data regarding the use of products 
containing SCs among Saudi people. Several studies indicate that SCs may cause 
serious toxicity and impairment to health therefore it is important to understand 
the scale of use within society.     
A simple and sensitive method was developed for the simultaneous analysis of 10 
parent SCs (JWH-018, JWH-073, JWH-250, JWH-200, AM-1248, UR-144, A-796260, 
AB-FUBINACA, 5F-AKB-48 and 5F-PB-22) in whole blood and 8 corresponding 
metabolites (JWH-018 4-OH pentyl, JWH-073 3-OH butyl, JWH-250 4-OH pentyl, 
AM-2201 4-OH pentyl, JWH-122 5-OH pentyl, JWH-210 5-OH pentyl, 5F-AKB-48 
(N-4 OH pentyl), 5F-PB-22 3-carboxyindole)in urine using LLE and LC-MS/MS. The 
method was validated according to the standard practices for method validation 
in forensic toxicology (SWGTOX, May 2013). All analytes gave acceptable 
precision, linearity and recovery for analysing blood and urine samples. The 
method was applied to 1,496 biological samples, a mixture of whole blood and 
urine. 
Blood and/or urine samples were analysed from 114 patients presenting at 
Accident and Emergency in Glasgow Royal Infirmary, in spring 2014 and June-
December 2015. 5F-AKB-48, 5F-PB-22 and MDMB-CHMICA were detected in 9, 7 
and 9 cases respectively. 904 urine samples from individuals admitted 
to/liberated from Scottish prisons over November 2013 were tested for the 
presence of SCs. 5F-AKB-48 (N-4 OH pentyl) was detected in 10 cases and 5F-PB-
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22 3-carboxyindole in 3 cases. Blood and urine samples from two post-mortem 
cases in Scotland with suspected ingestion of SCs were analysed. Both cases 
were confirmed positive for 5F-AKB-48. A total of 463 urine samples were 
collected from personnel who presented to the Security Forces Hospital in 
Ryiadh for workplace drug testing as a requirement for their job during July 
2014. The results of the analysis found 2 samples to be positive for 5F-PB-22 3-
carboxyindole. 
A further study in Saudi Arabia using a questionnaire was carried out among 3 
subpopulations: medical professionals, members of the public in and around 
smoking cafes and known drug users. With regards to general awareness of Spice 
products, 16%, 11% and 22% of those participants of medical professionals, 
members of the public in and around smoking cafes and known drug users, 
respectively, were aware of the existence of SCs or Spice products. The 
respondents had an overall average of 4.5% who had a friend who used these 
Spice products.  
It is clear from the results obtained in both blood and urine testing and surveys 
that SCs are being used in both Scotland and Saudi Arabia. The extent of their 
use is not clear and the data presented here is an initial look into their 
prevalence. Blood and urine findings suggest changing trends in SC use, moving 
away from JWH and AM SCs to the newer 5F-AKB-48, 5-F-PB-22 and MDMB-
CHMICA compounds worldwide. In both countries 5F-PB-22 was detected. These 
findings clarify how the SCs phenomenon is a worldwide problem and how the 
information of every country regarding what SCs are seized can help and is not 
specific for that country. The analytes included in the method were selected due 
to their apparent availability in both countries, however it is possible that some 
newer analytes have been used and these would not have been detected. For 
this reason it is important that methods for testing SCs are updated regularly 
and evolve with the ever-changing availability of these drugs worldwide. In 
addition, there is little published literature regarding the concentrations of 
these drugs found in blood and urine samples and this work goes some way 
towards understanding these. 
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Chapter 1 – Introduction and Aims 
1.1 Rationale and Aims  
Recently the use of new psychoactive substances (NPS) especially synthetic 
cannabinoids (SCs) has increased at an unprecedented pace around the world 
[1]. SCs typically act as agonists at cannabinoid receptors and are intended to 
mimic the effects of Δ9-tetrahydrocannabinol (THC), the primary psychoactive 
compound of the Cannabis sativa plant [2]. Some of these drugs seem to display 
more toxicity than THC due to their increased potency and uncontrolled dose 
that might cause overdose and serious clinical consequences [3]. They represent 
an emerging drug problem in many countries [4]. The response to this 
phenomenon varies from one country to another depending on the apparent 
extent of the problem, the availability of resources and information, and the 
awareness of their risks [5]. To study the extent of a drug problem in a 
particular society requires evaluation of their prevalence. Prevalence studies 
can help to outline the scale of the problem which is critical to prioritising 
resources around harm treatment and prevention. There is little evidence in 
terms of prevalence estimates for the use of synthetic cannabinoids 
internationally. The picture of the SCs-problem in Scotland is incomplete due to 
insufficient prevalence data, particularly that using biological samples to 
confirm the presence of specific compounds.      
The picture in Saudi Arabia is almost completely unclear. The government of 
Saudi Arabia exercises efforts in controlling drug addiction in Saudi society. 
Large amounts of illicit drugs enter Saudi Arabia through its borders. According 
to the Saudi General Directorate for Narcotic Control (GDNC), 181 million 
Captagon tablets (fenethylline, combination of amphetamine and theophylline), 
61 tons of hashish, 2.206 tons of khat and 222 kilos of heroin have been seized 
between 2010 and 2012 [6]. Despite the suggestion from different sources that 
use of SCs is widespread around the world, there is no data to determine their 
use in Saudi Arabia. However, the United Nations Office on Drugs and Crime 
(UNODC) reported that in 2011, 16 countries (including Saudi Arabia) reported 
seizures of SCs [7]. In addition, there are some indicators leading to assume the 
probability of the presence and use of these products in Saudi Arabia.    
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Saudi Arabia is considered the Islamic country which follows the Islamic 
traditions most strictly. The use of alcohol and illicit drugs is forbidden in Islam 
[8]. Therefore, the possession, sale, or consumption of illicit drugs including 
alcohol is strictly forbidden in Saudi Arabia [9]. The country’s religious beliefs 
and legislation have made the use of illicit drugs to be socially unacceptable, 
which may lead users to experiment with new drugs which are undetectable in 
common drug-screening tests. Other indicators come from neighbouring 
countries of Saudi Arabia where thousands of Saudi people travel to daily; nine 
individual SCs were identified in seizures in the United Arab Emirates [10], the 
Kuwait Ministry of Interior announced the seizure of “crazy monkey” which is a 
new “Spice” product, and Turkey has reported a 22-fold increase in the 
trafficking of SCs between 2011 and 2013 and that these products are smuggled 
into Turkey from China, United States (US) and European countries [11]. 
Moreover, there are several online stores selling SC products targeting Saudi 
individuals.               
The fight against drugs of abuse has to continue at various levels such as 
developing new analytical methods that can identify the new drugs. Hence, the 
work to monitor the world drug market can be more effective to ensure that 
clinical and forensic laboratories are keeping up with the illegal drug suppliers. 
In addition, the clinical challenge in the Accident and Emergency (A&E) is to 
treat patients who have taken these new drugs and therefore the analytical 
methods for the detection and determination of these drugs in biological 
samples has become a crucial issue. Prevalence studies to estimate the scale of 
use of these new drugs can lead to a better understanding of the scale of this 
issue in Scotland and Saudi Arabia. 
The purpose of the questionnaire study in this project was to explore the 
knowledge and usage of Spice among Saudi people. Questionnaire survey allows 
the collection of information relatively inexpensively and quickly. It also helps to 
obtain valuable information from a large sample of individuals and from all parts 
of Saudi Arabia, particularly for online survey. In addition, this can help to raise 
the awareness regarding these drugs and their risk to individuals, through 
information involved in a participant information sheet. 
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1.2 Project Objectives 
The main aim of this project was to assess the prevalence of SCs in Scotland and 
Saudi Arabia as well as the awareness of these new drugs within Saudi Arabia.  
The objectives to meet the aim were to:   
1) Develop and validate a sensitive method with low limits of detection for 
the identification of SCs in blood and urine samples using chromatographic 
analysis techniques. 
2) Test blood and urine samples for SCs from 3 different subpopulations in 
Scotland (A&E patients, prisoners and fatalities).  
3) Test urine samples for prevalence of SCs in Saudi individuals involved in 
workplace drug testing.  
4) Prepare a questionnaire and collect data among 3 subpopulations of Saudi 
Arabia (known drug users, medical professionals and members of the 
public in and around smoking cafes).  
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Chapter 2 – Background and Literature Review 
2.1 Forensic Toxicology 
Toxicology can be defined as the study of the toxic or adverse effects of 
chemicals on living organisms [12]. Forensic toxicology is a specialised area of 
toxicology concerned with the medicolegal (relating to both medicine and law) 
characteristics of the harmful effects of alcohol, drugs or poisons on humans and 
animals [12]. It has developed in recent years and includes theoretical 
considerations and methods from several sciences such as pharmacology, 
biochemistry, analytical chemistry, physiology, epidemiology and pathology. 
Forensic toxicology is widely used to assist in workplace, in criminal matters 
involving drug use, in death investigation, in road safety, in sports doping as well 
as in matters involving environmental pollution [13]. It is aimed at assisting in 
identification, determination and interpretation of drugs and chemical 
compounds in human biological matrices through toxicological analysis for 
medicolegal purposes [13].  
2.2 Drugs of Abuse and ‘Legal Highs’  
A drug can be described as a “Drug of Abuse” when it is inappropriately used in a 
maladaptive pattern or for recreational purposes, which does not necessarily 
include dependency [14]. Drug abuse is not limited to the use of drugs for 
recreational purposes but they include any drug used inappropriately such as the 
use of anabolic steroids, β blockers and diuretics in sports [13]. Drugs of abuse 
can be classified according to their actions and effects as narcotics, depressants, 
stimulants and hallucinogens. Drugs of abuse have been controlled by legislation 
and UN Conventions and scheduled to specify the degree of control and level of 
penalties. Forensic communities often describe the drugs of abuse which have 
been used for a long time (e.g. amphetamine, cannabis, cocaine, and common 
benzodiazepines) as “traditional drugs” or “classical drugs” [15].   
UNODC [16] estimates that a quarter of a billion people of the world population 
(1 out of 20 adults) aged between 15 and 64 years, used at least one drug in 
2014, and over 29 million of them were problem drug users, suffering from drug 
use disorders. Figure 2.1 shows annual prevalence of illicit drug use amongst the 
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world population aged between 15 and 64 years. Although with varying 
legislation around the world the data is limited because only “illegal” drugs are 
counted. Cannabis is the most frequently used illicit drug (183 million), followed 
by amphetamines  (33 million) [16]. 
 
Figure 2.1: Global Trends in the Estimated Prevalence of Illicit Drugs, 2008-
13 (Source: UNODC, 2015) 
 
Recently, the phenomenon of new drugs related to adverse effects and/or death 
has attracted much attention. The terms “legal highs”, “club drugs” and New 
Psychoactive Substances (NPS) are often used interchangeably to describe these 
new substances or drugs that mimic the effects of traditional recreational drugs 
[17]. The term “legal highs” is misleading for two reasons. Firstly, some of the 
drugs which appear on the drug market are already controlled under national 
legislation and international drug conventions. Secondly, not all these drugs are 
“highs” and have desired effects along the lines of euphoria: some may cause 
psychosis, anxiety or paranoia which can be caused by ATS, as well as some of 
these drugs are sedative in nature e.g. benzodiazepines. “Club drugs” are drugs 
associated with use by young adults and teenagers at parties, concerts and 
nightclubs. The term “club drugs” is also confusing because it includes long 
established drugs such as methamphetamine and MDMA. In general, NPS are 
defined as psychoactive drugs which are not prohibited by international drug 
conventions or national legislation created to implement the first UN 
international convention such as the Misuse of Drugs Act 1971 in the United 
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Kingdom (UK), but which can cause a threat for human health [18]. However, it 
is not always useful to consider the legal status of a drug when discussing NPS, 
as it suggests the moment it is controlled it is not an NPS. NPS may contain legal 
drugs, illegal drugs, or a mixture of both [18]. They can also contain a wide 
range of different kinds of drugs including prescribed medication e.g. 
gabapentin, historically controlled drugs e.g. Para-Methoxyamphetamine (PMA) 
and newly developed drugs which mimic the effects of controlled drugs such as 
synthetic cannabinoids [18]. These drugs can either be abused in a new way or 
are newly developed therefore the term “new”.      
2.3 Synthetic Cannabinoid Receptor Agonists 
Cannabinoids are a group of chemical compounds which act on specific receptors 
(CB1 and CB2) in the brain. Cannabinoids can be divided into three groups: 
phytocannabinoids (plant cannabinoids), endogenous cannabinoids and synthetic 
cannabinoids [19].   
Phytocannabinoids are cannabinoids produced by plants and were first used 
around 3000 years ago in India for therapeutic and religious purposes [20]. The 
interest in synthesising cannabinoids increased after the complete syntheses of 
Δ9-tetrahydrocannabinol (THC), the primary psychoactive compound of Cannabis 
sativa L plant, in 1964 by Raphael Mechoulam [21]. THC acts as a partial agonist 
at both CB1 and CB2 cannabinoid receptors, exhibiting lower CB2 than CB1 
efficacy. These receptors are G protein coupled receptors. The activation of CB1 
receptors by THC leads to an inhibition of cellular cyclic adenosine 
monophosphate (cAMP) levels and modulation of the ion channel activity leading 
to inhibition of sodium, potassium and N-, and P/Q- type-calcium channels [22]. 
After smoking cannabis, THC is rapidly distributed throughout the body. Phase-I 
oxidation reactions of THC include oxidation of alcohols (the 11-methyl groups 
oxidised to 11-hydroxy-THC and then to 11-carboxy-THC), allylic and aliphatic 
hydroxylations, β-oxidation, and degradation of the pentyl side chain [19]. The 
common Phase-II reaction is conjugation with glucuronic acid [23].  
Many people use cannabis for pain relief and there is a large body of evidence 
showing the health benefits for conditions such as acquired immune deficiency 
syndrome (AIDS) [24]. Doctors also could prescribe medical cannabis to treat 
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muscle spasticity, tremor and dystonia, nausea caused by anticancer drugs and 
poor appetite caused by chronic illness [25]. However, its use for medical 
purposes is controversial due to its addictive potential and threat to public 
health. For all these reasons the use of cannabis has been restricted in most 
countries. In the USA, there are critical differences in cannabis laws from one 
state to another. 24 states have passed laws allowing smoked cannabis to be 
used for medical purposes [26]. However, the use of cannabis continues to be an 
offence under Federal law [26].  
Endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol are 
produced naturally in the body [27]. Anandamide (N-arachidonoylethanolamine) 
was the first endogenous ligand of cannabinoid receptors isolated in 1992 [27]. 
Anandamide is structurally different from THC of plant origin but they share 
critical pharmacophores that allow for binding to common targets [28].    
Synthetic cannabinoid receptor agonists, also known as synthetic cannabinoids 
(SCs), are a large group of structurally dissimilar compounds that were originally 
created during the 1990s to investigate the human endogenous cannabinoid 
system and their potential as therapeutic agents but they emerged as a problem 
in the early 2000s [4]. Although, SCs were created as pharmaceutical agents, it 
was found that the separation of the desired effects from unwanted 
psychoactive effects is difficult. They typically act as agonists at cannabinoid 
receptors (CB1 and/or CB2) and mimic the effects of THC [29].   
2.3.1 The Emergence of Synthetic Cannabinoids in Herbal 
Products 
From 2004, illicit drug manufacturers began to produce herbal smoking materials 
under a variety of brand names, e.g. “Spice” [4, 30]. Google Insights web 
searches reports suggest that the availability of Spice products started in the 
beginning of 2004 [18, 31]. Figure 2.2 shows a comparison of the popularity of 4 
terms; “legal cannabis”, “synthetic cannabinoids”, “synthetic cannabis” and 
legal highs on Google over the period 2004-2016. The graph also shows the 
rapidly increasing popularity of these terms since 2009-10.    
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Herbal products have been sold in European countries such as Switzerland, 
Austria and Germany since at least 2006 [32]. They have been easy to buy for 
several years over the internet, from physical shops (such as petrol stations and 
“head shops") or from traditional ‘street dealers’ without age restriction [33, 34]   
 
Figure 2.2: Google Trends of “legal cannabis”, “synthetic cannabinoids”, 
“synthetic cannabis” and “legal highs”, 2004-16 (Source of Information: 
Google Trends) [31]. 
 
To produce these herbal smoking mixtures, SCs are dissolved in a solvent, usually 
one with a low boiling point e.g. acetone, then sprayed onto dried plant 
materials [35]. They have also been packaged in other forms including solids 
(resins) and powders [36]. Lately, liquid products containing SCs have been 
introduced on to the marketplace for use with electronic cigarettes. Some of 
these products come without declaration of ingredients and others may come 
with an ingredients list, however these do not always contain the true contents 
[37]. In addition, they do not often come with consumer information about the 
use and the effects.  
A study in 2009 of the available legal high products offered by UK-based Internet 
retailers found 1308 products; 91.9% of these products failed to list side effects, 
86.3% failed to list drug interactions, 81.9% failed to list contraindications and 
40.1% failed to list ingredients [38]. The language used on labels often makes 
users believe the effects come from the plant materials used. However, studies 
on the botanical materials in 62 Spice products prove that most of the plant 
species were free of psychoactive properties [39]. The authors identified the 
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origins of each plant species in these Spice products and found that Turnera 
diffusa (common name is Damiana) and Labiatae or Lamiaceae 
(the mint or deadnettle family) were the plants most frequently detected in the 
products. The authors also observed that most plant species identified in these 
products were different from the plants indicated on the ingredients list labels. 
Similar findings have been reported by Piggee [40] who noted that the 
ingredients list labelled on Spice products did not appear to cause psychoactive 
effects.  
For marketing, these herbal mixture products are typically sold as “incense”, 
“herbal blends” or legal highs and, being sold under the generic brand name 
Spice, these include, but are not limited to: “Spice Diamond”, “Spice Gold”, 
“Spice Silver”, “Spice Egypt”, “Spice Tropical Synergy”, “Spice Arctic Synergy”, 
“etc.” [32]. In the novel by Frank Herbert, Spice was the name of a drug used by 
the people on the planet Dune, and that might be where the term comes from 
[29]. These drugs have also been branded as “K2” in the USA [41]. Illicit 
manufacturers of Spice products continue evolving brand names.   
Some brand names of SCs have been chosen to help the marketing such as AKB-
48 which refers to a popular Japanese girl band [42]. Another example is XLR-11 
which has probably been named after the first developed liquid rocket fuel in 
the USA [42]. STS-135 potentially refers to the 135th and final mission of 
the American Space Shuttle program [43]. They are sometimes branded with 
names which are euphemistic and misrepresentative.  
Clandestine illicit laboratories may change active ingredients of the same 
product over time and location [44]. For instance, the forensic examinations of a 
product labelled as “MOCARZ” have confirmed the presence of high 
concentrations of the following SCs: XLR-144, UR-144, BB-22, 5F-PB-22, AB-
CHMINACA, and in other seizures the same product contained mixtures of the 
following SCs: JWH-203, JWH-019, JWH-081, AM-2201 [44]. Another example, 
“Black Mamba” initially contained natural mixtures called “Damiana” but 
latterly has contained various SCs when analysed [45]. The concentrations of SCs 
present in Spice products might also be variable within the same brand. For 
instance, samples of “Psyclone” have been tested and gave considerable 
variation in the ratio of 5F-AKB-48 and 5F-PB-22 [46]. This variation in different 
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concentrations of different active ingredients makes it very difficult to estimate 
the optimum dose, which can lead very easily to acute intoxications.  
Driving this changing market is complex legislation across countries and illicit 
drugs manufacturers trying to bypass the law by moving on to newer compounds. 
Most NPS including SCs follow a cycle of supply and prohibition as shown below 
in Figure 2.3.  
 
Figure 2.3: The Cycle of Supply and Prohibition of NPS Compounds [47]. 
 
Prices can vary from one product to another depending on the source and purity 
[48]. Generally, the prices of these herbal mixtures are affordable by young 
people (£6.3–12 per gram) making these products highly attractive [49]. 
Moreover, internet shops offer discounts of the products on individual or bulk 
purchases to help the marketing [34].    
It is still unclear where the production of SC actually takes place. However, 
some national systems suggest that some of these products have been 
manufactured in China and distributed around the world [32].  
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Other herbal preparations introduced on the marketplace claimed that they have 
a similar make-up to “Spice”: e.g. “Aroma”, “Dream”, “Scope”, “Earth Impact”, 
“Genie”, “Yucatan Fire”, “Blue Lotus”, “Smoke”, “Galaxy Gold”, “Skunk”, 
“Black Mamba”, “Kronic”, “Exodus Damnation”, “Annihilation”, “Clockwork 
Orange”, “Diesel”, “Psyclone (clown)”, “Spunout”, etc. [32, 50-52]. Despite 
various attempts to stem the flow of Spice products, it would appear that they 
continue to be available containing new derivatives of SCs making several waves 
or generations of products, most likely to continue circumventing legal actions. 
It was not really until August 2008 that these new products became popular, 
coinciding with the time that media in Germany claimed that they were a 
“legal” alternative to marijuana but could not be detected by common drug-
screening tests [40, 53, 54].  
By the end of 2008, forensic researchers in the German pharmaceutical company 
THC-Pharm first detected JWH-018, a synthetic cannabinoid, in 3 Spice products 
[54]. The compound was also detected at the same period in at least three 
versions of Spice (Spice Diamond, Gold and Silver) in Austria by the Austrian 
Agency for Health and Food Safety (AGES) PharmMed [32]. In the beginning of 
2009, researchers from University of Freiburg (Germany) identified and 
characterised another cannabinoid, the C8 homologue of CP47,497 in Spice 
products [33]. In March 2009, the United States Drug Enforcement Administration 
(DEA) reported the detection of SCs including HU-210 in five small foil packets 
containing plant materials [55]. In June 2009, the substance had also been 
identified in three Spice products in the UK [32]. In the first three months of 
2009, another synthetic cannabinoid, JWH-073 was detected in a herbal product 
called “Scope” and other products in Germany, and it was also found in powder 
seizures in Denmark and the Netherlands [32]. In the three months of 2009, two 
new substances from the JWH family, the phenylacetylindole JWH-250  and the 
napthoylindole JWH-398  were reported for the first time by Germany and the 
UK respectively [32].    
Since 2009, the number and type of Spice products has increased, and the list of 
SCs seems to grow almost daily [35]. In 2012, AKB-48 was identified in herbal 
smoking mixtures in Japan [56, 57]. In 2013, a new wave of compounds that 
involved a large change in chemical structure emerged such as 5F-AKB-48 and 
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5F-PB-22. 5F-AKB-48 had been identified in four products including both plant 
material and powder seized by Danish customs authorities [58], and 5F-PB-22 
was identified by a Japanese research group [56]. The new substance MDMB-
CHMICA was reported by Danish authorities in December 2014 [59]. Table 2.1 
lists the first identification of the most common SC compounds in herbal 
products from different generations.   
Table 2.1: List of Some SCs Identified in Herbal Products with the Date and 
Place of their First Appearance 
SCs Date and Place of First Detection Ref 
JWH‐018 December 2008 (Germany, Austrian) [33, 35] 
CP‐47,497 December 2008 (Germany, Japan) [33, 35] 
HU‐210 January 2009 (USA) /June 2009 (UK) [32, 55] 
JWH‐073 January 2009 (Germany) [32, 35] 
JWH‐250 October 2009 (Germany) [32, 35] 
JWH‐398 October 2009 (UK) [32, 35] 
JWH‐200 December 2009 (Russia) [35] 
JWH‐122 July 2010 (Latvia) [35] 
JWH‐210 September 2010 (Germany) [35] 
AKB-48 2012 (Japan) [56] 
5F-AKB-48 2013 (Denmark) [58] 
5F-PB-22 2013 (Japan) [56] 
MDMB-CHMICA December 2014 (Denmark) [59] 
 
According to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), a survey of the European Union countries in 2009 showed that Spice 
products were identified in 21 countries. EMCDDA reported that during 2014, a 
total of 101 NPS were notified for the first time through the organisation’s early 
warning system, up from 81 substances in 2013, 73 in 2012 and 49 in 2011, 
however, this increase in numbers may partly reflect increasing capability to 
detect NPS [60]. EMCDDA data shows that number of SCs detected continues to 
grow (Figure 2.4) with a total of 160 SCs having been monitored by the European 
Union (EU) Early Warning System (EWS) as of December 2015 [61]. In 2013, 
EMCDDA confirmed that 21,495 seizures of SCs were reported across Europe 
which represented 40 percent of the total number of seizures of NPS [60]. 
The same trend has been noted by UNODC: SCs are the largest drug group 
monitored in 2014 [4]. According to UNODC, a total of 541 NPS had been 
reported to UNODC Early Warning Advisory (EWA) by 95 member states and 
13 
 
territories by December 2014. The majority of countries that reported the 
emergence of NPS were from Europe, Asia, Africa, the Americas and Oceania 
respectively, and the majority of NPS reported in 2014 were SCs (39 per cent), 
followed by phenethylamines (18 per cent) (Figure 2.5) [4].   
 
Figure 2.4: Number of SCs detected through the EU Early Warning System, 
2008-15 
 
 
Figure 2.5: Number of NPS Reported, By Substance Group, 2014. (Source: 
UNODC, Early Warning Advisory on NPS, 2014) 
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2.3.2 Structural Classification of Synthetic Cannabinoids 
After the completion of THC synthesis in 1964 [21] and the identification of CB1 
[62] and CB2 cannabinoid receptors in rat brain and characterisation of these in 
the early 1990s [63], the interest in synthesising cannabinoids increased to yield 
a total number of 134 substances by the end of 2014 [64].  
The names of SCs often contain abbreviations and numbering. The abbreviations 
can refer to who had developed a substance or to the place where a compound 
was synthesised for the first time. Some SCs might have attractive names to help 
the marketing such as AKB-48 (See Chapter 2.3.1). More details of the reasons 
for the nomenclature of each compound will be explained later.      
SCs contain a great variety of structurally dissimilar compounds. Despite slight 
differences in the chemical structures, all SCs are non-polar, lipid-soluble, small 
molecules, containing 20 to 26 carbon atoms and are fairly volatile compounds 
[65]. Due to the wide chemical structure modifications of SCs and their ongoing 
development, the classification of SCs is not fully systematised. The 
classification of SCs, based on the chemical structures, was published by Howlett 
et al. [66] and Thakur et al. [67], and includes classical cannabinoids, 
nonclassical cannabinoids, eicosanoids, aminoalkylindoles (AAls) and others 
(Figure 2.6). However, the classifications can vary, depending on the source.  
The following paragraphs represent the main classification groups and principal 
representatives of each class of SCs with a special focus on the most commonly 
used. 
Classical cannabinoids (e.g. HU-210) are structurally similar to Δ9-THC, based on 
a dibenzopyran ring. Nonclassical cannabinoids, the cyclohexylphenol (CP) series 
(e.g. CP47,497), are structurally unrelated to THC. Eicosanoids are synthetic 
analogues of endocannabinoids such as methanandamide (also known as AM-356) 
which is a synthetic analogue of anandamide. Aminoalkylindoles (AAls) can be 
categorised into sub-groups which include naphthoylindoles, 
“phenylacetylindoles” and “benzoylindoles” [66, 67]. AAls are arguably the 
dominant components of several herbal products as they are relatively easy to 
synthesise [68]. The naphthoylindoles class includes JWH-018, JWH-073, 
JWH-122, JWH-210, JWH-200 and AM-2201. The JWH-series (ranging from JWH-
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001 to JWH-450) is named after John William Huffman, a professor at Clemson 
University, who first synthesised them in the laboratory during the 1990s while 
investigating the human endogenous cannabinoid system and their potential as 
therapeutic agents [69]. Phenylacetylindoles include JWH-250 and JWH-251. 
Benzoylindoles include AM-694 and RCS-4. The last group of SC classes is “other” 
which encompasses other structural types such as indazole carboxamides e.g. 
APINACA (AKB48).  
Analogues of SCs can be synthesised or modified by changing the length and 
arrangement of the alkyl chain [68]. Changes can also be made by the addition 
of an alkyl, alkoxy, halogen, or other substituents to the aromatic ring [68]. 
Examples of the addition of a halogen are AM-2201, F5-PB-22 and 5F-AKB-48. 
SC compounds included in the analytical method in this project were selected 
due to their apparent availability in Scotland and Saudi Arabia. The Scottish 
Police Authority kindly provided very useful information about the most 
significant SCs that are circulating and they are seeing in seizures in Scotland 
which helped target the analysis. According to the Scottish Police Authority, 5F-
AKB-48 and 5F-PB-22 were the most popular in 2014. The other selected drugs 
were the most prevalent SCs from different generations because the picture of 
use of SCs in Saudi Arabia is unclear. These included HU-210, CP47,497, JWH-
018, the major metabolite of AM-2201, JWH-073, JWH-250, JWH-200, UR-144, 
AM-1248, AB-FUBINACA and A-796260. The next paragraphs provide a review of 
each of the SCs that have been studied.  
JWH-018 and the major metabolite N-(4-hydroxypentyl) 
JWH-018 (Figure 2.7) has high pharmacological activity and is easily synthesised, 
and this may be why it was selected to be one of the first SCs abused [69, 70]. 
Several studies reported that typical metabolites of JWH-018 are formed in 
humans after ingestion of AM-2201 [71]. However, Hutter et al. [71] found that 
JWH-018 4-OH pentyl can serve as a good marker to distinguish consume of Spice 
containing AM-2201 from JWH-018 use. 
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AKB-48 
 
 
 
THC 
 
5. Others 
 
  
Figure 2.6: Structural Classes of SCs. 
 
* The structure of THC is given for comparison 
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CP 47,497 
CP 47,497 (Figure 2.7), which was developed by the biopharmaceutical company 
(Pfizer) in 1970 during the study of the potential value of these products [72], 
lacks the dihydropyran ring of THC. Auwarter and co-workers found that CP 
47,497 was the active compound in many kinds of herbal mixtures in Germany in 
2008 [33]. The popularity of CP 47,497 may be because it has high affinity for 
the CB1 receptor and it is more potent than Δ
9-THC [73, 74], like its derivative 
CP 55,940 [75].    
HU-210 
HU-210 (Figure 2.7) was first synthesized by a team led by Dr Raphael 
Mechoulam to advance medical treatments at the Hebrew University in 1988 
[76]. The letters HU followed by three numbers refer to the Hebrew University. 
HU-210 is a full agonist at CB1 and is reported to increase the duration of the 
effects compared with natural THC [77]. However, it is difficult to synthesise 
[75]. 
JWH-073 and one of the major metabolites JWH-073 3-OH butyl 
JWH-073 (Figure 2.7) is an alkyl homologue of JWH-018. Like JWH-018, JWH-073 
is poorly soluble in water and produces no hydrophilic conjugates [78]. The main 
metabolic pathways of JWH-073 and JWH-018 compounds might be hydroxylation 
and N-dealkylation of the parent compound [79].   
JWH-250 and one of the major metabolites JWH-250 4-OH pentyl 
JWH-250 (Figure 2.7) is potential AAls “phenylacetylindoles” contained in Spice 
products [80]. They are categorised in a different class because, unlike other 
JWH series, they do not have a naphthalene ring (fusion of a pair of benzene 
rings) [81]. 
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AM-2201 4-OH pentyl 
The AM-series is designated by the initials of Dr Alexandros Makriyannis from 
Northeastern University who synthesised them, followed by a series of numbers 
[82]. AM-2201 (Table 2.3) differs from JWH-018 in the presence of a fluorine 
atom on the pentyl chain [83]. AM-2201 has been detected in many herbal 
smoking mixtures [65, 82]. 4-hydroxpentyl (Figure 2.7) is one of the major 
metabolites of AM-2201 [83].   
AM-1248 
AM-1248 (Figure 2.7) has an amide and an adamantyl group [57]. AM-1248 was 
found in several illegal products [57].   
JWH-122 5-OH pentyl 
JWH-122 5-OH pentyl (Figure 2.7) has been detected in many acute intoxication 
cases [84, 85]. JWH-122 and its respective fluorinated analogue, MAM-2201 
produce common metabolites, N-4-hydroxylated, N-5-hydroxylated and 
carboxylated JWH-122 metabolites. The key factor to prove JWH-122 or MAM-
2201 abuse is the relative concentrations of JWH-122 N-4-OH M and JWH-122 N-
5-OH M [86]. N-4-hydroxylated JWH-122 metabolite is the predominant in JWH-
122 metabolism, whereas N-5-hydroxylated JWH-122 metabolite was the primary 
metabolite of MAM-2201 [86]. 
JWH-210 5-OH pentyl 
JWH-210 5-OH pentyl is one of the major metabolites of JWH-210 which is one of 
numerous potential AAls (“naphthoylindoles”) contained in Spice products. JWH-
210 5-OH pentyl (Figure 2.7) has been detected in many acute intoxication cases 
[85, 87].   
5F-PB-22 and one of the major metabolites 5F-PB-22 3-carboxyindole 
5F-PB-22 (Figure 2.7) is a quinolinyl carboxylate derivative that differs from AM-
2201, by replacing the naphthalene group with an 8-hydroxyquinoline moiety. It 
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has a fluorine atom on the pentyl chain that would offer the possibility of 
oxidative defluorination [88]. 5F-PB-22 and PB-22 were the first marketed SCs 
with an ester group [88]. 5F-PB-22 3-carboxyindole (Figure 2.7) is a potential 
marker for 5F-PB-22 [88]. 
5F-AKB-48 and one of the major metabolites 5F-AKB-48 (N-4 OH pentyl) 
5F-AKB-48 (Figure 2.7) is based on an indazole ring substituted at R1 with a 
fluoropentyl chain and connected to an adamantyl group through a carboxamide 
linkage [58]. 5F-AKB-48 (N-4 OH pentyl) (Figure 2.7) is a good target metabolite 
for 5F-AKB-48 [58].   
JWH-200 
JWH-200 (Figure 2.7) appeared on the market around 2009 [89]. JWH-200 has 
been detected in whole blood from some cases of severe intoxication [90]. 
AB-FUBINACA 
AB-FUBINACA (Figure 2.7) appeared on the market around 2013 and has been 
detected in many severe toxicity cases [91]. 
UR-144  
UR-144 (Figure 2.7) is originally designated by Abbot Laboratories [92]. It 
contains a cyclopropane ring, which is thermally unstable [93]. UR-144 has also 
been detected in many acute intoxication cases [87, 90].    
A-796260 
A-796260 (Figure 2.7) has been identified in a seizure of the German Customs 
[94].  
Figure 2.7 shows chemical structures of all analytes included in this project.    
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Figure 2.7: Chemical Structures of All SCs Included in this Project
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2.3.3 Pharmacokinetics of Synthetic Cannabinoids 
SCs have structural features that allow binding to cannabinoid receptors CB1 or 
CB2 or to both of them, in the brain [95]. CB1 receptors are found in the central 
and peripheral nervous system, reproductive system, vascular endothelium, 
lungs, liver, bone and heart, and are responsible for the psychoactive or 
euphoric effects of cannabinoids, while CB2 receptors are located in immune 
system cells and may mediate immune modulatory effects and possibly play a 
minor role in pain control [96]. CB2 receptors are also found in the central 
nervous system but in smaller numbers relative to CB1 receptors [97].  
SC substances bind mostly to CB1 receptors as full agonists, rather than as partial 
agonists, as with THC, and then trigger a biological response [98]. CB1 receptors 
are present everywhere in the brain and when SC compounds bind in a strong-
binding and long-lasting way, they can cause an enormous variety of side 
effects. However, the picture of the pharmacology and toxicology of many SCs in 
humans is not clear.      
Different methods have been used in order to measure the binding affinity of a 
substance for a specific receptor. For SCs, most published studies have measured 
the affinity of binding according to the competitive binding assay illustrated by 
Compton et al. [99]. In in vitro studies, it was found that some SCs bind to 
cannabinoid receptors (mostly CB1) more avidly than THC as measured by the 
affinity constant Ki and the effect of this is to produce a stronger response, 
depending on the dose [2, 85]. Binding affinity (Ki) might provide a useful 
indicator for assessing the abuse potential of SCs. The Ki values of many SCs have 
been measured experimentally and they are available in published papers [100]. 
However, it can vary depending on the experimental set-up used. A low affinity 
for a receptor means a higher concentration of the compound is needed for 
binding. THC binds almost equally to CB1 with a receptor affinity of 40 nM and 
CB2 with an affinity of 36 nM. As an example of SCs, JWH-018 binds to CB1 and 
CB2 with receptor affinities of 9 nM and 2.9 nM, respectively. Therefore, most 
SCs may be 4-5 times more potent than THC [101]. SC substances with a lower 
affinity for the CB1 receptor than THC such as JWH-015 are not likely to be used 
in herbal products.  
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There are an increasing number of SCs featuring a terminal fluorine atom on 
substituted N-pentylindoles such as 5F-PB-22 and 5F-AKB-48. Banister et al. 
[102] studied the in vitro functional activities of JWH-018, PB-22, APICA and UR-
144, and their respective fluorinated analogues AM-2201, 5F-PB-22, STS-135 and 
XLR-11 at CB1 and CB2 receptors. They found that the fluorinated analogues 
generally have higher potency at the CB1 receptor by 2-5 times. 5F-PB-22 binds 
to CB1 with a receptor affinity of 0.13 nM [103] which is more than 69 times 
lower than that of JWH-018. This increased potency of 5F-PB-22 subsequently 
increases the risk of toxicity. Table 2.2 shows the published receptor affinities Ki 
for a selection of SCs of current interest or concern. 
Table 2.2: Affinity of Some Synthetic Cannabinoid Agonists for CB1 and CB2 
Receptors 
Compound CB1 Ki (nM)
a CB2 Ki (nM)
a Ref 
JWH‐015 336±36.0 13.8±4.60 [104] 
JWH‐200 42±5 - [104] 
THC 40.7±1.7 36.4±10 [104] 
UR-144 29±(0.9) 4.5±(1.7) [105, 106] 
JWH‐250 11±2 33±2 [2, 106] 
JWH‐018 9.0±5.0 2.9±2.7 [104, 106] 
JWH‐073 8.9±1.8 38.0±24.0 [104] 
AM-2201 1 2.6 [104, 107] 
5F-AKB-48 0.87±0.14 - [103] 
JWH‐122 0.69±0.5 1.2±1.2 [2, 105] 
JWH‐210 0.46±0.03 0.69±0.01 [106, 108] 
5F-PB-22 0.13±0.01 - [103] 
a Results are reported as mean plus/minus standard deviation or (standard error 
of the mean). 
 
The pharmacokinetics of compounds includes the absorption, distribution, 
metabolism and excretion of compounds throughout the body. There are only a 
few studies on the absorption and distribution of SC compounds. SCs are 
lipophilic substances like THC. The usual mode of administration for the SCs is 
smoking via a conventional pipe, in cigarette papers or via a water pipe [35]. 
After inhalation, SCs are absorbed through the lungs and diffuse rapidly to fat 
tissue and can accumulate, leading to a quick decrease of parent drug 
concentration in blood after administration [109]. Saito et al. [110] reported the 
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accumulation of some SCs such as MAM-2201 in adipose tissue due to their high 
lipophilicity. SCs can also cross the blood brain barrier and accumulate in brain 
tissues [111]. At the time Spice products containing SCs were introduced on the 
marketplace the metabolism pathways of these compounds were generally 
unknown [112]. Therefore, it has been necessary to study their metabolism in 
order to identify probable urinary markers to document intake of these products 
[113]. These studies can also help in developing analytical methods and 
illustrate the shared metabolism pathways which make the interpretation of 
results easier.  
There are few self-experiments or controlled administration studies for SCs 
intake in humans because they are ethically questionable [113]. Therefore, most 
investigations on the metabolism of SCs use models in in vitro experiments with 
human or rat liver microsomes, which is one of the most common approaches 
used to identify possible metabolites [66, 88, 89, 113-125]; however, some 
studies of SCs are based on in vivo experiments [97, 81, 89, 113, 115, 126-132]. 
Generally, the metabolism studies showed that SCs are easily metabolised and 
have extensive metabolism pathways. The most common metabolic pathway of 
naphthoylindole compounds was the hydroxylation at the indole, alkyl and 
naphthyl substructures. Figure 2.8 shows the hydroxyl metabolites of JWH‐018. 
Carboxylation, N-dealkylation and dihydrodiol formation at the naphthyl group 
were also observed [79, 114]. 5F-PB-22 can be metabolised with a specific 
biotransformation (ester hydrolysis) which is the predominant metabolic 
pathway, yielding a variety of (5-fluoro)pentylindole-3-carboxylic acid 
metabolites [88]. Pentanoic acid metabolites are generally favoured by the 
fluorinated analogues. Phase II conjugates of most SC metabolites are 
glucuronides. The other conjugates include sulphate- (e.g. JWH-122 and JWH-
200) and cysteine-conjugation (e.g. 5F-PB-22).  
The metabolites of SCs are mainly excreted in urine as glucuronide and/or 
sulphate conjugates. It was found that monohydroxylated [79] and carboxylated 
[129] metabolites are present in urine in the highest quantities. Due to the 
speed of both the emergence and spread of SCs on the world market, the 
pharmacokinetic properties of some SCs have not been satisfactorily investigated 
to date. Table 2.3 lists metabolic pathways of a selection of SCs included in this 
study and the major metabolite for each parent compound. 
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Figure 2.8: Chemical Structures of Alkyl Side Chain (M1 & M2), and Indole-ring (M3-M6) Hydroxylated Metabolites of JWH-018 
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Table 2.3: Metabolism of SCs  
SC Chemical Structure 
Metabolic Pathways 
Major Metabolite 
Phase І Phase II 
JWH-018 
 
Hydroxylation, Carboxylation, 
Dehydrogenation, N-
Dealkylation, Dihydrodiol 
formation 
Glucuronide 
conjugates 
 
JWH-018 N-(4-hydroxypentyl) 
JWH-073 
 
Hydroxylation, Carboxylation 
Glucuronide 
conjugates 
 
JWH-073 N-(3-hydroxybutyl) 
JWH-250 
 
Hydroxylation, Carboxylation, 
Dehydrogenation, N-Dealkylation 
Unspecified 
 
JWH-250 N-(4-hydroxypentyl) 
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Table 2.3: Metabolism of SCs (Continued…) 
SC Chemical Structure 
Metabolic Pathways 
Major Metabolite 
Phase І Phase II 
JWH-122 
 
Hydroxylation, Carboxylation, 
Dehydrogenation, N-
Dealkylation, Dihydrodiol 
formation 
Glucuronide/ 
Sulphates 
conjugates 
 
JWH-122 N-(4-hydroxypentyl) 
AM-2201 
 
Hydroxylation, Carboxylation, N-
Dealkylation, Dihydrodiol 
formation, Oxidative 
defluorination 
Glucuronide 
conjugates 
 
AM-2201 N-(4-hydroxypentyl) 
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Table 2.3: Metabolism of SCs (Continued…) 
SC Chemical Structure 
Metabolic Pathways 
Major Metabolite 
Phase І Phase II 
5F-AKB-48 
 
Hydroxylation, Carboxylation, N-
Dealkylation, Ketone formation, 
Oxidative defluorination 
Glucuronide 
conjugates 
 
5F-AKB-48 N-(4-hydroxypentyl) 
5F-PB-22 
 
Hydroxylation, Carboxylation, 
Dihydrodiol formation, Oxidative 
defluorination 
Glucuronide/Cy
steine 
conjugates 
 
5F-PB-22 3-carboxyindole 
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2.3.4 Pharmacological Effects of Synthetic Cannabinoids 
It is difficult to predict the harmful or desired effects on the human body after 
smoking SCs due to the significant variability in the amount and type of SCs 
between herbal blends and within a package. After use of SCs, clinical symptoms 
can start immediately or after some minutes or hours; however, the duration of 
symptoms is variable and may last hours [133]. Most of the information comes 
from case reports in the medical literature, from Poison Control Centres and 
from emergency service calls.    
Like THC, SC compounds bind to cannabinoid receptors [95] which results in the 
creation of cannabis-like effects (e.g. impaired sense of time, paranoia, 
sedation, hallucinations and anxiety [85, 134]. THC in high dose is a hallucinogen 
and can cause negative effects such as panic attacks which are reported as 
effects from SCs [135]. However, some users reported and/or showed additional 
unique effects from SCs such as agitation [85], acute kidney injury [136], stroke 
[137], myocardial ischaemia [138], hypokalaemia, hyperglycaemia, seizures and 
emesis [139, 140]. Other side effects of SCs, including tinnitus, coughing, 
conjunctival hyperaemia, sensitivity to light, blurred vision and mouth dryness 
have also been reported [29]. It has been reported that the duration of 
psychoactive effects exerted by fluorinated SCs (e.g. 5F-PB-22, 5-F-AK48) may 
be longer than that of non-fluorinated parent compounds [64]. 5F-PB-22 potently 
produced depressant effects lasting 120–150 minutes [141].  
There are few studies of the toxicological properties of SCs at the cellular level 
[142-144]. Although the authors described several processes contributing to this 
action, like interference with protein synthesis, DNA damage, apoptosis and 
damage of cell membrane, molecular mechanisms of SCs-induced cell death are 
still not very clear [64].   
Symptoms may depend on the duration and frequency of use and dose. Chronic 
use and overdrose of SCs may cause adverse effects including tachycardia and 
altered mental status [145]. Withdrawal symptoms of SCs have been documented 
in two case reports, and include but are not limited to nausea, vomiting, 
diarrhoea, headache, insomnia, palpitations, tremor, diaphoresis (sweating) and 
uneasy feelings [29, 139].      
29 
 
2.3.5 Concentration of Synthetic Cannabinoids in Fatal Cases 
SCs have been reported in association with deaths in several publications. 
Behonick et al. [3] reported four deaths following use of 5F-PB-22. In one case, 
an autopsy revealed pulmonary oedema in both lungs, the congestion of visceral 
organs and necrotising granulomatous inflammation with histo-plasma 
microorganisms and the toxicology report confirmed the presence of 1.5 ng/mL 
of 5F-PB-22 in superior vena cava blood. The cause of death was suspected acute 
drug intoxication by 5F-PB-22. In two cases, the cause of death was attributed to 
5F-PB-22 intoxication. The fourth case showed that the cause of death was 
fulminant liver failure caused by 5F-PB-22 and THC.  
Another case associating SCs with death has been reported by Patton et al. [146] 
involving a 23-year-old man found with a stab wound to the neck, with no known 
history of previous psychiatric care, mental illness, or past or current use of 
illicit drugs or antipsychotics. Toxicological analysis of blood was negative for 
alcohol, THC, cocaine, amphetamines, benzodiazepines and opiates. Further 
testing using procedures capable of detecting many types of SCs and their 
metabolites proved the presence of 12 ng/mL of AM-2201 along with 2.5 ng/mL 
of oxidised metabolite of AM2201. The case indicated the potential mortality 
associated with the psychiatric complications of AM-2201 use.  
Recently, ADB-CHMINACA (also known as MAB-CHMINACA) has been reported in 
association with two deaths. The first one was reported by the Hungarian 
National Focal Point [147] and it was amongst other substances. The second one 
was reported by Hasegawa et al. [148] that occurred in Japan. MAB-CHMINACA 
was found in nine solid tissues; the highest concentration was found in the liver 
(156 ng/g) followed by the kidney, pancreas and heart muscle. 
2.3.6 Concentration of Synthetic Cannabinoids in Cases of Abuse 
At present, there are deficiencies in the literature regarding toxic and lethal 
concentrations of most of the SCs. Teske et al. [149] reported maximum 
concentrations of SCs in serum at 5 minutes after smoking (administration of 
approximately 50 μg/kg of JWH-018) in the range of 10 ng/mL, and then 
decreasing rapidly to less than 10 % of the maximum concentration within 3 
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hours. This study is compatible with the observations of the effects of Spice by 
users in several cases [150].  
A single self-administered dose of herbal products named “Kronic” containing 
JWH-073 and JWH-018 was smoked to assess the authors’ analytical method 
[151]. Peak urine concentrations of 1 ng/mL JWH-073 N-butanoic acid, 10 ng/mL 
JWH-018 N-5-hydroxypentyl and 2 ng/mL JWH-018 N-pentanoic acid were found. 
In contrast, in some severe intoxications or psychiatric clinics cases, 
concentrations might be much higher, for example, in one case the 
concentration of JWH-122 was up to 230 ng/mL in urine [152].     
Hermanns-Clausen et al. [85] studied the clinical and laboratory findings for 29 
patients seeking emergency treatment after use of SCs between September 2008 
and February 2011. Table 2.4 shows acute and death levels of some SCs in blood. 
In most of these cases, SCs were considered as a contributory factor in the death 
or as the cause of death. It can be observed that there is an overlap in the 
concentration ranges between Accident and Emergency (A&E) admissions with 
fatal concentrations, and this may be due to individual variation or cases of 
poly-drugs consumption. However, the lethal doses for many SCs are still 
unknown [153]. 
Table 2.4: Concentrations of Some SCs in Blood in Acute and Fatal 
Intoxication Cases 
Compound Acute Level ng/mL Death Level ng/mL 
JWH-018 0.05-11 [90] 0.1-199 [154] 
JWH-073 0.1 [87] 0.1-68.3 [154] 
JWH‐250 0.14-0.73 [90] - 
JWH-122 0.05-21.8 [90] - 
JWH-210 0.05-8.1 [90] - 
AM-2201 0.05-7.85 [90] 12 [146] 
UR-144 0.05-25.9 [90]  
5F-PB-22 - 1.1-1.5 [3] 
MAM-2201 0.05-21.3 [90] 12.4 [110] 
ADB-CHMINACA - 6.05-10.6 [148] 
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2.3.7 Legal Status of Synthetic Cannabinoids 
The emergence of NPS is clearly a global phenomenon. In response to the rising 
popularity of these compounds, many national systems and organisations have 
been established around the world to monitor and share information about NPS 
to restrict the supply of them.   
The EMCDDA plays an important role in Europe’s response to NPS. The EMCDDA is 
the main source of information on drug related issues in Europe. Information 
from the European countries on the trends and appearance of NPS, along with 
reported harms can be provided by the EU EWS. In the beginning of 2009, the 
EMCDDA convened a meeting and produced a report on the problem and 
situation of the emergence of SCs. The UNODC [4] launched Global Synthetics 
Monitoring: Analyses, Reporting and Trends (SMART) Programme to address the 
challenge of NPS through the review of existing legislation and to explore how 
countries have introduced new legislation to control synthetic drugs. It provides 
capacity building to research officers, law enforcement and laboratory personnel 
in the Pacific, Latin America, Africa, the Near and Middle East, South Asia and 
East and South-East Asia and regularly reviews the situation of NPS and ATS. In 
the UK, the Advisory Council on the Misuse of Drugs (ACMD) was established 
under the Misuse of Drugs Act 1971. It provides recommendations regarding to 
the classification of new drugs which appear to them to be abused and causing 
harmful effects to society.           
2.3.7.1 Generic Legislation     
SCs usually take several months to ban [155]. Generic legislation is a faster 
procedure that prohibits clusters of substances showing similarity with the 
chemical structure of an existing compound [155]. In the UK, generic definitions 
for cannabinoid receptor agonists were developed. In December 2009, a number 
of SCs were controlled under the Misuse of Drugs Act as Class B drugs on 
recommendation from the ACMD [156]. Psychoactive Substances Act 2016 [157] 
applies across the UK and had been into force from 26 May 2016. The act makes 
it an offence to produce, supply, possess, import or export psychoactive 
substances. Most substances were subsumed by several generic definitions (e.g. 
the indole-3-methanone, cyclohexylphenols and dibenzopyran nucleus) and only 
32 
 
a few were added as named entities. Many SCs have been successfully controlled 
based on these generic definitions in 2009. The generic definitions were 
incorporated into the national drugs legislation of several countries (e.g. 
Lithuania, Denmark, and Austria). Four years later, in 2013, further controls 
included five named substances and seven principal definitions controlled by the 
Misuse of Drugs Act [156]. The generic legislation allows countries to ban large 
numbers of SCs found in the marketplace [158]. However, the diversity of SC 
families makes generic control an inefficient process and there is also concern 
when using such a broad definition about unintentionally including a 
therapeutically useful drugs not yet discovered. 
2.3.7.2 Analogue Legislation  
The analogue approach is an alternative method for legislation and was first 
utilised in the USA. A new substance can be controlled based on the analogue 
approach when it meets specific conditions i.e. it has a chemical structure 
similar to a controlled substance and either has an effect on the central nervous 
system greater than or similar to a controlled substance. The conditions were 
defined by the Federal Controlled Substances Analogue Act, 1986 [159]. In 2010, 
only the State of Kansas and the U.S. Military had banned Spice products [160]. 
In 2012, the DEA classified five specific SCs (JWH-018, JWH-073, JWH-200, CP 
47,497, and CP 47,497 C8 homologue) as Schedule 1 drugs under the United 
States Controlled Substance Act [161]. Following frequent waves of different 
structures, many SCs have since had to be temporarily designated into Schedule 
I: ADB-PINACA, AB-FUBINACA, PB-22  and 5F-PB-22 in 2014 [162] and MAB-
CHMINACA in 2015 [163]. Analogue legislation presents a new set of problems as 
most SCs are not considered to be analogues of controlled substances because 
they have different chemical structures. For this reason, it does not appear to 
offer an efficient way of controlling SCs [164]. Although governments and 
national organisations make concerted efforts to address the challenge of SCs 
and start banning many of them gradually, the absence of an international 
regulation makes it difficult to control this issue. Moreover, legal confusion 
remains because Spice drugs shipped with certificates indicate the absence of 
regulated substances [75]. In addition, Spice products are still offered on the 
internet with manufacturers continually changing the chemical structures in an 
attempt to avoid regulations [75].   
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2.3.8 Prevalence of Synthetic Cannabinoids  
The prevalence of SCs is still largely unknown and hard to ascertain. However, 
the picture is getting clearer because questions about the use of SCs are 
incorporated in national surveys in many countries [61]. Despite all the hard 
work around the world against the use of SCs, their use has increased at an 
alarming rate [61]. This may due to the late response to the emergence of these 
new drugs as well as the lack of focussed strategies that have led to the absence 
of the knowledge of the extent of the problem.     
There are notable differences in the prevalence of SCs in drug markets around 
the world. In the UK, a national survey on Spice use showed low lifetime 
prevalence rates for adults aged 16 to 64 at 0.2% in 2010-2011 and 0.1% in 2011-
2012 [61]. In Spain, in 2012, a global survey on drug use for students (14 to 18) 
with a sample of 27,503 reported low lifetime prevalence levels of use of herbal 
mixtures and Spice at 1.4% [61]. In France, in 2014, a survey of young people 
aged 17 years showed that 1.7 % of the sample population had already used SCs 
[61]. In Scotland, the Scottish Schools Adolescent Lifestyle and Substance Use 
Survey (SALSUS) conducted in 2013 found 4% of 15 year-olds reported having 
used one or more NPS at least once in their lifetime; the most commonly used 
NPS were mephedrone, SCs and salvia [165]. They used for the SCs question the 
terminologies Spice, “Black Mamba” and “Clockwork Orange”, that could 
probably be considered the most popular brand names in Scotland at that time 
and reflected their attempt to avoid users misunderstanding the question. In 
Arabian Gulf countries, particularly Saudi Arabia, there is currently no 
prevalence data regarding the use of products containing SCs among Saudi 
people.        
The selection of terminologies used is important in any questionnaire but seems 
especially crucial around the topic of SCs due to the mismatch between terms 
commonly used by users and by health professionals. Users sometimes use street 
names for drugs therefore it is quite important to use different terminologies to 
describe them. These studies have provided useful information; however, 
differences in their methodologies and definitions make comparisons between 
the data very difficult. 
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Prevalence studies of use of SCs are often heterogeneous and derived from a 
limited number of countries. Several papers were reviewed regarding the 
prevalence of SCs using different methods, including analytical investigation of 
biological samples, questionnaires/surveys, information on A&E admissions 
related to SCs use and calls to poison centres. Table 2.5 summarises the studies 
of the prevalence of use of SCs and the following paragraphs include examples 
studies of each method.     
The first study looking at the prevalence of use of SCs using the analysis of 
biological specimens was conducted in Germany in 2009. 7,500 authentic 
specimens from doping controls were analysed for the presence of JWH-018 and 
metabolites. Two specimens were found positive [120]. In 2011, another study 
from the USA was performed. 5,956 urine samples from athletes without a 
suspicion of use were screened for JWH-018, JWH-073 and their metabolites. 
The prevalence was 4.5% for JWH-018, JWH-073, or any of their metabolites 
[166]. During 2011–2012, a study in Norway was conducted [167]. 762 blood 
samples collected from drivers suspected of driving under the influence of drugs 
(DUID) were analysed for 18 different SCs. The prevalence of the selected SCs in 
the tested material was 2.2%. A comparison cannot be made between these sets 
of data because the studies were conducted at different times and the biological 
samples were analysed for different groups of SC compounds.   
For questionnaire or survey studies, the first paper was published in 2009, from 
the UK [168]. An online survey, with an invitation to participate, was posted on a 
website to the readers of the dance magazine MixMag in the UK. 2295 
participates responded. The use of Spice, “Warrior” or “Magic” smoking blend 
was reported by 12.6% of the sample population. This high prevalence may 
indicate the popularity of using these products among this kind of population. 
Another survey, originating in the USA explored the prevalence of K2 use among 
college students in 2010 [169]. A mailed survey was sent to a total of 2396 
college students. 8% (69 out of 852) of the sample population reported that they 
had been using SCs. K2 was more common among males and the high prevalence 
may reflect the popularity of using Spice products among college students. The 
response rate was 36%. There is no agreed norm as what would be received as an 
acceptable response rate (also termed return rate) [170], However several 
studies indicated the acceptiable response rate was approximately 56% [170, 
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171]. In 2011, another study from the UK, explored the use of NPS including SCs 
among gay nightclubs in South London [172]. 313 customers were surveyed over 
4 nights. The prevalence of lifetime use of Spice was 9% whereas it was 0.6% for 
use on the same night. A global online survey was conducted in 2011 and data 
from 14,966 participants was collected [173]. The use of SCs was reported by 
2513 (17%). This study had a good sample size; however, it was limited by the 
self-report methodology and the self-nominating nature of the sample.     
The prevalence of SCs through the statistics of visits to hospital emergency 
departments or calls to poison centres can offer a vital role in prevalence 
studies. According to the American Association of Poison Control Centres 
(AAPCC), the number of calls related to SCs exposure sharply increased from 
2096 calls in 2010 to 6968 in 2011, but decreased to 5230 in 2012, and dropped 
to 2668 in 2013; the trend of the exposures to SCs increased again with 3,679 
calls in 2014 [174]. The decrease in the number of calls received in 2013 was 
most likely due to improving public awareness of SCs toxicity and moving some 
types of SCs to Schedule I. In the AAPCC data, the exposure to SCs was highest 
for subjects aged 13-19, comprising 48.8 % of the calls [175]. They observed that 
men prefer to use SCs more than women. In a sample of calls received during 
the time period 2010–2011 at the Texas Poison Centres [176], the prevalence of 
the exposure to SCs was 4.1 per 100,000 inhabitants. The rate was 4.90 in rural 
counties and 4.02 in urban counties. Another study [177] from the Drug Abuse 
Warning Network on visits to A&Es involving SCs was performed in 2010. Among 
the AE visits linked to SCs, a total of 8,557 visits (75%) were made by patients 
aged 12–29.  
There is not much data regarding the types of group(s) of SCs that were present 
in each country, however, it is clear that this can vary from one region to 
another and from time to time. For example, according to the Welsh Emerging 
Drugs and Identification of Novel Substances (WEDINOS) project which was 
designed for the collection and testing of substances to identify what chemicals 
are in circulation in Wales, 5F-AKB-48 was the most commonly identified SC 
during 2013 and the beginning of 2014, and the rise in prevalence of 5F-PB-22 
resulted in the displacement of 5F-AKB-48 [44].     
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Table 2.5: Summary of Prevalence Studies 
Drugs 
Included 
Duration 
Time 
Number 
of Cases 
Description of Study Study Findings Ref 
Biological Matrices 
JWH-018 2009 7500 
A selection of urine specimens from 
athletes in doping controls 
0.03 % Positive for JWH-018 [120] 
JWH-018 
JWH-073 
2010 25 
Urine specimens from athletes who 
suspected of using Spice products 
92% Positive for JWH-018 and/or JWH-
073 
[178] 
JWH-018 
JWH-073 
JWH-250 
2010 
679, 
50,000 
679 Oral fluid 
50,000 urine 
15% Positive, 679 Oral fluid 
specimens; 
18% Positive, 50,000 urine specimens 
[179] 
JWH-018 
JWH-073 
2010-11 2060 
Urine specimens from users who 
suspected of using Spice products 
29.6% Positive for at least one SC; 
20.3% positive for JWH-018 
metabolites; 
one case positive only for JWH-073; 
8.9% positive for metabolites from 
both 
[180] 
JWH-018 
JWH-073 
2011 5956 Urine specimens from athletes 4.5% Positive for JWH-018 or JWH-073 [166] 
Surveys 
Spice 2009 2295 
Online survey targeting dance drug 
users 
Lifetime use rate: 12.6% [168] 
Spice 2010 - 
Survey (aged 15–18) in Frankfurt am 
Main 
9% Lifetime; 2% last 30 days [181] 
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Table 2.5: Summary of Prevalence Studies (Continued…) 
Drugs 
Included 
Duration 
Time 
Number 
of Cases 
Description of Study Study Findings Ref 
Surveys 
SCs 2012 
45,000-
50,000 
Students from three grades 
11.3% (12th graders); 8.8% (10th 
graders); 4.4% (8th graders) 
[182] 
SCs 2010-11 - 
Survey (aged 16–59) in England and 
Wales 
Past year use rate: 15–24 years, 0.4% 
25–59 years, 0.1% 
[183] 
Spice 2011 313 
Questionnaire in gay nightclubs in 
London 
9% Lifetime; 2.2% past month; 
0.6% same night 
[172] 
Calls and Accident and Emergency Data 
SCs 2010 - Accident and Emergency cases 
Rate per 100,000: 11.1, 12–29 years; 
14.9, 12–17 years; 13.9, 18–20 years; 
11.8, 21–24 years; 4.1, 25–29 years 
[177] 
SCs 2010-11 - Callers to the poison centre of Texas 
Exposure rate per 100,000: 2.79–7.14 
(11 health regions in Texas); 
4.90, rural counties; 4.02, urban 
counties. 
[176] 
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2.3.9 Biological Sample Preparation and Extraction Techniques 
for Synthetic Cannabinoids 
Before introducing any samples to chromatographic techniques such as gas 
chromatography-mass spectrometry (GC-MS), liquid chromatography-mass 
spectrometry (LC-MS) or liquid chromatography-tandem mass spectrometry (LC-
MS/MS), the analytes first need to be extracted from either the product or 
matrix and concentrated.  
Sample preparation is an essential stage of the analytical process to convert the 
biological specimen into a form that is suitable for analytical investigation. The 
extraction step is the main part of the procedure of sample preparation, and 
presents two major advantages for the analysis process [184]. Firstly, it removes 
interfering matrix compounds (such as proteins, salts and phospholipids) which 
reduces background noise. Secondly, it concentrates the target drugs, increasing 
sensitivity and achieving lower limits of detection.  
In LC-MS/MS, suitable sample preparation is important to reduce matrix effects, 
which is a measure of the change in signal caused by matrix components. Matrix 
effects may alter the MS response of the target drug or internal standard 
resulting in ion enhancement (gain in signal) or suppression (loss of signal) 
leading to effects on the precision, accuracy and robustness of the method. 
Matrix effects depend mainly on the sample matrix, ionisation type, mobile 
phase additives, quality of chromatographic separation and sample preparation 
procedure. Matrix components are changeable between samples (inter-individual 
variability) and It is not known which matrix components cause ionisation 
enhancement (or suppression); however, they interfere with the processes 
involved in the transfer of the ion into the gas phase, leading to a decrease or 
increase in the ionisation efficiency [185].        
Simple dilution, protein precipitation, liquid-liquid extraction (LLE), solid phase 
extraction (SPE), supported liquid extraction (SLE) and salting-out LLE (SALLE) 
have been used for the extraction of SCs. The following paragraphs describe the 
main extraction methods used for SCs.  
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2.3.9.1 Dilute and Shoot 
Dilute and shoot (also called simple dilution) is a simple sample preparation 
method in which one simply dilutes the sample with compatible liquid (e.g. 
solvent, mobile phase). The diluted sample is then injected into a 
chromatograph.  
The main advantage of this procedure is that it is very quick. It can also reduce 
the matrix effect when using LC-MS [186]. However, it has many limitations such 
as the injected sample is usually unclean due to the interferences. These 
interferences might build up in the system column and inlet leading to many 
chromatographic problems such as ion suppression, reduced detectability and 
carryover [186]. Cleaning and troubleshooting the system cost the lab time and 
money. Few authors have used the dilute and shoot method for the sample 
preparation of SCs [187, 188]. 
2.3.9.2 Protein Precipitation  
Protein precipitation (PPT) has been found to be more useful when analysing 
protein rich matrices, such as whole blood, serum and plasma. An organic 
solvent, commonly acetonitrile, is added to the specimen to reduce the 
solubility of the solute and precipitate the protein, and then it can be removed 
from the specimen by centrifugation or filtration.  
Protein precipitation is a rapid and simple extraction technique; however, it 
does not remove many of the matrix interferences. Some authors have used 
protein precipitation for the extraction of SCs [146, 189]. 
2.3.9.3 Liquid-Liquid Extraction      
LLE is applicable with most types of matrices. In SCs extraction, LLE is usually 
used because of their high hydrophobicity. It has been used for the extraction of 
SCs in the following matrices: blood [3, 90, 154, 167, 190, 191] , serum [149, 
152, 192-194], plasma [195], urine [79, 82, 114, 120, 127, 129, 151, 196-200], 
oral fluid [201, 202] and hair [203-207].  
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It involves adding an immiscible organic solvent such as tert-butyl methyl ether 
[114, 198], chloroform [130] or diethyl ether [79, 132, 151] to the sample, and 
mixing, removing the organic solvent. The target compounds transfer from the 
sample layer to the organic layer. The more dense solvent will be the lower 
layer, while the less dense solvent will be the upper layer. The distribution of 
the components of the initial mixture amongst the two immiscible solvents is 
determined by their partition coefficients. A compound that is more soluble in 
the more dense solvent will preferentially reside in the lower layer. Conversely, 
a compound more soluble in the less dense solvent will preferentially reside in 
the upper layer. A sufficient amount of solvent should be used to capture all of 
the drugs from the original sample. The two phases are agitated by shaking the 
mixture, and then the organic phase is allowed to separate. Generally after 
extraction hydrophobic compounds (e.g. SCs) are found mainly in the organic 
solvents. Compounds extracted into the organic phase are simply recovered by 
evaporation of the solvent and then reconstituted with a small volume of an 
appropriate solvent (e.g. mobile phase). The Nernst distribution law (Equation 1)  
can help illustrate the extraction process, and states that any neutral species 
will distribute amongst two immiscible solvents so that the ratio of the 
concentration remains constant [184, 208]. 
                                               
aq
o
D
C
C
K 
                                        Equation 1 
Where KD is the distribution constant, Caq is the concentration of the analyte in 
the aqueous phase and Co is the concentration of the analyte in the organic 
phase. 
The extraction of analyte from the aqueous phase depends on several factors 
including solubility of analyte in the organic solvent, pH of the aqueous phase 
and polarity of the organic solvent. The ideal solvent should be highly selective 
and allow only the active agent to be extracted, high capacity in order to reduce 
the amount of solvent necessary and high positive difference in density. There 
are also practical concerns when selecting extraction solvents [184].  
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LLE offers better clean up than protein precipitation because LLE removes many 
of the matrix interferences. In addition, it can be optimised for different 
compound classes. However, it is labour intensive and it is also possibly less 
reproducible than SPE. In addition, it sometimes requires an evaporation step to 
remove excess solvent prior to analysis.  
2.3.9.4 Solid Phase Extraction 
In recent years, SPE has become more popular as an extraction technique for the 
analysis of illicit drugs. Different types of SPE columns can be used depending on 
the cost, availability and the nature of the analytes of interest. The sample 
matrix is allowed to pass via the sorbent to waste, with the target analytes 
being retained. A series of washing steps is essential to remove matrix 
interferences, and then target analytes are eluted off the sorbent and collected 
in a clean vial [209]. Extraction of SCs using SPE has been used in blood and 
serum [210], urine [81, 166, 211-213] and oral fluid [126, 214, 215]. 
SPE will potentially remove the endogenous compounds that cause technical 
problems such as co-elution which may cause matrix effects. The use of a 
suitable sample preparation technique (e.g. SPE) and deuterated internal 
standards (ISDs) can help reduce matrix effects and their impact on accurate 
quantitation. However, Grigoryev et al. [78] reported nearly identical amounts 
of matrix elements for LLE and SPE in the extracts of SCs in urine samples. 
Rigdon et al. [216] reported SPE gave better recovery of carboxylated 
metabolites of JWH-018 and JWH-073 in urine samples than LLE. The 
disadvantages of SPE are the cost of consumables and hardware required.  
2.3.10 Analytical Methods for Synthetic Cannabinoids 
Immunoassays (e.g. enzyme linked immunosorbent assays ‘ELISA’) and separation 
methods such as GC/MS, LS-MS/MS and liquid chromatography–high resolution 
mass spectrometry (LC–HR/MS) have all been used for studying SCs and 
metabolites in biological samples as well as in seized products, such as herbal 
blends and powders.  
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2.3.10.1 Immunoanalysis   
An immunoassay is a biochemical test which incorporates the binding reaction of 
an antibody with a target substance (antigen) [217]. “Immuno” refers to an 
immune response, and “assay” refers to a test. Immunoassay is a rapid 
technique used as an initial screening test to eliminate negative samples. Whilst 
quick, it has limitations, such as lower specificity, potentially leading to false 
positives. As such, it is highly recommended that all positive immunoassay 
findings be retested and confirmed by chromatographic analysis. Immunoassay 
tests have been used for the screening of SCs in oral fluid [218] and their 
metabolites in urine samples [198, 211, 219-221]. Different commercial kits have 
been available for detecting SCs and metabolites, including those made by 
Randox Toxicology, Neogen Corporation, Cayman Chemical, Immunalysis 
Corporation and National Medical Services [220]. The main limitation of 
immunoassay is the inability to cross-react with newer analogues of SCs as they 
become more widely used. It is difficult for the manufacturers to keep up within 
the rapidly changing analogues in use.  
Rodrigues et al. [218] evaluated an ELISA targeting JWH-200 in oral fluid. They 
reported that in oral fluid ELISA targeting JWH-200 had limited cross-reactivity 
to JWH-018, JWH-073, JWH-015, JWH- 022, AM-2201, AM-2232 and AM-1220. 
Kronstrand et al. [222] compared the performance of an immunoassay screening 
for SCs with a newly-developed non-targeted qualitative LC-HR/MS confirmation 
method in urine. The screening method included metabolites from AM-2201, 
JWH-073 and JWH-018. The confirmation method included metabolites from AM-
2201, JWH-073, JWH-018, JWH-398, JWH-250, JWH-210, JWH-122, JWH-081, 
JWH-019, MAM-2201, UR-144 and RCS-4. The authors observed no cross-reactivity 
with UR-144 metabolites but there was cross-reactivity with JWH-122 and MAM-
2201 metabolites for the immunoassay. They also evaluated the specificity and 
sensitivity of the immunoassay with 87 real urine samples and found these to be 
82% and 87%, respectively. They concluded that the immunoassay performed 
well for SCs present in the urine samples tested. Due to the rapid changing of 
SCs, which may cause problems for immunoassays and for confirmation methods, 
the authors also recommended using a time-of-flight/mass spectrometry 
(TOF/MS) for forensic laboratories as new SCs can be quickly included in the 
method and identified.  
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2.3.10.2 GC-MS 
Gas chromatography (GC) coupled with mass spectrometry (MS) is a useful 
technique for analysing compounds in forensic toxicology. Gas chromatography is 
used for sample separation whereas mass spectrometry is for detection.  
GC refers to group of analytical separation techniques utilised to separate 
volatile analytes in the gas phase. The term chromatography (derived from the 
Greek for colour-chroma and to write-graphein). The main components of a GC 
instrument are carrier gas, injector and column (Figure 2.9). The extracted drug 
should be injected onto the GC column via the injection port which is connected 
to the top of the column. The sample should be vaporised in the injection port 
before entering the column. The injection port contains a rubber septum 
through which a syringe needle is pierced to inject the sample. The sample is 
then transported by a gaseous mobile phase, usually helium or nitrogen through 
a capillary column to the detector [223]. 
 
Figure 2.9: Gas Chromatography Components 
 
Capillary columns can made from fused silica or metal, although the latter 
cannot be connected to the source directly. Columns vary according to 
stationary phase composition, from non-polar to polar and their length, from 10-
100 m [223]. The separation of mixtures is based on the degree of interaction, as 
expressed by the partition coefficients of the components, with silicone polymer 
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(stationary phase), chemically bound to the silica of the column. The thickness 
and the properties of the stationery phase as well as length and diameter of the 
column influence the final extent of the interactions. Therefore, compounds 
travel through the column at different times (retention times). Highly volatile 
molecules travel via the column faster than less volatile compounds. Molecules 
that elute quickly have short retention times whereas analytes with higher 
molecular weights, many functionalities, higher boiling points, higher solubility 
in the stationary phase or higher polarity are retained for longer. They require 
higher temperatures to elute them because they are preferentially attracted to 
the stationary phase. The molecules are then transferred to the detector, of 
which there is a variety to choose from, including a flame ionisation detector 
(FID) and MS [224]. 
MS can be divided into three parts: the ion source, the mass analyser and the 
detector. Figure 2.10 shows the different components of the mass spectrometer 
in simplified form.  
 
Figure 2.10: Mass Spectrometer Components 
 
Molecules are ionised and fragmented by the ion source. In order to allow for 
transfer of ions through the system without collisions with molecules present in 
air, a vacuum is required. Data is sent to a computer which processes the huge 
amount of data and presents information in an accessible format. Electron 
impact (EI) and chemical ionisation (CI) are the most common ionisation 
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techniques in GC/MS. In EI, the parent molecules are impacted by a high energy 
electron beam in the ionisation chamber that is enough to ionise the molecules 
and form positive, negative, and neutral molecular fragments. When forming 
positive ions the reaction between gas-phase molecules and the electron beam 
causes the loss of an electron from the compound following the equation:  
                                            M + e-  M+. + 2e-                                Equation 2    
The ions then pass through the mass analyser via magnetic or electric fields that 
separate ions depending on their mass (m) to charge (z) ratios (m/z). The mass 
analyser filters masses by selected ion(s) monitoring (SIM) or scanning them in 
scan mode (SCAN). In SIM mode, only pre-selected ions are monitored leading to 
greater sensitivity, whereas SCAN is advantageous in cases of identifying 
unknown analytes in specimens. The ions finally pass to a detector system where 
they are counted. The detector records the induced charge which represents the 
ions that hits its surface. This technique provides huge structural information. 
Therefore, GC-MS has become the common separation technique for 
identification and quantitation of drugs of abuse in most laboratories [225].  
In the analysis of SCs, MS is mostly used as the detection system [226]. Other 
types in use are the nitrogen phosphorus detector (NPD) [227] which is suitable 
for most types of aminoalkylindoles, and FID [228, 229]. Most molecules 
fragment at 70 electron volts (eV) ionisation energy, producing several fragment 
ions, more than are acquired by LC–MS, that can provide useful structural 
information. Mass spectra under EI conditions differ significantly from one SC to 
another due to the great variety of their chemical structures. The fragmentation 
of several SC compounds can take place on both sides of the carbonyl group. The 
mass-spectral fragmentation pattern of SCs also involves formation of different 
ammonium ions at m/z = 127 and 155 (naphthyl and naphthoyl moieties) or 144 
(indole moiety) [230]. 
Derivatisation  
Although, GC-MS has become more widely used for forensic toxicology, there are 
some disadvantages of using GC-MS. Analytes which are thermally labile might 
decompose in the GC injection port. Many compounds with a polar functional 
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group such as an amino or hydroxyl group can cause a polar interaction between 
the compound and the column stationary phase leading to poor chromatography 
and detection of the analyte. To overcome these problems, a derivatisation step 
must be added after the extraction method for these compounds. Derivatisation 
can change the functional groups and chemical properties of the molecule, 
making them less reactive with the stationary phase and more stable. 
Derivatisation can also improve the mass spectrum, peak shape, sensitivity and 
specificity, reduce tailing of polar compounds and increase volatilisation and 
ionisation to promote chromatography. However, this additional step consumes 
more time and reagent, which can be toxic. Moreover, it may introduce another 
source of possible error. 
Derivatisation can be classified into three main groups: alkylation, acylation and 
silylation. The combination of N,O-bis(trimethylsilyl)trifluoroacetamide and 
trimethylchlorosilane (BSTFA + TMCS) is the preferred reagent for 
trimethylsilylation of carboxylic acids, phenols, amines, biogenic amines, 
alcohols, alkaloids and steroids [231] and was used in this experimental work. In 
the analysis of SCs using GC-MS, it seems essential to include a derivatisation 
step prior to GC analysis to increase detectability and stability of compounds 
and help to improve analytical efficiency [232]. SCs are organic compounds 
containing active and polar functional groups, and these react with different 
types of derivatisation reagents. The following derivatisations have been used 
for SCs: trimethylsilylation [33, 78, 81, 196], methylation [196], acetylation [78, 
81] or trifluoroacetylation [78, 81]. Acetylation is preferred for routine analyses 
despite the slightly lower sensitivity because trifluoroacetylation can cause low 
thermal stability for JWH-018, JWH-073, JWH-250 and their metabolites [78].  
Overall, GC-MS is the most widely used technique for analysis of SCs in Spice 
products in the majority of publications [30, 33, 65, 233]. GC-MS can be 
considered as the gold standard because it provides extensive fragmentation by 
EI that allows for initial identification of active ingredients [48, 65]. GC has also 
been used for the analyses of SCs in biological fluids [78, 83, 132, 234]; however, 
there are some disadvantages including the poor sensitivity, ester analogs (e.g. 
PB-22) decompose (or participate in ester-exchange reactions) in the injection 
port, and cyclopropyl compounds (e.g. UR-144) undergo thermal rearrangement 
(isomerisation) mainly in the injector [235, 236].      
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2.3.10.3 LC-MS/MS 
LC-MS/MS is high performance liquid chromatography (HPLC) coupled with a 
tandem quadrupole mass spectrometer. HPLC utilizes a mobile phase, pump, 
autosampler and column, whereas the mass spectrometer contains 3 main 
components; the ion source, the mass analyser and the detector (Figure 2.11). 
 
Figure 2.11: The Components of an LC-MS System 
      
The mobile phase is an important component for both the separation and 
ionisation of compounds. It often consists of two parts, the aqueous phase and 
the organic phase. In SCs analysis, as with most LC-MS methods, methanol or 
acetonitrile are commonly used for the organic solvent of the mobile phase. 
Acetic acid, formic acid or their salts are mainly chosen as buffer additives. 
Buffers are commonly used in the mobile phase to enhance the ionisation of 
compounds. Reconstituting samples in the mobile phase before they are injected 
onto the system leads to increases in the response of the analyte [237]. The 
concentrations of buffer are very important because concentrations that are too 
low could lead to poor efficiency and peak shape, while concentrations that are 
too high could cause ion suppression of the compound.  
The column is a very important component of the HPLC because the separation 
of analytes is achieved when those analytes pass through the column. Standard 
columns used in HPLC typically range from 2  to 4.6 mm internal diameter and 
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150, 250, 300 mm in length [238]. They are normally filled with modified silica 
gel because its pore structure, surface properties and particle shape help to get 
a good separation. They are usually protected by a guard column which is a 
disposable filter located at the top of the column. Columns can be classified 
according to their function into normal phase, reverse phase, size exclusion and 
ion exchange. In reverse phase, the stationary phases are non-polar such as C8- 
and C18-substituted silica, whereas the solvents are polar aqueous-organic 
mixtures such as acetonitrile-water or methanol-water. C18 columns are mainly 
used for the separation of SCs and their metabolites during LC. The interactions 
between the stationary phase and the sample analytes in the mobile phase 
influence the speed of the passing analytes and depend on their physical and 
chemical properties. The separation of the sample components in LC is greatly 
enhanced by gradient elution, which is changes the mobile phase composition 
during the chromatographic run. As a result, the detection limit is improved and 
the analysis time is reduced. Another elution method is isocratic elution, in 
which the composition of the mobile phase is kept constant [238].  
LC-MS uses atmospheric pressure ionisation (API) to interface the LC with the 
MS. The interface helps to avoid excess contamination of the source through its 
position orthogonal to the source [237]. The two most common API techniques 
are electrospray ionisation (ESI) and atmospheric pressure chemical ionisation 
(APCI). The interface can be interchanged easily, in most instruments, allowing 
the use of either [237]. In contrast to GC-EI-MS, both ESI and APCI use soft 
ionisation to ionise the molecules and the pseudo molecular ion is formed [237]. 
If it is an acidic molecule a proton is removed [M-H]-, or if a basic molecule a 
proton is added [M+H]+. The fragmentation of the parent drug and its 
metabolites is similar for ESI+ collision and EI modes. However, the m/z of the 
fragments is different. It was found that most SCs are affected by the matrix 
compounds found in the sample [151, 191], particularly when ESI is used [239]. 
ESI has the ability to ionise larger compounds, such as SCs, therefore it has been 
used more frequently than APCI [237]. ESI can be applied to a wide spectrum of 
molecules of varying polarity and molecular weight. However, APCI has some 
advantages. For example, due to the different ionisation processes, APCI seems 
to be less susceptible to matrix effects than ESI [240]. However, it was found 
that the responses of SCs are lower using APCI than with ESI [192]. ESI and APCI 
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interfaces operate in positive and negative polarity. In SCs analysis, positive 
polarity is commonly performed [230]. The negative ionisation mode has been 
used for HU-210, CP 47,497 and its homologue due to the absence of nitrogen in 
the chemical structures of these compounds, in contrast to almost all other SCs 
[198].  
ESI generates molecular ions in solution before the molecule enters the MS. 
Therefore, thermally labile compounds can be ionised without degradation 
[241]. Ions can be formed in ESI by exposing a metal capillary to a high voltage 
varying from 3-5 kV. The mobile phase is then evaporated and the ions enter the 
MS. 
There are many mass analysers available for LC-MS including tandem 
quadrupole, time-of-flight and ion trap. The quadrupole is the most widely used 
analyser [242]. Quadrupole mass analysers contain four rods parallel to each 
other making a square. The ions are directed pass to the centre of the square. 
Electromagnetic fields are generated by exposing the rods to a voltage. These 
fields allow only ions of a certain mass/charge ratio to pass through the filter 
onto the detector. The quadrupole can be used singularly or in tandem (triple 
quadrupole). There are three quadrupoles in a tandem mass analyser (Figure 
2.12): Q1 and Q3 are used as mass analysers whereas Q2 is used as a 
fragmentation zone [243]. Q1 selects a precursor ion. In Q2, fragmentation is 
achieved by applying collision energy and introducing a collision gas. The 
precursor ion is fragmented to form product ions. Q3 selects product ions of 
interest for detection. 
MS detection can be performed in full scan, product ion scan, SIM and multiple 
reaction monitoring (MRM) modes. When using full scan, the quadrupole mass 
analysers scan over a range of mass/charge ratios. Whereas, when SIM is used, 
the quadrupole mass analysers identify specific ions chosen by the user.  
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Figure 2.12: Schematic of Triple Quadrupole Mass Spectrometer 
Full scan mode reduces sensitivity, however, and this may cause false negative 
results for analytes at low concentrations. The use of LC-MS/MS in MRM mode 
will increase the specificity and enhance the sensitivity. Fragment ions are 
observed using product ion mode method when the protonated molecular ion 
([M+H]+) is utilized as the precursor ion. Two product ions of acceptable 
abundance should be determined to ensure that the correct compound is 
detected and to achieve good sensitivity. SIM and MRM modes elevate sensitivity, 
however, it is important to have information about the compounds and 
fragmentation patterns. Tandem quadrupole mass analysers increase sensitivity 
and selectivity as well as giving more structural information.    
Overall, LC-MS/MS plays an important role in routine forensic toxicology, 
particularly for quantification of the analytes identified. It has the advantage of 
being able to quantify high molecular mass, low-dose, polar and thermo-labile 
compounds [244]. In addition, it might be the best instrumentation to improve 
the detection of analytes in biological specimens [242]. Unlike GC-MS, LC-MS/MS 
is able to directly analyse almost all the compounds that are soluble in the 
mobile phase. Since most drugs are water soluble, LC-MS(MS) is allows the 
detection of a wide range of drugs. The majority of published methods for 
different types of human matrices containing SCs and their metabolites used LC 
techniques for the analyses. LC-MS/MS has also been used for the analyses of SCs 
in Spice products in several studies [65, 84]. 
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2.3.10.4 LC-HR/MS 
The newer technique LC–HR/MS has recently been introduced to forensic 
toxicology. Several non-targeted methods using the HR/MS technique for 
screening of drugs of abuse including SCs in biological matrices were published 
[206, 212, 222, 245].  
Similar or overlapped mass spectra of SCs are sometimes obtained by GC-MS due 
to their structural similarities and isomeric forms. The misidentification of these 
drugs might increase when using only the information from the mass spectra 
without retention time information.  
To overcome the misidentification of various SCs, which have similar chemical 
structures that can produce very similar fragmentation patterns or to identify 
new compounds in a biological material, HRMS or TOFMS can be used to 
determine the elemental composition of the structure and screen for parent 
drugs and their metabolites of SCs in specimens. The development of non-
targeted methods using HRMS techniques facilitates the detection of known or 
unknown compounds at the time of analysis. It can distinguish between different 
substances with the same nominal molecular mass. Unlike conventional MS 
analysers, new HRMS technology enables the identification of analytes based on 
the exact molecular formula because it offers mass assignment with an accuracy 
of 0.001 atomic mass units (amu) [246].  
This new technology allows for retrospective data inquiry after library updates 
like the World Anti-Doping Agency (WADA) accredited laboratories have done 
with athletes’ urine samples. The main challenge of non-targeted LC-HRMS 
screening methods is the toned for a library with all the analytes in it. HRMS can 
give an elemental composition but you may not know what the analyte is. 
Another challenge is to achieve sufficient selectivity to identify low 
concentrations of SCs [247]. These methods are enabling forensic laboratories to 
obtain accurate MS and MS/MS data without pre-selecting substances. 
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2.3.10.5 Identification Criteria  
Many identification parameters are available that can be used to increase the 
confidence of the toxicologist in the presence of toxicants in biological samples. 
Sample preparation and chromatographic separation are important issues to 
eliminate unwanted drugs and interference [248]. Contamination from the ion 
source can be addressed through the use of high organic modifier percentages to 
eliminate potential in-source dissociation of metabolites [248].     
It has been recommended that a deuterated internal standard should be 
included whenever available to achieve an accurate identification and 
quantification procedure [249, 250]. Deuterated internal standards are the best 
way to minimize the matrix effect phenomenon and examine the efficiency of 
extraction and ionisation of analytes [250]. Different types of internal standard 
can be used in LC-MS applications including deuterium-labelled analogues, 
structurally similar compounds (e.g. homologue), and any other compounds (e.g. 
a drug) [251]. Analytes can be labelled with stable isotopes - hydrogen 
(deuterium is the most common isotope used in forensic laboratories - with 
masses different from the analytes by at least 3 mass units to avoid interference 
between analyte and its internal standard [250]. The use of any other 
compounds (e.g. a drug) is not recommended because they may be found in case 
samples due to drug ingestion, and can cause misinterpretation of results [244, 
249]. 
Retention times play an important role in identification in all chromatography 
systems, and compounds should be satisfactorily separated from each other. The 
retention times of the analytes detected in real cases should match that of 
standards or positive controls included in the same run within a range of 2 
percent or ±0.1 minutes (whichever is smaller) using GC or LC [252]. 
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2.3.11 Synthetic Cannabinoids and Biological Matrices 
Multiple analytical methodologies have been reported since 2010 for the 
detection of SCs in various body fluids, including blood, urine, oral fluid and 
hair. These methods have widely differing purposes, strengths and weakness. 
These publications study various aspects such as pharmacokinetics, 
pharmacodynamics, method development and clinical investigations. Some of 
them included toxic and lethal concentrations as a result of studying the adverse 
effects or drug-related deaths (DRD) involving these drugs. 
The choice of the kind of sample matrix is a critical component of forensic 
toxicology investigation. It depends on many factors such as the availability of 
specimens and the purpose of the analysis. Urine is the most widely used matrix 
for SC detection [247], which is also likely to be the case for other drugs due to 
its ease of collection. Figure 2.13 illustrates the number of publications for each 
biological matrix since 2010. 
 
Figure 2.13: Methods for SC Detection in Different Biological Specimens 
Published Between 2010 and 2015 
  
2.3.11.1 Blood, Plasma and Serum 
Blood can offer unique advantages over other matrices. It can be used for the 
determination of recent drug use as in the case of identifying drivers under the 
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influence of illicit drugs [253, 254]. It also can be used for the determination of 
the ratio of parent drug to metabolites that could yield useful information 
relating to acute or chronic drug use [253]. However, blood sampling requires 
the presence of medical staff for the collection and there is a risk of infection. 
The concentrations of SCs in blood are usually very low however, and as such, 
analytical methods for detection need to be very sensitive. Another difficulty in 
determining SCs in blood specimens is the window for detecting acute intake is 
short (hours–days) [149]. In the case of long-term use of SCs, the windows for 
detection can be longer due to their accumulation in fatty tissues [109]. 
19 methods for SC detection in blood, serum and/or plasma have been published 
between 2010 and 2014. A summary of the majority of these methods is found in 
Appendix 1. LLE was the most common technique used for the extraction of SCs 
from these matrices. These methods have some strengths and weaknesses at the 
same time. For example, a method, developed by Dresen et al. [192] for the 
quantitation of JWH-018, JWH-073, JWH 200, JWH-250, JWH-081, JWH-015, WIN 
55,212-2 and methanandamide in serum, has less sample preparation but it has 
more matrix effects (40.2 to 134.7%). In general, no method is perfect: there is 
always a compromise. 
2.3.11.2 Urine 
Urine is the most widely used matrix for toxicological analysis in providing 
evidence of drug use and assessing drug exposure [247]. It is the preferred 
specimen for many laboratories because the collection of urine samples is easy 
and non-invasive and the concentrations of analytes are often higher when 
compared with samples of blood or oral fluid. Moreover, the detection time in 
urine is longer than blood (days–weeks) [255]. The prevalence of positive results 
in urine specimens for some compounds is higher than those observed in blood 
because the detection windows are longer for urine samples. However, there are 
some disadvantages with using urine as a sample. For example, it is not suitable 
for identifying drivers suspected of being under the influence of drugs as it only 
gives evidence of past use. In addition, urine concentrations cannot correlate 
with pharmacodynamic effects.    
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The parent compounds of SCs may not be detectable in urine due to their 
extensive metabolism; therefore it seems essential to focus on metabolites 
[114]. The metabolism of some of SCs are still under investigation which also 
makes analysis of urine samples more complicated.  
32 articles published between 2010 and 2014 described method validation for 
the identification of SCs and the metabolites in urine [236, 256-260]. The first 
publication to identify the JWH-018 urinary markers after the smoking of illicit 
herbal mixtures was by Sobolevsky et al. in 2010 [79]. Urine samples were 
collected from three intoxicated people taken into police custody. The parent 
compound JWH-018 was not detected whereas the phase-1 metabolites were 
identified after de-conjugation. The authors suggested a low content of the 
metabolites phase-1 in urine. A summary of the majority of these published 
methods is found in Appendix 2.  
SPE, LLE, PPT and dilution techniques have been used for the extraction of SCs 
from urine. Hydrolysis with acids [78, 81, 196] or enzymes [79, 120, 130, 131, 
261] is required in the procedure of urine sample preparation for SCs because it 
was found that the percentage of conjugated form excreted of the hydroxylated 
metabolites of many SCs is very high [81, 131, 262]. It can be noticed that these 
methods vary in their scope of drugs analysed. For example, a method, 
developed by Grigoryev et al. [236] focused on the metabolites of UR-144 
whereas a method developed by Holm et al. [58] studied 5F-AKB-48 and its 
metabolites. These variations in scope of drugs between the methods might 
explained by the time of the study, aims of the method or the availability of 
resources such as standards.  
2.3.11.3 Alternative Samples 
The use of alternative samples such as oral fluids and hair could be required in 
different cases when the desired samples are not available [263].   
Drugs are readily detectible in oral fluid specimens. Oral fluid can be used as an 
alternative to blood for identifying drivers that are suspected of driving under 
the influence, and in place of urine samples when testing for drugs usage in the 
work place. It is easy and rapid to obtain and is less prone to adulteration [201]. 
56 
 
In addition, oral fluid containing parent SCs makes the sample a good choice for 
testing in cases where metabolite reference standards may be lacking, or if the 
target metabolites are still unknown [218]. However, there are some 
disadvantages: the sample volume must be sufficient for the analysis, and this 
amount could be difficult to obtain from some SC abusers. Low sample volume 
can also occur without adequate devices for collecting the sample. Different 
collection devices have been used for oral fluid collection including DCD 5000 
Dräger [201], Intercept [202] and QuantisalTM  [214, 218]  
Hair was first described as an alternative specimen for drugs testing in the field 
of toxicology in 1979, when used to document long-term drug exposure. Hair 
testing provides long-term histories via segmental analysis, because hair offers a 
larger detection window when compared with all the other types of specimens 
(up to months) [264]. Another advantage of hair as a sample is low potential for 
donor manipulation. However, hair testing has its disadvantages too. 
Environmental contamination, especially through smoking of drugs, can have an 
effect on hair analysis, leading to false-positive results [265]. According to the 
Society of Hair Testing (SoHT), preparation of a hair sample should include a 
washing step in the procedure prior to analysis to remove superficial or surface 
drug [266]. This allows for demonstrating that the drug being recovered by the 
extraction procedure is an internally consumed drug.  
8 and 6 methods for SC detection in oral fluid [267] and hair [268] respectively 
were published between 2010 and 2014. A summary of these published methods 
is found in Appendixes 3 and 4.  
To sum up, numerous methods have been developed to analyse these drugs for 
different purposes in blood, plasma, serum, urine, oral fluid and hair but only a 
few studies have been reported for analysing these drugs in post-mortem 
matrices. The main weaknesses of some of these methods may be the poor 
sensitivity, inappropriate scope of drugs due to the speed of the emergence of 
SCs or the lack of some validation parts. Blood and urine were selected as the 
matrices for the current study.  
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Chapter 3 - Method Development for Synthetic 
Cannabinoids Using GC-MS and LC-MS/MS 
3.1 Introduction  
Several studies indicate that SCs may cause serious toxicity and impairment to 
health (see 2.3.4) therefore, forensic toxicology laboratories have made 
concerted efforts to update the analytical methods that can detect the newer 
compounds. A number of simultaneous chromatographic assays for SCs and 
metabolites in biological samples have been developed using GC-MS and LC-
MS/MS.  
Identifying SCs in biological samples challenges toxicologists and drug testing 
programmes. The speed of the emergence of SCs has resulted in several 
analytical challenges for clinical and forensic laboratories. The initial 
simultaneous chromatographic assays, from 2008, studied the first generation of 
SCs such as JWH-018 and JWH-073. Certified drug reference material for use in 
positive identifications is not readily available. In blood and oral fluid, parent 
compounds are found at extremely low concentrations therefore methods for 
analysis of SCs in these matrices must be very sensitive. Libraries of reference 
mass spectra are not commercially available to assist the identifications, 
especially for the most recent drugs. 
To overcome these emerging challenges, different strategies should be applied. 
Analytical methods for the identification of SCs should be continuously updated, 
improved and revalidated to cover the new compounds available. Because SCs 
contain a variety of functional groups, the extraction of SCs requires a general 
procedure. Very limited data on cut-offs, detection windows or expected 
concentrations of SCs have been published. Therefore, limits of detection (LODs) 
should be determined as low as analytically possible.  
GC-MS and LC-MS/MS have different advantages and disadvantages. The majority 
of published methods use LC techniques for the analyses of different types of 
human matrices containing SCs and their metabolites. However, most of these 
methods need extensive extraction procedures or have lengthy chromatographic 
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run times that can affect the throughput capacity, particularly in the case of 
analysis of many samples. 
3.2 Aim and Objectives                 
The aim was to develop a testing method using chromatographic techniques to 
quantitate a range of synthetic cannabinoids in urine samples.  
The analytes including in the method were selected due to their apparent 
availability in Scotland and Saudi Arabia (See 2.3.2). These included HU-210, 
CP47,497, JWH-018 and one of its major metabolites JWH-018 4-OH pentyl, 
JWH-073 and one of its major metabolites JWH-073 3-OH butyl, JWH-250 and 
one of its major metabolites JWH-250 4-OH pentyl, JWH-200, AM-2201 4-OH 
pentyl, JWH-122 5-OH pentyl, JWH-210 5-OH pentyl, AM-1248, AB-FUBINACA, 
UR-144, A-796260, 5F-AKB-48 and one of its major metabolites 5F-AKB-48 (N-4 
OH pentyl), and 5F-PB-22 and one of its major metabolites 5F-PB-22 3-
carboxyindole (Figure 2.7).    
The objectives included: 
 Developing a method to detect synthetic cannabinoids in biological 
sample extracts using GC-MS. 
 Developing a method to detect synthetic cannabinoids in biological 
sample extracts using LC-MS. 
3.3 Chemicals and Reagents 
JWH-018, JWH-073, JWH-250, HU-210, CP47,497, JWH-200, 5F-AKB-48, 5F-PB-
22, AM-1248, AB-FUBINACA, A-796260, UR-144, JWH-018 4-OH pentyl, JWH-073 
3-OH butyl, AM-2201 4-OH pentyl, JWH-250 4-OH pentyl, JWH-122 5-OH pentyl 
and JWH-210 5-OH pentyl were purchased from Sigma Aldrich (Basingstoke, UK). 
5F-AKB-48 (N-4 OH pentyl) and 5F-PB-22 3-carboxyindole were obtained from 
LGC Standards (Teddington, UK). JWH-073, JWH-250, JWH-200, 5F-AKB-48 (N-4 
OH pentyl) and 5F-PB-22 3-carboxyindole were purchased as 1 mg of powder, 
whereas the rest of the drugs and metabolites were purchased as solutions with 
the concentration of 100 μg/mL in methanol.  
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Deuterated standards JWH-018 4-OH pentyl-d5, JWH-250 4-OH pentyl-d5, AM-
2201 4-OH pentyl-d5, JWH-073 3-OH butyl-d5 and JWH-200-d5 were obtained 
from Sigma Aldrich (Basingstoke, UK). All these drugs were purchased as 
solutions with the concentration of 100 μg/mL in methanol.   
N,O-Bis(trimethylsilyl)trifluoroacetamide containing 1% trimethylchlorosilane 
(BSTFA + 1 % TMCS) were manufactured by Cerilliant (Texas, USA) and purchased 
from Sigma Aldrich (Basingstoke, UK).     
Methanol (MeOH) (HPLC grade), ethyl acetate, acetonitrile (ACN), isopropanol, 
dichloromethane (DCM) n-hexane and methyl-tert-butyl-ether (MTBE) were 
obtained from VWR International Ltd, (Lutterworth, UK). Sodium acetate 
trihydrate, disodium hydrogen orthophosphate anhydrous, sodium dihydrogen 
orthophosphate monohydrate, ammonium acetate (HPLC grade), formic acid and 
beta-glucuronidase from Helix pomatia containing ≥85,000 units/ml of beta-
glucuronidase and ≤7,500 units/ml of sulphatase per mL were supplied by Sigma 
Aldrich (Basingstoke, UK). Purified water was obtained from the in-house Merck 
Millipore system. 
3.4 Solutions 
3.4.1 Preparation of Drug Standard and Internal Standard 
Solutions 
3.4.1.1 Stock Solutions 
Stock solutions were prepared in methanol for each drug individually giving a 
concentration of 10 μg/mL. This was achieved by transferring 1 mL of each drug 
(100 μg/mL) into a single 10 mL volumetric flask, and making up to the mark 
with methanol. The entire amount was transferred to individual amber glass 
bottles and stored at −20°C for 6 months. 
3.4.1.2 Working Solutions 
Working solutions were prepared by dilution of stock solutions in methanol to 
obtain 1 μg/mL for each drug. This was achieved by adding 1 mL of the stock 
solution to a 10 mL volumetric flask and making up to volume with methanol, 
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then transferring to individual amber glass bottles and storing at −20°C for 6 
months.      
3.4.1.3 Preparation of Working Drug Standard Mixture Solution  
A 0.5 μg/mL mixture solution containing 10 SCs was prepared in methanol by 
adding 500 μL of each drug (stock solution) to a 10 mL volumetric flask and 
making up to volume with methanol. All mixture solutions were transferred to 
amber glass bottles and stored at −20°C. 
3.4.1.4 Preparation of Working Internal Standard Mixture Solution  
The working internal standard mixture solution was prepared in methanol at 0.5 
μg/mL by adding 500 μL of each drug (stock solution) to a 10 mL volumetric flask 
and making up to volume with methanol. All mixture solutions were transferred 
to amber glass bottles and stored at −20°C.  
3.4.2 Preparation of Buffers 
3.4.2.1 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
1.7 g of disodium hydrogen orthophosphate anhydrous (Na2HPO4) and 12.14 g of 
sodium dihydrogen orthophosphate monohydrate (NaH2PO4.H2O) were 
transferred to a 1 L beaker. They were dissolved in 800 mL of deionised water 
and the pH was adjusted to 6.0 with 0.1 M dibasic sodium phosphate or 0.1 M 
monobasic sodium phosphate. The entire amount was placed in a 1 L volumetric 
flask and made up to volume with deionised water. This solution was then 
mixed, and then stored at 4°C for up to 1 month.  
3.4.2.2 Preparation of 1.0 M, pH 5.0 Sodium Acetate Buffer  
13.6 g of sodium acetate trihydrate was dissolved in 6 mL of glacial acetic acid, 
made up to 1 L with deionised water. The pH was adjusted with acetic acid to 
result in pH 5.0. The solution was mixed and stored at 4°C for up to 1 month.       
3.4.2.3 Preparation of 2 M Ammonium Acetate in Methanol 
15.42 g of ammonium acetate was weighed out into a 100 mL volumetric flask 
and made up to the mark with methanol and stored at 4°C for up to 1 month. 
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3.4.2.4 Preparation of 2 mM Ammonium Acetate  
1 mL of 2 M ammonium acetate was added to a 1 L volumetric flask and made up 
to the mark with deionised water and stored at 4°C for up to 1 month.  
3.4.2.5 Preparation of Formic Acid 0.1% (pH=2.8) 
1 mL of concentrated formic acid was transferred to a 1 L volumetric flask and 
made up to the mark with deionised water. 
3.4.2.6 Infusion Solution  
500 mL of methanol was added to a 1 L volumetric flask and made up to the 
mark with deionised water and then 1 mL of 2 mM ammonium acetate and 1 mL 
of formic acid were added. 
3.4.3 Blank Matrix 
3.4.3.1 Drug-free Urine 
Blank urine from ten healthy volunteers was used. The urine samples were 
stored at 4°C.  Existing blank urine samples from a previous research project, 
obtained with informed consent and appropriately stored in Forensic Medicine 
and Science, were used. The chair of the University Medical Research Ethics 
Committee, Dr Jesse Dawson, Institute of Cardiovascular and Medical Sciences, 
University of Glasgow confirmed that approval would not be needed for these 
samples.  
3.4.3.2 Blank Blood 
Expired packed red blood cell pouches were provided from the Scottish National 
Blood Transfusion Service (SNBTS) (submission reference number 14-07) based at 
Gartnaval General Hospital (Glasgow, UK). They were stored at −20°C on receipt 
within Forensic Medicine and Science. In order to prepare blank blood, packed 
red blood cells were defrosted and suspended in a ratio of 1:1 with 1% saline 
solution which was prepared by dissolving 9.5 g of sodium chloride in 1 L of 
deionised water.    
62 
 
3.5 Method Development Using GC-MS 
3.5.1 Instrumentation 
An Agilent Technologies GC-MS; (Autosampler 7683B, Gas Chromatograph 7890A 
and Mass Spectrometer 5975C), using a HB-5MS + DG column Crawford Scientific 
(30 m x 0.25 mm id x 0.25 μm) was used. Data analysis was performed using 
GC/MSD ChemStation Software (E.02.02.1431). 
3.5.2 Derivatisation 
At this stage of method development, only JWH-018, JWH-073, JWH-250, JWH-
200, HU-210 and CP47,497 standards were available. 100 μL unextracted drug 
standards for JWH-018, JWH-073, JWH-250, JWH-200, HU-210 and CP47,497 at 
concentrations of 1000 ng/mL in MeOH were individually evaporated under a 
stream of nitrogen to dryness at room temperature and were redissolved in 50 
μL MeOH. HU-210 and CP47,497 were derivatised with 50 μL BSTFA + 1% TMCS for 
I hour at 70C. None of the JWH compounds form TMS derivatives as they do not 
have suitable functional groups. All analytes were then transferred to 
autosampler vials.  
3.5.3 GC-MS Procedure 
1μL of each standard sample was used for injection on to GC-MS to obtain their 
mass spectra. Table 3.1 summarises the GC-MS procedure and Table 3.2 shows 
the selected ions and retention times for JWH-018, JWH-073, JWH-250, HU-210 
and CP47,497.  
Table 3.1: GC-MS Procedure 
GC-MS Parameters Setting 
Inlet temperature 230 C 
Injection volume 1 μL 
Injection port type Splitless mode 
Flow rate of carrier gas 1.5 mL/min 
Column HP-1 30 m x 0.25 mm id x 0.25 μm 
Oven programme 
50 C initial & ramped to 320 C @ 20 C/min. Hold 4 
minutes 
Interface temperature 230C 
Ionisation mode EI mode, ionisation energy 70 eV 
Detection mode Full Scan over the range m/z 40-600 
Run time 17.5 minutes 
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3.5.4 Sensitivity Assessments of Unextracted Standards 
Sensitivity assessment was carried out to evaluate the analytical method. The 
sensitivity of each SC was assessed using serial dilution of unextracted drugs 
standards for each drug individually at the following concentrations: 1000, 500, 
250, 125, 62.5 and 31.25 ng/mL.   
Table 3.2: Selected Ions and Retention Times for CP47,497, HU-210, JWH-
250, JWH-073 and JWH-018. 
Drug 
Quantitative 
Ion (m/z) 
Qualitative 
Ion 1 (m/z) 
Qualitative 
Ion 2 (m/z) 
Retention 
Time (min) 
CP47,497 377 462 287 11.9 
HU-210 446 530 359 13.3 
JWH-250 214 144 335 13.9 
JWH-073 327 200 310 14.6 
JWH-018 341 284 214 15.0 
3.5.5 Results of GC-MS Method Development 
JWH-018, JWH-073, JWH-250, HU-210 and CP47,497 were detected by GC-MS 
except JWH-200 which was not eluted from the column and this may because it 
has a high molecular weight. Figure 3.1 shows GC-MS chromatograms and full-
scan mass spectra of 0.5 ng on-column of un-extracted standards for these 
drugs. The developed method gave a poor response for all analytes. JWH-018, 
JWH-073 and JWH-250 were undetectable at 0.25 ng on-column and, CP47,497 
and HU-210 were undetectable at 0.031 ng on-column.   
Due to the low concentrations (1 ng/mL) detected in reported biological case 
samples in the literature (see 2.3.6 and 2.3.7), the developed method was 
altered several times to improve the sensitivity. Several GC oven programmes in 
combination with changes to the flow rate were tested. The method was also 
altered from SCAN to SIM, thus allowing for higher sensitivity. The injection port 
temperature was reduced from 265C to 230C to prevent injection port 
degradation but less efficient vapourisation. The sensitivity remained 
unsatisfactory for the project aims. Indeed, SCs are not ideal compounds for GC-
MS analysis because they have high molecular weights. It was concluded that the 
only option was to try a different technique more suitable to these compounds 
(LC-MS/MS). 
64 
 
 
 
Figure 3.1: GC-MS Chromatograms and Full-Scan Mass Spectra of 0.5 ng on-column of CP47,497-bis-TMS, HU-210-bis-TMS, JWH-
250, JWH-073 and JWH-018 (Unextracted) 
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Figure 3.1 (Continued): GC-MS Chromatograms and Full-Scan Mass Spectra of 0.5 ng on-column of CP47,497-bis-TMS, HU-210-bis-
TMS, JWH-250, JWH-073 and JWH-018 (Unextracted)  
66 
 
 
 
Figure 3.1 (Continued): GC-MS Chromatograms and Full-Scan Mass Spectra of 0.5 ng on-column of CP47,497-bis-TMS, HU-210-bis-
TMS, JWH-250, JWH-073 and JWH-018 (Unextracted)  
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3.6 Method Development Using LC-MS 
3.6.1 Method Designing 
The development of an LC-MS/MS method is usually time-consuming, especially 
if the method requirements are challenging. Therefore, strategies for LC-MS/MS 
method development should be used to save time and money as well as 
achieving adequate sensitivity and selectivity. These strategies involve research 
and planning, and development of three main separate methodologies; MS/MS, 
LC and sample preparation (Figure 3.2). Iterative approaches may be required 
for optimising an LC-MS/MS method since changes in one method can affect 
another. 
 
Figure 3.2: Stepwise Optimisation of LC-MS/MS Method 
 
An MS/MS method development can give the developer a clear picture of 
whether the compounds of interest are detectable in this type of technique. It 
can also provide the optimum MS conditions for the compound detection. During 
this step of the method development process, the mode of ionisation (e.g. ESI, 
APCI) and the polarity should be evaluated to achieve the optimum set of 
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conditions. LC method development plays an important role to ensure the 
compounds of interest separate from each other and from endogenous or 
exogenous interferences. The last step is the sample preparation method 
development. Selection of the appropriate sample preparation is a crucial step. 
It depends on many factors such as the type of matrix, the availability of 
materials, duration of use of the assay and the purpose of analysis. The method 
of sample preparation should eliminate endogenous molecules such as 
phospholipids that may cause ion enhancement or ion suppression in LC-MS. In 
addition, it should concentrate analytes of interest to enhance assay sensitivity. 
3.6.2 Optimisation of MS/MS Method 
All SC compounds and their internal standards were ionised using ESI mode and 
generated prominent protonated molecular ions [M+H]+ in positive-ion mode 
because they are basic molecules. 
10 SCs and 4 internal standards were prepared individually in the infusion 
solution (see 3.4.2.6), at a concentration of 1 μg/mL and then a constant stream 
of each drug solution was directly introduced into the ESI interface using a 
syringe infusion pump. This can determine whether the compounds will ionise in 
the mass spectrometer and allows for parameters to be ‘tuned’ to the 
compounds, leading to optimal conditions for ionisation and therefore optimal 
sensitivity. All SCs and internal standards were individually tuned in order to 
detect the precursor ions and then optimise their product ion responses, with 
individual fragmentor voltages and collision energies. In the tuning process, four 
steps were performed for each analyte as follows: 
1) MS1 scan method in order to determine the precursor ions.  
2) Fragmentor voltage optimisation for each precursor ion. 
3) Product ion mode method in order to determine the product ions using 
the data from the previous steps.  
4) Optimising the collision energy of each transition through a range 0 – 60 V 
by increasing the value of collision energy by 5 V each time.   
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MRM mode was used to monitor 2 ion transitions (quantifier and qualifier) for 
each analyte because of sensitivity requirements and 1 transition was used for 
the internal standard. The fragmentor voltage was optimised for the analytes to 
maximize precursor ion intensity. The fragmentor voltage for all the analytes 
investigated in this study was 140 V. The collision energy was optimised to 
achieve the highest abundance of product ions. The optimal collision energy of 
the majority of these analytes was less than 40 eV. The major product ions were 
selected for quantification in all analytes.  
Although there are LC-MS/MS methods in the literature for the determination of 
CP47,497 and HU-210, it was not possible to detect them in either positive or 
negative mode. It was unclear whether the lack of detection of CP47,497 and 
HU-210 resulted from contamination in ion source or because they are weakly 
acidic compounds with phenolic hydroxyl groups. These 2 drugs belong to the 
first generation of SCs therefore it was decided to exclude them from the 
method. 
Optimised results for precursor ions, product ions, fragmentor voltages, collision 
energies, collision cell exit potential and retention times for 10 SCs and 4 
internal standards are shown in Table 3.3. The optimal conditions were achieved 
using nitrogen gas heated to 300C and delivered at 10 L/min, a capillary voltage 
of 4,000 V and a nebulizer pressure at 15 PSI in order to obtain the highest 
sensitivity. 
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Table 3.3: Optimisation of MRM Transitions, Fragmentor Voltage, Collision Energy, Collision Cell Exit Potential and Retention Time 
of 10 SCs and 4 Internal Standards 
Analyte Q1 mass (m/z) 
Q3 mass (m/z) 
Frag
a
 (V) CE
b 
(eV) 
 
CXPc (V) 
 
RT
d
 (min) Quantifier Qualifier 
JWH-018 4-OH 
pentyl 
358.2 155.1 127.0 140 5 4 4.5 
JWH-073 3-OH 
butyl 
344.2 155.1 216.0 140 20 4 4.3 
AM-2201 4-OH 
pentyl 
376.2 155.1 248.0 140 30 4 3.9 
JWH-250 4-OH 
pentyl 
352.3 121.1 186.0 140 20 4 3.5 
JWH-122 5-OH 
pentyl 
372.0 169.0 230.0 140 20 4 5.4 
JWH-210 5-OH 
pentyl 
386.1 183.0 155.0 165 20 4 6.2 
JWH-018 342.2 155.1 214.0 140 30 4 7.4 
JWH-073 328.2 155.1 200.1 140 20 4 7.0 
JWH-250 336.2 121.1 200.1 140 20 4 6.9 
JWH-200 385.2 155.1 114.0 140 20 4 3.4 
JWH-018 4-OH 
pentyl-D5 
363.1 155.1 140 20 4 4.4 
JWH-250 4-OH 
pentyl-D5 
357.2 121.0 140 20 4 3.4 
AM-2201 4-OH 
pentyl-D5 
381.1 154.9 140 20 4 3.8 
JWH-073 3-OH 
butyl-D5 
349.2 155.1 140 20 4 4.2 
aFragmentor voltage.  bCollision energy. cCXP Collision cell exit potential. dRT Retention time. 
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3.6.3 Development of LC Method  
A reversed-phase column such as C18 is usually suitable for non-polar and 
lipophilic compounds. Therefore, a C18 column was used in these experiments. 
Suitable LC conditions were identified in the planning stage from the literature 
[79, 127, 259] and used initially. A suitable eluent for ESI should contain an 
organic modifier (acetonitrile or methanol) and a volatile buffer. 
An Agilent LC/MS-MS triple quadrupole 6420 mass spectrometer equipped with 
an Agilent 1260 Infinity autosampler, binary pump with degasser was used. A 
Phenomenex Gemini C18 (150 x 2.0 mm, 5 µm) column coupled with a C18 guard 
column (4.0 × 2.0 mm) was used with a gradient elution system consisting of two 
mobile phases, A) 2 mM ammonium acetate and 0.1% formic acid in de-ionised 
water and B) 2 mM ammonium acetate and 0.1% formic acid in methanol, at a 
flow rate of 0.3 mL/min. The temperature of the column oven was 40C.   
It was decided to make a balance between a useable analysis time and a good 
chromatographic separation. Several gradient systems were applied to get the 
best separation and improve the resolution for all the analytes with satisfactory 
run time in one analysis. This was achieved by modifying the aqueous/organic 
phase percentage of the mobile phase. 
The Gemini C18 column gave good separation of all SCs with a run time of 14 
min (Figure 3.3). The method run time was reduced from 14 to 11.5 minutes by 
modifying the initial mobile phase composition from 50:50 B/A to 70:30 B/A. 
This is because the reversed-phase column contains a non-polar stationary phase 
and, when using mobile phase with higher organic content, analytes would elute 
out more quickly. The gradient mobile phase system started at 70:30 B/A, 
increasing to 95:05 B/A within 2.5 minutes. This percentage was maintained for 
3 minutes before being decreased to 70:30 B/A for 6.5 minutes in order to 
condition the column before the next injection. Data analysis was performed 
using Agilent MassHunter™ Workstation software (version: B.05.00).   
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3.6.4 Initial Sensitivity and Linearity Assessments 
Following development of the instrumental method, sensitivity and linearity 
assessments were carried out to evaluate the suitability of the analytical method 
before starting the development of sample preparation.  
The sensitivity is based on the Limit of Detection (LOD). LOD is considered the 
lowest concentration of analyte that gives a reproducible instrument response 
with signal-to-noise (S/N) ratio greater than 3 [269]. Acceptable LODs should 
achieve the purpose of the method. In the current study, the main aim was to 
develop an analytical method for the identification of SCs in urine samples. 
Thus, LODs were assessed based on the concentrations that were found in case 
urine sample in the literature. The sensitivity of the method for each SC was 
assessed using serial dilution of un-extracted drug standard solutions within the 
expected range of the LODs at concentrations of 0.39, 0.78, 1.56, 3.13, 6.25, 
12.5, 25.0, 50.0 and 100 ng/mL.  
All the analytes gave good responses at a concentration of 0.39 ng/mL with 
signal-to-niose ratios in excess of 3 for the quantification transition, which 
allowed continuation of the development of the current method (Figure 3.3).   
In order to evaluate the linearity, the peak area ratios of each SC to the 
respective internal standard were calculated and calibration curves were 
generated by plotting the concentration against the area ratio. The correlation 
coefficient (R2) was calculated for each graph. The linearity of un-extracted SCs 
investigated in this study was evaluated over the concentration range 0.39–100 
ng/mL for a 10 µL injection. SCs were found to have a linear response over the 
concentration range 0.39–100 ng/mL in un-extracted samples with R2 values 
greater than 0.994 (Figure 3.4). 
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Figure 3.3: LC-MS/MS Quantifier MRM Transition Chromatograms of 0.039 ng on-column of 8 SCs Using a Standard Mixture  
 
JWH-250 4-OH pentyl JWH-018 4-OH pentyl 
JWH-018  
JWH-200 
JWH-250  JWH-073 3-OH butyl 
AM-2201 4-OH pentyl JWH-073  
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Figure 3.4: Calibration curves and Linear Correlation Coefficients (R2) for Unextracted SC Standards over the Concentration Range 
0.39–100 ng/mL in Un-extracted Samples (10 µL injection volume) Analysed by LC-MS/MS 
75 
 
 
Figure 3.4: Calibration curves and Linear Correlation Coefficients (R2) for Unextracted SC Standards over the Concentration Range 
0.39–100 ng/mL in Un-extracted Samples (10 µL injection volume) Analysed by LC-MS/MS (Continued…) 
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3.6.5 Development of Extraction Method 
In order to analyse SCs in biological samples, the compounds first need to be 
extracted from the matrix and concentrated. This is likely to be the most 
technically demanding step in the method development process. The procedure 
needs to be able to remove as many interferences as possible without 
diminishing the recovery of the compounds. Iterative extraction experiments 
were carried out to optimise the best conditions for the extraction of 10 SCs as a 
mixture from urine. Recoveries, matrix effects, the cleanliness of the extracts, 
time of extraction and peak shapes were evaluated when optimising extraction 
methods. It was decided to evaluate the recovery of three extraction 
techniques; dilute and shoot, PPT (with/without evaporation step) and an LLE 
method using methyl-tert-butyl-ether, modified from the literature. Sample 
recovery can be described as the percent of analyte that was recovered during 
the extraction process. 
3.6.5.1 Dilute and Shoot 
A volume of 100 μL blank urine was transferred to 3 mL vial followed by 40 μL of 
mixed standard solution at 0.5 μg/mL. And then 30 μL of 1 M sodium acetate 
buffer (pH 5.0) and 20 μL of β-glucuronidase were added. A 50 μL internal 
standard mix solution at a concentration of 0.5 μg/mL was added to the sample. 
This was vortexed briefly to mix and heated (in heating block) at 60C for 1h for 
enzymatic hydrolysis. The samples were left to cool down for approximately 3 
minutes. A volume of 100 μL was transferred to a labelled Eppendorf vials and 
diluted with 900 μL of mobile phase. These were centrifuged at 13,000 rpm for 
15 minutes. The samples were then transferred to labelled LC autosampler vials. 
A 10 μL volume was injected into the LC-MS/MS.  
3.6.5.2 Protein Precipitation 
40 μL of 0.5 μg/mL mixed standard solution was added to blank urine (100 μL) in 
a 3 mL vial. 30 μL of 1 M sodium acetate buffer (pH 5.0) and 20 μL of β-
glucuronidase were added. This was vortexed briefly to mix. The samples were 
incubated at 60 C for 1h for enzymatic hydrolysis. The samples were left to cool 
down for approximately 3 minutes. A volume of 600 μL acetonitrile was added 
and samples were then transferred to labelled Eppendorf vials. These were 
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vortexed briefly to mix and then centrifuged at 13,000 rpm for 15 minutes. The 
supernatants were transferred to 3 mL vials. 50 μL internal standard mix solution 
at a concentration of 0.5 μg/mL was added to the supernatants which were then 
evaporated to dryness at 40C. Finally, the samples were reconstituted in 100 μL 
of 50:50 A/B mobile phase mixture and transferred to labelled LC autosampler 
vials. A 10 μL volume was injected into the LC-MS/MS. 
The same procedure was also applied without evaporation of the supernatant. 
Supernatant (200 μL) was transferred to a labelled LC vial and a 10 μL volume 
injected. 
3.6.5.3 Liquid-Liquid Extraction 
A volume of 100 μL of blank urine was transferred to a 3 mL vial followed by 40 
μL of the mixed standard solution at 0.5 μg/mL. Then 30 μL of 1 M sodium 
acetate buffer (pH 5.0) and 20 μL of β-glucuronidase were added. This was 
vortexed briefly to mix and heated at 60C for 1h for enzymatic hydrolysis. The 
samples were left to cool down for 3 minutes. A volume of 300 μL methyl-tert-
butyl-ether was added and the mixture was then transferred to a labelled 
Eppendorf vial. The samples mixed by shaking for 10 minutes and then 
centrifuged at 13,000 rpm for 15 minutes. The upper organic layer was 
transferred to a 3 mL vial. 10 μL internal standard mix solution at a 
concentration of 0.5 μg/mL was added to the upper organic layer which was 
then evaporated to dryness at 40C. Finally, the samples were reconstituted in 
100 μL of 50:50 A/B mobile phase mixture and transferred to a labelled LC vial. 
A 10 μL volume was injected into the LC-MS/MS. 
3.6.5.4 Results of Recovery of Extraction Methods (Dilute and Shoot, PPT 
and LLE) 
3 extraction techniques were used to extract 8 SCs out of urine: dilute and 
shoot, PPT (with/without evaporation step) and LLE. It was decided to exclude 
SPE methods of extraction optimisation for many reasons. It is often time 
consuming in method development due to the multiple steps involved with 
sample preparation, particularly for the washing and conditioning of the 
cartridge. It is also very expensive, especially in the case of high throughput of 
samples. The selectivity achieved when using LLE is generally as good as that 
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obtained with SPE [270]. Moreover, urine is quite a clean sample compared with 
blood or oral fluid therefore LLE or PPT might be satisfactory for sample 
preparation.  
Choosing which extraction approach is best can be determined in practice. The 
comparison of the recovery of the three methods is necessary to decide which 
method is the best for further use, without changing any factor. Recoveries of 
analytes were calculated at a concentration of 200 ng/mL of urine and extracted 
in duplicate. At the same concentration duplicate un-extracted standards were 
also prepared without internal standard and kept in the fridge during the 
extraction. Internal standard mix solution was added to each vial for extracted 
and unextracted standards after the extraction. After analysing the samples, the 
peak area ratios between the compound and its respective deuterated standard 
were calculated. The recovery of each compound was calculated using the 
following equation [237]:  
     100
Standards ed Unextractof Ratio AreaPeak 
 Standards Extracted of Ratio AreaPeak 
 (%)Recovery          Equation 3 
The chromatograms for the compounds were also analysed in order to determine 
which extraction gave the cleanest extract.  
In the dilute and shoot method, the time of sample preparation compared with 
PPT and LLE was generally shorter. However, it is clear that, it is not the best 
method for the analysis of SCs. Urine samples following dilute and shoot method 
were not clean (brownish). JWH-200, JWH-018 and JWH-073 were not well 
recovered (21.8, 39.1 and 43.6% respectively). One potential reason for this 
might be because this method does not remove any interferences, however the 
use of a deuteron-labelled internal standard might compensate for matrix 
effects. 
In PPT extraction, it seemed that recoveries of analytes with evaporation were 
slightly lower than without evaporation. JWH-200 showed poor recovery using 
the PPT method with evaporation step (17.7%) and JWH-018 and JWH-073 were 
not well recovered (36.2% and 37.6% respectively). For PPT extraction without 
the evaporation step, the recoveries for all parent analytes investigated in this 
79 
 
study were lower than 52%. The urine samples in PPT extraction without an 
evaporation step were slightly dirty which might cause as many chromatographic 
problems as the dilute and shoot method. The lower apparent recovery of some 
analytes using the PPT extraction method is probably because it does not remove 
many of the matrix interferences.    
The LLE method compared with simple dilution and PPT methods gave cleaner 
extracts. This is potentially the reason why the analytes had nice 
chromatography. LLE attained recoveries higher than 69% for all the compounds. 
In addition, SCs are highly hydrophobic and LLE is a suitable method for the 
extraction of these types of compounds from biological matrices. An LLE method 
has relatively low costs and is easy to transfer from one laboratory to another. 
For all these reasons, it was decided to use LLE as the extraction method for all 
the compounds and to try to improve the sample preparation and the recovery 
of the analytes.  
The results for recoveries for all extraction techniques used in this study are 
shown in Figure 3.5. 
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Figure 3.5: Recoveries of 8 SCs from Urine at a Concentration of 200 ng/mL by Dilute and Shoot, PPT with Evaporation, PPT 
without Evaporation and LLE Extraction Methods
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3.6.5.5 Extraction Optimisation – Comparison of 6 LLE Methods (3 
Solvents vs 2 Buffers) 
It was decided to continue using the LLE method and to try to improve the 
sample preparation and the recoveries of the analytes. The aim of this study was 
to assess recoveries using three LLE solvents, MTBE, DCM and n-hexane, and two 
buffers with different pH, 0.1 M phosphate buffer (pH 6.0) and 1 M sodium 
acetate buffer (pH 5.0).  
It was found that the time of extraction was slightly long due to the transfer 
step of the samples between 3 mL and Eppendorf vials. Therefore, the volume of 
urine was increased to 1 mL and the procedure was slightly changed as follows:    
A volume of 1 mL blank urine was transferred to a test tube followed by 400 μL 
of mixed standard solution at 0.5 μg/mL. Then 300 μL of (buffer) and 20 μL of β-
glucuronidase were added. This was vortexed briefly to mix and heated at 60C 
for 1h for enzymatic hydrolysis. The samples were left to cool down for 3 
minutes. A volume of 3 mL (solvent) was added and then mixed by shaking for 
10 minutes. The samples were centrifuged at 3500 rpm for 10 minutes. The 
upper or lower organic layer (depending on the solvent) was transferred to a 
labelled 3 mL vial. 100 μL of internal standard mix solution at a concentration of 
0.5 μg/mL was added and then the mixture was evaporated under a nitrogen 
stream at 40C. The samples were reconstituted in 100 μL of 50:50 A/B mobile 
phase mixture and transferred to a labelled LC vial. A 10 μL volume was injected 
into the LC-MS/MS.    
Recoveries of analytes were calculated at a concentration of 200 ng/mL of urine 
and were bead on duplicate extractions; refer to Equation 3 above for the 
calculation.  
3.6.5.6 Results of Recovery of 6 LLE Methods (3 Solvents vs 2 Buffers) 
Practical work on different buffers and pH values might help to choose suitable 
conditions of ionisation especially in the case of the analysis of many dissimilar 
compounds. SCs included in this method are non-ionised and have indole rings 
which don’t protonate easily. 
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An organic solvent should be selected depending on the analyte’s solubility in 
the particular solvent to obtain maximum recovery. The method was evaluated 
by using three LLE solvents, MTBE, DCM and n-hexane, and two buffers, 0.1 M 
phosphate buffer (pH 6.0) and 1 M sodium acetate buffer (pH 5.0).  
LLE with MTBE as a solvent gave better recoveries for most of the analytes than 
DCM and n-hexane. Recovery depends primarily on solubility of the analyte in 
the solvent - the partition coefficient. Recovery was greater than 75.3% for all 
the analytes using LLE/MTBE/1 M sodium acetate buffer (pH 5.0). JWH-018 
showed poor recovery using LLE/DCM/0.1 M phosphate buffer (pH 6.0) method 
(16.3%). The results for recoveries for all these methods are shown in Figures 
3.6, 3.7 and 3.8. 
Nonpolar compounds (e.g. SCs) by their nature prefer to stay in the organic 
phase more than in the aqueous phase. MTBE and n-hexane have a lower density 
than water and, unlike DCM, the organic phase forms the upper layer during 
phase separation that makes the collection simpler and minimises dripping losses 
[270]. Time of extraction was shorter when using MTBE as a solvent, allowing 
more samples to be analysed in each batch.  
It was decided to use the LLE/MTBE/1 M sodium acetate buffer (pH 5.0) method 
because it gave higher recoveries for most of the analytes compared with the 
other methods and for its ease in practice.   
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Figure 3.6: Recoveries of 8 SCs Using LLE Methods with (Hexane Solvent & Sodium Acetate Buffer (red)) and (Hexane Solvent & 
Phosphate Buffer (blue))  
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Figure 3.7: Recoveries of 8 SCs Using LLE Methods with (DCM Solvent & Sodium Acetate Buffer (red)) and (DCM Solvent & 
Phosphate Buffer (blue)) 
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Figure 3.8: Recoveries of 8 SCs Using LLE Methods with (MTBE Solvent & Sodium Acetate Buffer (red)) and (MTBE Solvent & 
Phosphate Buffer (blue)) 
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3.6.5.7 Extraction Optimisation – Matrix Effects and Sensitivity 
Assessments 
At this stage of method development JWH-122 5-OH pentyl and JWH-210 5-OH 
pentyl were obtained from the supplier and added to the standard mixture. It 
was decided to use the LLE method with MTBE as a solvent and 1 M sodium 
acetate (pH 5.0) as a buffer. Matrix effects and sensitivity were assessed for the 
developed method using two sample volumes, 0.1 and 1 mL, in duplicate. The 
matrix effects of the developed method were further assessed with a sample 
volume of 0.5 mL using two sample reconstitution volumes, 100 and 200 μL of 
mobile phase (50:50 V/V A/B). The main parameters of the procedures are given 
in Table 3.4. 
Table 3.4: Comparison of 3 Sample Volumes  
Sample 
Volumes 
Urine (mL) 
Mixed STD 
Solution (μL) 
Buffer 
(μL) 
Solvent 
(mL) 
Centrifuge 
rpm/min 
IS Mix 
Solution 
(μL) 
0.1 40 30 0.3 13000/15 10 
0.5 200 150 1.5 3500/10 50 
1.0 400 300 3 3500/10 100 
 
The matrix effect was studied to assess ionisation enhancement/suppression for 
the developed method using the post-extraction addition approach (Matuszewski 
strategy) [271]. Mixed standard solution was added to each vial for extracted 
standards after the extraction. To calculate the matrix effects, a pure standard 
at the same concentration in mobile phase was prepared in duplicate at the 
same time. After analysing the samples, the matrix effect was calculated for 
each compound using the following equation:  
100
Solventtion Reconstituin  Analytes Pure of Ratio AreaPeak 
 Spike extraction-Post of Ratio AreaPeak 
(%)ME     Equation 4 
The sensitivity of the method for each SC was assessed instrumentally using 
blank urine samples spiked with the serially-diluted standard solutions. The LOD 
is considered to be the lowest concentration of analyte that gives a reproducible 
instrument response with S/N ratio greater than 3. 
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3.6.5.8 Results of Matrix Effects and Sensitivity Assessments 
It was found that the most effective way to minimise matrix effects is to use 
stable isotope-labelled internal standards [272]. However, this is not always 
possible for various reasons. With respect to SCs, it is very difficult to obtain 
stable isotope-labelled internal standards for all analytes of interest due to the 
rapid proliferation of SCs on the world market.  
Matrix effects and sensitivity were assessed for the developed method in urine 
using two different sample volumes; 0.1 and 1 mL. The LLE method using MTBE 
as solvent, 1 M sodium acetate (pH 5.0) as a buffer and 0.1 mL as a sample 
volume gave better results for matrix effects for most of the analytes, with 
response ratios in the range 71.1-115% compared to those for a 1 mL sample 
volume, which had more ion suppression (Figure 3.9). A potential reason for this 
might be because the method using 0.1 mL as a sample volume gave a cleaner 
extract which led to reduced matrix effects and potentially more accurate 
quantitations. It is clear that this would be better for the instrument and for 
conserving sample. 
However, the developed method gave a very good sensitivity when using 1 mL as 
a sample volume with LODs ranging from 0.05 to 0.2 ng/mL with signal-to-niose 
ratios in excess of 3 for the quantification transition, compared to those 
obtained with a sample volume of 0.1 mL. LODs with 0.1 mL samples were not 
10 times higher for most of the analytes. Potential reasons for this might be 
because the accuracy of measuring the LODs or due to the matrix effects. LOD 
results of all SCs investigated in this study for both methods are presented in 
Figure 3.10.  
Based on these results, it was decided to continue to use the developed method 
with a sample volume of 0.5 mL as a compromise without decreasing the 
sensitivity too much.  
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Figure 3.9: Comparison of Matrix Effects During LC-MS/MS Analysis of 10 SCs in Urine at a Concentration of 200 ng/mL Using Two 
Sample volumes
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Figure 3.10: LODs for the Analysis of 10 SCs in Urine by LC-MS/MS Based on 2 LLE Methods Using Sample Volumes of 1.0 and 0.1 
mL.
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3.6.5.9 Extraction Optimisation – Sample Reconstitution  
Two reconstitution volumes; 100 and 200 μL were used for the same extracted 
sample to achieve the best results with respect to sensitivity and matrix effects. 
The developed method using 0.5 mL sample and 200 μL reconstitution volume 
gave lower matrix effects while at the same time LODs under these conditions 
were still about 0.1 ng/mL. Matrix effects were acceptable, ranging from 76 to 
110.5% for all analytes at concentrations of 200 ng/ml in urine (Figure 3.11).  
The dilution of samples by increasing the reconstitution volume reduced the 
matrix effects and helped to improve the linearity. A potential reason for this 
might be because the use of low concentrations prevents the MS source from 
saturating or may due to the detector. 
 
Figure 3.11: Matrix Effects for the LC-MS/MS Analysis of 10 SCs in Urine at a 
Concentration of 200 ng/mL Using the Final Developed Method 
 
3.7 Conclusions 
The sensitivity of GC-MS was unsatisfactory, which would make the 
determination of SCs in biological samples, particularly blood, more challenging. 
In contrast, the newer technique of LC-MS/MS seems to be more convenient for 
the detection of SCs and their metabolites in biological samples because it 
provides better sensitivity; indeed, most of the published literature uses LC-
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MS/MS. It has become more common for the analysis of illicit drugs in biological 
specimens, specifically for simultaneous multicomponent analysis. It is a much 
softer option to GC-MS, so can be used for non-volatile, high molecular weight 
and thermally labile compounds. Sample preparation time is shorter compared 
to GC-MS because the derivatisation of polar functional groups is not required. 
Moreover, the variation of derivatisation agents yields different spectra for the 
compound and this can lead to an unwanted diversity between laboratories. LC-
MS/(MS) has been shown to be a perfect supplement to GC-MS/(MS).  
A simple and cost-effective LC-MS/MS method using LLE for the simultaneous 
quantification of 4 SCs and 6 of their metabolites in urine has been developed. It 
is sometimes difficult to judge if a method is ‘good enough’ because there is 
always a possibility of improving it at every stage. However, it is all about 
balancing things and the current developed method seems to be fit for the 
purpose of the project. The sensitivity of the method was satisfactory  and LODs 
were low enough to detect SCs that have been seen in other cases. It is clear 
that LC-MS/MS is one of the best chromatographic techniques for the analysis of 
SCs. Prior to using the developed method to analyse samples, the overall 
performance had to be evaluated through a formal validation procedure. 
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Chapter 4 - Method Validation of 18 Analytes in 
Blood and Urine Using LC-MS/MS 
4.1 Introduction   
Reliable results are very important in forensic toxicology investigations which in 
turn need reliable analytical methods that give accurate and reproducible data. 
Methods in forensic toxicology should be able to distinguish between a diversity 
of drugs which might be sharing the same chemical behaviour and could be 
present in the samples at the same time. Therefore, prior to using a new 
analytical method, it should be validated according to international 
recommendations to ensure that the method is fit for use for a particular 
analysis. The validation of a method proves the scientific soundness of the 
characterisation or measurement. It demonstrates that a developed method 
measures the correct compound in the correct amount for the intended samples. 
The validated method also allows the analyst to establish the performance limits 
of the method as well as to understand the behaviour of the method. According 
to the International Organization for Standardization (ISO), validation can be 
defined as “verification, where the particular requirements are adequate for an 
intended use” [273].         
Before starting any validation experiments, a validation plan should be in place. 
A validation plan should contain the parameters which need to be examined 
depending on the requirements for a method [274, 275]. Thus, the method can 
be validated for use as a qualitative or quantitative method. For a qualitative 
method, few parameters require to be examined. Specificity/selectivity, 
precision (intra and inter-day precision), the limit of detection and stability of 
analytes have to be investigated. In the case of a quantitative method, more 
parameters also need to be optimised; accuracy, linearity within the 
quantitation range, carryover and recovery. It has been recommended that 
matrix effects should be evaluated in the method validation process for 
quantitative methods using LC-MS/MS [276, 277]. 
Useful protocols for method validation have been published by different 
organisations to ensure high quality that contributes to achieving the most 
reliable results, such as the United Kingdom and Ireland association of forensic 
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toxicologists forensic toxicology laboratory guidelines (2010) [278] the 
SOFT/AAFS Forensic Toxicology Laboratory Guidelines (2006) [279] and the 
standard practices for method validation in forensic toxicology which was 
published in 2013 by the Scientific Working Group for Forensic Toxicology 
(SWGTOX) [269]. Several articles [274, 280] have been published discussing 
important considerations in analytical method validation which may be used as 
guidance.  
Due to the rapid appearance of SCs in the market, it was necessary to add a 
further 6 drugs (5F-AKB-48, 5F-PB-22, AM-1248, AB-FUBINACA, A-796260, UR-144) 
and 2 metabolites (5F-AKB-48 (N-4 OH pentyl) and 5F-PB-22 3-carboxyindole) 
(See Figure 2.7). Initial experiments were carried out on these drugs and it was 
found that they were compatible with the already developed method.  
Both urine and blood samples might play an essential role in the forensic analysis 
of SCs. While urine is the best matrix to indicate past exposure of ingested 
drugs, blood is the preferred sample in post-mortem toxicology. The analysis of 
blood increases the chance of identifying the ingested parent compound. 
Analysing blood is also important for assessing whether the deceased was under 
the influence of a drug at the time of death.  
As mentioned previously, SCs undergo extensive metabolic conversion and the 
parent compounds are rarely observed in urine [236]; therefore it seems 
essential to focus on metabolites. It was found that structurally similar SCs 
follow common metabolic pathways leading probably to produce metabolites 
with similar metabolic transformations [281]. Dresen et al. [192] reported that it 
is very important in developing analytical methods to detect parent compounds 
of SCs in the blood and also to correlate SCs in blood to their major urinary 
metabolites.  
For all these reasons, it was decided to validate the optimised method in 
Chapter 3 for the quantitation of a selection of SC parent compounds along with 
their corresponding metabolites in blood and urine using LC-MS/MS. The method 
was validated according to the SWGTOX guidelines [269] for urine and whole 
blood.    
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4.2 Materials and Methods 
4.2.1 Chemicals and Reagents  
The chemicals and reagents were the same as those described in Section 3.3 
4.2.2 Calibrators, Internal Standards and Controls  
Stock and working solutions were the same as those described in Section 3.4.1  
Two mixture solutions (0.5 μg/mL) were prepared as follow:  
(A) ‘0.5 μg/mL mixture solution 1’ containing 10 SCs was prepared in 
methanol and used to make up calibrators at 0.5, 1.0, 2.0, 5.0, 10.0, 25, 
50, and 100 ng/mL in blood. 
(B) ‘0.5 μg/mL mixture solution 2’ containing 8 metabolites of SCs was 
prepared in methanol used to make up calibrators at 1.0, 2.0, 5.0, 10.0, 
25, 50, and 100 ng/mL in urine.  
The internal standard solution contained JWH-018 4-OH pentyl-D5, JWH-250 4-
OH pentyl-D5, AM-2201 4-OH pentyl-D5, JWH-073 3-OH butyl-D5 and JWH-200-D5 
and was prepared in methanol at 0.5 μg/mL. All stock and working solutions 
were transferred to amber glass bottles and stored at −20°C for up to 6 months. 
Three quality control (QC) working solutions at concentrations of 5, 40 and 75 
ng/mL were prepared in methanol for all the analytes.  
4.2.3 Instrumentation    
An Agilent LC/MS-MS triple quadrupole 6420 mass spectrometer equipped with 
an Agilent 1260 Infinity autosampler, binary pump with degasser was used. 
Chromatographic separation (run-time 11.5 mins) was achieved using a 
Phenomenex Gemini C18 (150 x 2.0 mm, 5µm) column and a gradient elution 
system consisting of two mobile phases; 2mM ammonium acetate and 0.1% 
formic acid in de-ionised water and in methanol. The temperature of the column 
oven was 40C. The gradient mobile phase system started at 70:30 B/A, 
increasing to 95:05 B/A within 2.5 minutes. This percentage was maintained for 
95 
 
3 minutes before being decreased to 70:30 B/A for 6.5 minutes in order to 
condition the column before the next injection. Agilent LC-MS/MS equipped with 
an electrospray ionisation interface, operated in positive polarity, was used for 
analysis. Multiple Reaction Monitoring (MRM) mode was used to monitor 2 ion 
transitions (quantifier and qualifier) for each analyte and 1 transition was used 
for the internal standard. Data analysis was performed using Agilent 
MassHunter™ Workstation software (version: B.05.00). The MS/MS parameters for 
all SCs used in this project are detailed in Table 4.1. 
4.2.4 Extraction Methodology  
A volume of 0.5 mL blank urine was transferred to a test tube followed by 200 μL 
of mixed standard solution at 0.5 μg/mL. Then 150 μL of 1 M sodium acetate 
buffer (pH 5.0) and 20 μL of β-glucuronidase were added. This was vortexed 
briefly to mix and heated at 60C for 1h for enzymatic hydrolysis. The samples 
were left to cool down for 3 minutes. A volume of 1.5 mL methyl-tert-butyl-
ether was added and then mixed by shaking for 10 minutes. The samples were 
centrifuged at 3500 rpm for 10 minutes. The upper organic layer was transferred 
to a labelled 3 mL vial. 50 μL of internal standard mix solution at a 
concentration of 0.5 μg/mL was added and then the mixture was evaporated 
under a nitrogen stream at 40C. The samples were reconstituted in 200 μL of 
50:50 A/B mobile phase mixture and transferred to a labelled LC vial. A 10 μL 
volume was injected into the LC-MS/MS.    
4.2.5 Limit of Detection and Lower Limit of Quantification 
LOD of an analyte can be defined as that concentration giving a signal 
significantly different from the background signal. Several approaches for 
determining LOD are possible, depending on whether the procedure is 
instrumental or non-instrumental [274, 282]. It can be determined by visual 
inspection, from the S/N ratio or using a statistical method based on the 
standard deviation (SD) of the response and the slope.   
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Table 4.1: Multiple Reaction Monitoring Transitions, MS/MS Parameters and 
Retention Times for SCs, their Metabolites and Internal Standards 
 
Analyte 
 
Q1 
mass 
(m/z) 
Q3 mass (m/z) 
Frag
a
 
(V) 
CE
b 
(eV) 
CXPc 
(V) 
RT
d
 
(min) Quantifier Qualifier 
JWH-018 4-OH 
pentyl 
358.2 155.1 127.0 140 5 4 4.5 
JWH-073 3-OH 
butyl 
344.2 155.1 216.0 140 20 4 4.3 
AM-2201 4-OH 
pentyl 
376.2 155.1 248.0 140 30 4 3.9 
JWH-250 4-OH 
pentyl 
352.3 121.1 186.0 140 20 4 3.5 
JWH-122 5-OH 
pentyl 
372.0 169.0 230.0 140 20 4 5.4 
JWH-210 5-OH 
pentyl 
386.1 183.0 155.0 165 20 4 6.2 
5F-AKB-48 (N-4 OH 
pentyl) 
400.1 135.0 107.0 150 25 4 6.5 
5F-PB-22 3-
carboxyindole 
250.1 118.0 206.0 145 20 4 2.8 
JWH-018 342.2 155.1 214.0 140 30 4 7.4 
JWH-073 328.2 155.1 200.1 140 20 4 7.0 
JWH-250 336.2 121.1 200.1 140 20 4 6.9 
JWH-200 385.2 155.1 114.0 140 20 4 3.5 
5F-AKB-48 384.2 135.0 - 210 22 4 5.5 
5F-PB-22 377.1 232.1 144.0 235 27 4 7.7 
AM-1248 391.1 135.0 112.0 190 30 4 2.0 
AB-FUBINACA 369.1 252.9 324.1 100 25 4 3.5 
A-796260 355.2 125.0 114.0 155 20 4 4.3 
UR-144 312.1 125.0 214.0 160 25 4 7.8 
JWH-018 4-OH 
pentyl-D5 
363.1 155.1 140 20 4 4.4 
JWH-073 3-OH 
butyl-D5 
349.2 155.1 140 20 4 3.4 
AM-2201 4-OH 
pentyl-D5 
381.1 154.9 140 20 4 3.8 
JWH-250 4-OH 
pentyl-D5 
357.2 121.0 140 20 4 3.4 
JWH-200-D5 390.1 155.0 185 20 4 3.4 
aFragmentor voltage.  bCollision energy. cCXP Collision cell exit potential. dRT 
Retention time. 
In this project, the S/N ratio approach was used. LOD is considered the lowest 
concentration of analyte that gives a reproducible instrument response with S/N 
ratio greater than 3 [269]. Specifically, LOD can be identified when the lowest 
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concentration of analyte met these identification criteria; quantifier ion peaks 
greater than 3 times the background noise and presence of qualifier ions at the 
known retention time. LOD is not a rugged or robust parameter. Minor changes 
in the analytical system (e.g. instrumental conditions, matrix effects, purity of 
reagents) can affect the LOD. The lower limit of quantification (LLOQ) is 
considered the lowest concentration that gives a reproducible instrument 
response with acceptable precision (<20% coefficient of variation) and S/N ≥ 10 
[274]. MassHunter™ software was used to calculate the S/N ratio. 
LOD and LLOQ were determined instrumently for each analyte of interest by 
lowering the concentrations of calibration standards in blood and urine at eight 
different concentrations: 0.01, 0.025, 0.05, 0.075, 0.1, 0.25, 0.5 and 0.75 
ng/mL. The samples were prepared in duplicate and analysed using the 
optimised method. 
4.2.6 Linearity 
Linearity was determined by preparing and analysing eight calibrators over the 
concentration range of 0–100 ng/mL (0.5, 1, 2, 5, 10, 25, 50, 100 ng/mL) in 
blood and seven calibrators (1, 2, 5, 10, 25, 50, 100 ng/mL) in urine. Five 
separate calibrations were prepared freshly in duplicate by spiking blank blood 
and urine with working mixture solutions 1 and 2 respectively and extracted in 
accordance with the method reported in Chapter 3, over 5 different days. Drug-
free matrix and internal standard mixture added at 50 ng/mL were included with 
each run.  
Calibration curves were obtained by plotting peak area ratios of analytes to 
internal standards against concentration. The linear correlation coefficient, R2, 
often used as criterion of linearity, was calculated. Acceptable values should be 
greater than 0.99.  
4.2.7 Selectivity and Specificity  
Selectivity is tested to confirm the ability of a method to distinguish the target 
analyte(s) in a complex matrix without any potential interference from other 
matrix components of similar behaviour (e.g. degradation products, impurities 
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and metabolites) whereas specificity can be described as the ultimate selectivity 
where the possibility of interference is 0% [283, 284].  
The selectivity of the method was assessed by analysing 10 different sources of 
blank blood and urine (each), and comparing their chromatograms with those of 
corresponding standards spiked with 10 SC and 8 metabolites in blood and urine 
respectively at a concentration of 50 ng/mL. Specificity was evaluated by spiking 
drug-free matrix with each analyte and internal standard individually, at a 
concentration of 50 ng/mL. For the exogenous interference from other drugs, it 
was evaluated by analysing drug-free matrix containing tetrahydrocannabinol, 
amphetamine, cocaine, benzoylecgonine, anhydroecgonine methyl ester, 
ecgonine methyl ester, methadone, codeine, morphine, diazepam, gabapentin 
and mephedrone at a concentration of 500 ng/mL. All of them were separately 
spiked into blood and urine, and extracted. 
PB-22 and its fluorinated analogue 5F-PB-22 share some metabolites [88]; 
therefore the identification of unique metabolites for proof of compound 
consumption in forensic toxicology is a crucial issue. 5F-PB-22 3-carboxyindole is 
a potential marker for 5F-PB-22 with 2 MRM transition (250.1> 118.0) and 
(250.1> 206.0) [88]. A similar phenomenon may also occur in the case of other 
fluorinated analogues of SCs. 5F-AKB-48 (N-4 OH pentyl) is a good target 
metabolite for 5F-AKB-48 [58]. All the metabolites of SCs in the urine method 
used in this project were the major metabolites and good targets for their 
parents. Using authentic matched blood and urine samples can often overcome 
that issue.    
4.2.8 Carryover 
As part of method validation requirements, carryover has to be investigated 
under analysis conditions. Carryover is the inadvertent transfer of analyte into a 
subsequent sample during instrumental analysis. Carryover of analyte from one 
sample to the subsequent sample might cause an inaccurate result when using 
instrumental methods [269]. Carryover was tested by triplicate injecting of 
blank samples after two injections of an extract of blood/urine containing all 
analytes at a concentration of 100 ng/mL. To establish if there is carryover, the 
chromatograms were analysed visually.     
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4.2.9 Bias and Precision 
Bias (accuracy) is defined as the degree of closeness of the mean concentration 
obtained by the analytical method to the true concentration of the analyte 
under the prescribed conditions [285]. Precision can be described as the 
closeness of agreement between a series of measurements obtained from 
multiple sampling of the same homogeneous samples [274].  
Method bias/precision is determined using two main condition sets called intra-
day and inter-day bias/precision and which are also known as repeatability and 
reproducibility, respectively. Intra-day bias/precision is measured by analysing 
replicate samples containing drugs in the same day using the same analytical 
method and extraction. The inter-day bias/precision is determined in a similar 
manner to the intra-day bias/precision but on different days.              
Bias and precision were determined by replicate analysis of drug-free matrix 
spiked at three different concentrations (low, medium and high) as QCs. Each 
batch of QCs involved a freshly prepared calibration curve to calculate the 
concentrations using the optimised method. Intra-day bias and precision were 
calculated from five replicates per QC in one batch. For the determination of 
inter-day bias and precision, five replicates per QC were analysed on five 
different days (n=25). Bias and precision were calculated using the following 
formula [269]:    
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100×
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Equation 9 
 
Where x  is mean measured concentration, SD is standard deviation, x  is 
nominal concentration and CV is the co-efficient of variation.    
Bias was expressed as a percentage of the nominal concentration. The maximum 
acceptable bias is ±15% and ±20% at high and low concentrations respectively 
[274]. Precision was expressed as the co-efficient of variation (%CV). The %CV 
should not exceed 15% at each concentration [274]. 
4.2.10 Recovery and Matrix Effects 
Recovery can be defined as the percentage of the analyte of interest originally 
present in the sample that reaches the end of the procedure [275]. The 
assessment of the matrix effects on ionisation of analytes is an important aspect 
of validation of LC-MS method due to the susceptibility of the technique to ion 
enhancement or suppression that could lead to erroneous quantitative results. 
Several papers describing the evaluation and strategies for reducing matrix 
effects have been published [271]. Recoveries and matrix effects were measured 
using the approach of Matuszewski [269].  
3 sets of drug-free matrix spiked with analytes at three different concentrations 
(5, 50 and 100 ng/mL) were prepared in triplicate as follows: neat standard (set 
1), drug-free matrix from 10 different sources spiked with mixture solutions 1 
and 2 as appropriate after LLE (set 2), and drug-free matrix from 10 different 
sources spiked with mixture solutions 1 and 2 as appropriate before LLE (set 3).  
For the recoveries, internal standards were added after extraction to allow 
direct comparison with un-extracted standards and recoveries of each compound 
were investigated using the following equation:   
        100×
Spike extraction-Post of Ratio AreaPeak 
 Spike extraction-Pre of Ratio AreaPeak 
 = (%)Recovery     Equation 10 
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The recovery of an analyte need not be 100%: a low recovery can be accepted if 
bias, precision and LLOQ of the method are within the acceptable limits. It has 
been recommended that the recovery should be reproducible and at least 50% 
for all concentrations tested. Recovery may be reported higher than 100% that 
probably indicates the presence of matrix effects, particularly when using LC-
MS/MS [271].   
Matrix effects of endogenous components were calculated using the Equation 4. 
Matrix effects are considered acceptable if they do not exceed ±25% in the 
absence of matrix. Matrix effect values less than 100% indicate ion suppression 
and values greater than 100% indicate ion enhancement.  
4.2.11 Stability 
4.2.11.1 Stability as Part of Validation 
Analytical challenges might arise from the degradation of drugs and their 
metabolites which should be considered when planning an analytical strategy. 
Therefore, the validation of the analytical method should demonstrate the 
extent to which the analytes in a given matrix under specific conditions are 
stable for given time intervals in order to ensure accurate quantitative results 
[285], particularly if no information is available from previous work [274].  
Stability studies measure the differences in drug concentration that could be 
encountered between the time of sampling and the time of analysis [286]. Two 
concentrations have to be tested at low and high points of the calibration range 
[286]. The stability of parent SCs in blood and their metabolites in urine were 
evaluated using three types of stability study; 
A) Benchtop Stability 
This refers to the stability of the analyte under the conditions of sample 
preparation. It should be evaluated to discover if preservatives have to be added 
to the sample during the preparation in order to prevent degradation of the 
analytes. Drug-free blood and urine samples were spiked with 10 SCs and 8 
metabolites individually at 2 concentrations QC1 and QC2 (5 and 75 ng/mL). To 
determine time zero concentrations, freshly spiked samples were immediately 
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extracted and analysed in triplicate. Short-term stability was evaluated for 
fortified drug-free matrix stored in the dark in glass tubes for 24 hours at room 
temperature (18 ±1ºC). Stability samples were prepared and stored under 
previous conditions until analysis. On the day of each experiment, samples were 
extracted and a freshly prepared mixture of internal standard solutions was 
added to each specimen and processed in triplicate along with freshly spiked 
calibration standards and then analysed.  
B) Freeze-thaw Cycle Stability: 
Freeze-thaw cycle stability is also very important because biological samples are 
often frozen and thawed (e.g. for reanalysis). Drug-free blood and urine samples 
were spiked with 10 SCs and 8 metabolites individually at 2 concentrations QC1 
and QC2 (5 and 75 ng/mL). Short-term stability was evaluated for fortified drug-
free matrix after three freeze-thaw cycles at (-20 ±1ºC). Samples were left at 
room temperature to defrost after 24, 48 and 72 hours and analysed in triplicate 
after the three cycles. 
C) In-process Stability: 
In-process (autosampler) stability is a critical issue in the case of unexpected 
delays in analysis (e.g. breakdown of instrument). The stability of analytes was 
also evaluated in-process stability using reconstituted extracted sample at 24 
hours after extraction at approximately 20ºC.  
Stability of benchtop and in-process were calculated by dividing the calculated 
concentrations after 24 hours by the initial concentrations of analytes and 
multiplying by 100. Stability of freeze-thaw cycle was calculated by dividing the 
calculated concentrations after the three cycles by the initial concentrations of 
analytes and multiplying by 100. If the bias was ±10% of the time zero 
concentration, the analyte was considered stable. The experiments were 
conducted together with the bias and precision experiments. 
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4.2.11.2 Long Term Stability Study of 5F-AKB-48 (N-4 OH pentyl) and 5F-
PB-22 3-carboxyindole in Methanol/Acetonitrile Solutions for Up to 
3 Months  
A long-term stability study was conducted using methanol and acetonitrile 
spiked with 5F-AKB-48 (N-4 OH pentyl) and 5F-PB-22 3-carboxyindole. 
12 mL of methanol or acetonitrile was spiked with 5F-AKB-48 (N-4 OH pentyl) 
and separately with 5F-PB-22 3-carboxyindole at a concentration of 80 ng/mL. 
Each solution was transferred equally to 3 vials and stored under three different 
conditions; at room temperature (18 ±1ºC), in the fridge at (4 ±1ºC), and in the 
freezer at -20 ±1ºC until analysis. 
After freshly spiking the solutions were analysed in duplicate to establish time 
zero concentrations. On the day of the experiment, freshly prepared internal 
standard solution was added to each sample in duplicate along with freshly 
spiked calibration standards and then analysed. Samples were analysed on the 
first, third, fifth and seventh day during the first week, then once a week for 12 
weeks. Stability was calculated by dividing the calculated concentration at the 
selected days by the initial concentrations of analytes and multiplying by 100.  
4.3 Results and Discussion  
4.3.1 Chromatography 
Good chromatography of all SCs was achieved using a gradient elution system 
containing 2 mM ammonium acetate and 0.1% formic acid. The analysis of SCs in 
both the blood and urine specimens was operated in MRM acquisition mode. 
The chromatograms of the 10 parent SCs in whole blood and 8 corresponding 
metabolites in urine are shown in Figures 4.1 and 4.2, respectively and the 
chromatograms of the 5 internal standards can be seen in Figure 4.3.
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Figure 4.1: Examples of LC-MS/MS Quantifier MRM Chromatograms of Parent SCs in Blood at concentrations of 0.5 ng/mL                                              
JWH-018  
JWH-073  
JWH-250  
JWH-200  AM-1248 
AB-FUBINACA 
A-796260 
UR-144  
5F-AKB-48 
5F-PB-22  
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Figure 4.2: Examples of LC-MS/MS Quantifier MRM Chromatograms of SC Metabolites in Urine at concentrations of 1.0 ng/mL  
 
JWH-018 4-OH pentyl 
JWH-073 3-OH butyl 
AM-2201 4-OH pentyl 
JWH-250 4-OH pentyl 
JWH-122 5-OH pentyl JWH-210 5-OH pentyl 
5F-PB-22 3-carboxyindole 
5F-AKB-48 (N-4 OH pentyl) 
106 
 
                              
                              
                                                                 
Figure 4.3: Examples of LC-MS/MS Quantifier MRM Chromatograms of Internal Standards of SCs in Blood at concentrations of 50 
ng/mL 
JWH-073 3-OH butyl-D5 JWH-250 4-OH pentyl-D5 
AM-2201 4-OH pentyl-D5 
JWH-200-D5 
JWH-018 4-OH pentyl-D5 
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4.3.2 Limit of Detection and Lower Limit of Quantification 
Sensitivity of the method was assessed by determining the LOD and LLOQ 
instrumentally for each analyte. LODs were determined by lowering the 
concentrations of calibration standards in blood and urine samples to the range 
of expected LODs: 0.010, 0.025, 0.050, 0.075, 0.100, 0.250, 0.500 and 0.750 
ng/mL.  
LOD was determined to be the lowest concentration which meets all 
identification criteria including quantifier ion peaks greater than 3 times the 
background noise and presence of qualifier ions at the known retention time. 
The concentrations ranged from 0.010 to 0.750 ng/mL.  LODs were all very low 
and fitted within concentrations found in blood and urine in case samples from 
Spice users [3, 85, 146, 154, 256, 259, 260]. The LLOQs were administratively set 
at 0.5 and 1.0 ng/mL for blood and urine methods respectively. These were the 
lowest concentrations that met all quantitation acceptance criteria for each 
analyte of interest. LODs values are shown in Table 4.2 along with LLOQs. 
4.3.3 Linearity  
The peak area ratios of each SC to its assigned internal standard were 
calculated, and calibration curves were generated by plotting the peak area 
ratio against the concentration. The correlation coefficient, R2, was calculated 
for each linear regression curve. 
The calibration curves were linear for all analytes within the range 0.5 or 1.0–
100 ng/mL with R² values of 0.996 or higher (Table 4.2). Figure 4.4 illustrates 
examples of the calibration curves for the parent SCs in blood and their 
metabolites in urine. In addition, Figure 4.5 shows the residual data for these 
calibration curves confirming their linearity. 
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Table 4.2: Experimentally Determined LODs, LLOQs and Correlation Coefficients for SCs in Blood and SC Metabolites in Urine 
Specimens 
Analyte Internal Standard LOD (ng/mL) LLOQ (ng/mL) 
Calibration Range 
(ng/mL) 
(R2) (range) (n=5) 
Blood 
JWH-018 JWH-018 4-OH pentyl-D5 0.05 0.5 0.5-100 0.997-0.999 
JWH-073 JWH-073 3-OH butyl-D5 0.075 0.5 0.5-100 0.998-0.999 
JWH-250 JWH-250 4-OH pentyl-D5 0.05 0.5 0.5-100 0.998-0.999 
JWH-200 JWH-200-D5 0.1 0.5 0.5-100 0.997-0.999 
5F-AKB-48 JWH-250 4-OH pentyl-D5 0.25 0.5 0.5-100 0.997-0.999 
5F-PB-22 JWH-250 4-OH pentyl-D5 0.25 0.5 0.5-100 0.997-0.999 
AM-1248 AM-2201 4-OH pentyl-D5 0.1 0.5 0.5-100 0.996-0.999 
AB-FUBINACA JWH-200-d5 0.1 0.5 0.5-100 0.997-0.999 
A-796260 JWH-250 4-OH pentyl-D5 0.1 0.5 0.5-100 0.997-0.999 
UR-144 JWH-250 4-OH pentyl-D5 0.075 0.5 0.5-100 0.996-0.999 
Urine 
JWH-018 4-OH pentyl JWH-018 4-OH pentyl-D5 0.01 1.0 1.0-100 0.998-0.999 
JWH-073 3-OH butyl JWH-073 3-OH butyl-D5 0.05 1.0 1.0-100 0.998-0.999 
AM-2201 4-OH pentyl AM-2201 4-OH pentyl-D5 0.05 1.0 1.0-100 0.998-0.999 
JWH-250 4-OH pentyl JWH-250 4-OH pentyl-D5 0.05 1.0 1.0-100 0.998-0.999 
JWH-122 5-OH pentyl JWH-018 4-OH pentyl-D5 0.075 1.0 1.0-100 0.996-0.999 
JWH-210 5-OH pentyl JWH-250 4-OH pentyl-D5 0.075 1.0 1.0-100 0.996-0.999 
5F-AKB-48 (N-4 OH pentyl) JWH-250 4-OH pentyl-D5 0.1 1.0 1.0-100 0.997-0.999 
5F-PB-22 3-carboxyindole JWH-250 4-OH pentyl-D5 0.25 1.0 1.0-100 0.997-0.999 
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Figure 4.4: Calibration Curves for 10 SCs in Blood and 8 of their Metabolites in Urine 
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Figure 4.4 (continued): Calibration Curves for 10 SCs in Blood and 8 of their Metabolites in Urine 
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Figure 4.4 (continued): Calibration Curves for 10 SCs in Blood and 8 of their Metabolites in Urine 
 
 
 
112 
 
 
Figure 4.4 (continued): Calibration Curves for 10 SCs in Blood and 8 of their Metabolites in Urine 
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Figure 4.4 (continued): Calibration Curves for 10 SCs in Blood and 8 of their Metabolites in Urine 
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Figure 4.5: Residual Plots for 10 SCs in Blood and 8 of their Metabolites in Urine 
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Figure 4.5: (continued) Residual Plots for 10 SCs in Blood and 8 of their Metabolites in Urine 
  
116 
 
4.3.4 Selectivity and Specificity 
Typical endogenous components (e.g. proteins, lipids, minerals, salts and small 
molecules) are the most abundant source of possible interferants [210]. 
Selectivity studies were carried out using 10 drug-free sources of blood and urine 
(each) to be sure no endogenous interference occurred. Specificity studies were 
also carried out by spiking drug-free matrix with each analyte and internal 
standard individually. Exogenous interference from other drugs was evaluated by 
analysing drug-free matrix containing 12 of the most commonly detected drugs 
in forensic cases (tetrahydrocannabinol, amphetamine, cocaine, 
benzoylecgonine, anhydroecgonine methyl ester, ecgonine methyl ester, 
methadone, codeine, morphine, diazepam, gabapentin and mephedrone) at a 
concentration of 500 ng/mL. All these drugs were separately spiked into drug-
free blood and urine and extracted.      
Clean base lines with negligible matrix components were found. No interfering 
peaks were detected from the other common drugs at the retention times of any 
of the analytes used in both methods.     
4.3.5 Carryover 
Carryover was evaluated by triplicate injections of drug-free blood and urine 
extracts after two injections of extracts of blank blood containing parent SCs 
and drug-free urine containing SC metabolites at the highest concentration of 
the calibration range (100 ng/mL). No carryover was observed in any of the 
retention time windows corresponding with the transitions of SC parent 
compounds or their metabolites.  
4.3.6 Bias and Precision 
Intra- and inter-day bias and precision were assessed for both methods at three 
different concentrations (5, 40, and 75 ng/mL). Intra-and inter-day accuracy 
results for 10 parent SCs in blood and 8 of their metabolites in urine are 
presented in Table 4.3. Good accuracy was obtained for all analytes within the 
acceptable range of ±15% of the nominal concentrations. The intra-day accuracy 
ranged from 90.2-110.6% and 91.9-109.8% for blood and urine respectively. The 
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inter-day accuracy ranged from 87.1-110.7% and 87.4-108.8% for blood and urine 
respectively.  
Table 4.3: Intra- and Inter-Day Assay Accuracy Results for SCs in Blood (A) 
and SC Metabolites in Urine (B) at Low (5 ng/mL), Medium (40 
ng/mL) and High (100 ng/mL) concentrations 
Analyte 
Intra-day Accuracy (%) Inter-day Accuracy (%) 
Low 
(n=5) 
Mean 
Medium 
(n=5) 
Mean 
High 
(n=5) 
Mean 
Low 
(n=25) 
Mean 
Medium 
(n=25) 
Mean 
High 
(n=25) 
Mean 
(A) Blood 
JWH-018 105.5 94.1 96.8 94.5 93.4 93.6 
JWH-073 95.5 96.5 106.1 108.8 106.2 95.7 
JWH-250 96.2 99.1 104.2 101.2 103.4 95.4 
JWH-200 107.8 105.0 99.5 110.7 105.1 96.3 
5F-AKB-48 102.6 96.3 95.1 89.4 92.9 91.7 
5F-PB-22 95.8 98.0 101.7 92.7 89.7 88.4 
AM-1248 104.2 94.9 108.9 90.5 90.9 95.1 
AB-FUBINACA 96.3 97.2 91.2 88.8 91.2 92.6 
A-796260 110.6 105.2 92.4 92.4 93.1 94.4 
UR-144 90.2 95.7 94.3 87.1 94.5 96.2 
(B) Urine 
JWH-018 4-OH 
pentyl 
105.1 101.6 103.0 96.5 99.4 97.8 
JWH-073 3-OH 
butyl 
106.2 97.2 99.3 92.8 98.0 97.8 
AM-2201 4-OH 
pentyl 
104.0 99.1 95.1 89.9 98.0 94.9 
JWH-250 4-OH 
pentyl 
100.1 99.1 91.9 88.2 99.6 97.2 
JWH-122 5-OH 
pentyl 
99.5 92.0 96.1 104.6 88.4 95.4 
JWH-210 5-OH 
pentyl 
96.6 99.4 102.0 101.4 105.6 87.4 
5F-AKB-48 (N-4 
OH pentyl) 
109.8 103.0 96.2 98.1 101.4 98.8 
5F-PB-22 3-
carboxyindole 
94.1 105.0 104.0 108.8 96.3 94.8 
 
Precision values were acceptable and less than 15% for blood and urine methods 
(Table 4.4). The intra-day precision values were less than 9.5% and 9.0% for 
blood and urine respectively. The inter-day precision values for both methods 
were less than or equal to 13.5%.   
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Table 4.4: Intra- and Inter-Day Assay Precision Results for SCs in Blood (A) 
and SC Metabolites in Urine (B) at Low (5 ng/mL), Medium (40 ng/mL) and 
High (100 ng/mL) concentrations 
Analyte 
Intra-day Precision (%) Inter-day Precision (%) 
Low 
(n=5) 
Mean 
Medium 
(n=5) 
Mean 
High 
(n=5) 
Mean 
Low 
(n=25) 
Mean 
Medium 
(n=25) 
Mean 
High 
(n=25) 
Mean 
(A) Blood 
JWH-018 2.5 2.1 1.9 4.6 5.2 3.4 
JWH-073 4.5 2.2 4.1 6.2 7.1 6.9 
JWH-250 6.2 3.5 3.2 9.8 4.6 5.5 
JWH-200 3.7 3.1 2.7 4.9 7.8 6.7 
5F-AKB-48 4.7 5.3 4.2 7.7 7.1 6.3 
5F-PB-22 9.3 5.8 7.5 12.9 5.1 7.3 
AM-1248 3.3 4.6 2.1 9.6 6.6 6.8 
AB-FUBINACA 7.6 7.8 5.9 6.4 7.4 8.4 
A-796260 5.8 7.1 6.2 13.2 5.1 4.1 
UR-144 8.2 5.1 7.2 8.7 8.4 4.7 
(B) Urine 
JWH-018 4-OH 
pentyl 
8.9 4.6 4.5 10.2 3.4 4.3 
JWH-073 3-OH 
butyl 
7.0 3.6 6.3 9.7 2.4 3.1 
AM-2201 4-OH 
pentyl 
3.4 3.3 3.7 10.0 3.9 2.1 
JWH-250 4-OH 
pentyl 
3.3 1.0 7.0 7.3 2.4 4.7 
JWH-122 5-OH 
pentyl 
6.5 4.1 5.7 13.4 9.4 11.0 
JWH-210 5-OH 
pentyl 
6.8 1.9 2.8 4.4 10.8 5.9 
5F-AKB-48 (N-4 
OH pentyl) 
3.9 7.8 1.4 12.4 11.5 6.5 
5F-PB-22 3-
carboxyindole 
3.0 1.6 4.7 8.7 5.2 11.5 
 
 
4.3.7 Recovery and Matrix Effects 
The evaluation of recoveries and matrix effects was carried out at three (low, 
medium and high) concentrations within the linear range, using 10 different 
sources of urine and 10 different sources of whole blood. Recoveries and matrix 
effects were measured using the approach of Matuszewski et al.[269].  
Urine method recoveries meet the validation criteria. They were from 77.4 to 
108.1%; while matrix effects were from 81.1 to 108.0% for all analytes of 
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interest at concentrations of 5, 50 and 100 ng/mL. It is clear that the average 
value of the ion enhancement or ion suppression of all urinary metabolites 
investigated in this study were within the accepted limit of the validation 
procedure (±25%).       
For the blood method, the recoveries of parent SCs ranged from 71.1 to 126.3% 
and matrix effects were from 75.0 to 90.4% at concentrations of 5, 50 and 100 
ng/mL (except for UR-144 (48.9%-51.5%) and JWH-200 (136.3%-138.1%)). It was 
clear that UR-144 and JWH-200 both had unacceptable matrix effects when 
extracted from blood, despite the compensating effects of deuteron-labelled 
internal stanards. One potential reason for this unacceptable ion suppression of 
UR-144 and ion enhancement of JWH-200 might be because UR-144 is a late-
eluting compound. It was found that late-eluting interferents can appear in 
subsequent runs, leading to ion suppression [287]. This could arise from 
cholesterols, phospholipids or column components that elute during the later 
portion at the same time as these analytes [287]. It was very difficult to 
determine the actual reason for the unacceptable ion enhancement of JWH-200. 
However, the basicity of the morpholine ring of its structure may contribute in 
this issue [89].    
Results for recoveries and matrix effects are presented in Table 4.5. 
4.3.8 Stability 
Drugs can break down in a biological specimen even after collection to form 
other compounds [286]. Breakdown will lead to a reduction in the concentration 
of the original drug and an increase in the concentrations of the 
breakdown/instability products. Breakdown involves enzymatic or chemical 
processes (e.g. oxidation, hydrolysis and de-esterification), typically in blood. In 
some extreme circumstances, the original drug can completely disappear. The 
stability of parent SCs in blood and their metabolites in urine was evaluated 
under various conditions. 
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Table 4.5: Recoveries and Matrix Effects for SCs in Blood (A) and SC 
Metabolites in Urine (B) Using 3 Different Concentrations (5, 50 and 100 
ng/mL) and 10 Different Drug-free Matrices (n=5 per Concentrations per 
Matrix). 
Analyte 
Recovery (%) Matrix effect (%) 
Low 
(n=5) 
Mean 
Medium 
(n=5) 
Mean 
High 
(n=5) 
Mean 
Low 
(n=5) 
Mean 
Medium 
(n=5) 
Mean 
High 
(n=5) 
Mean 
(A) Blood 
JWH-018 75.5±4 76.9±4 74.5±3 77.5±2 75.0±3 76.8±3 
JWH-073 84.1±3 83.2±3 84.4±3 79.9±3 80.0±2 82.7±2 
JWH-250 100.5±4 97.5±3 97.9±2 86.1±4 84.9±4 87.2±3 
JWH-200 72.7±5 71.1±4 74.2±4 137.4±7 136.3±4 138.1±7 
5F-AKB-48 118.9±3 120.1±2 122.1±2 75.5±3 77.2±2 77.7±2 
5F-PB-22 105.2±2 100.0±3 101.1±2 84.9±3 85.1±3 84.4±4 
AM-1248 80.1±3 79.5±3 84.2±3 86.2±4 85.2±3 84.2±3 
AB-FUBINACA 78.1±3 81.5±4 81.3±4 84.7±5 83.3±3 90.4±4 
A-796260 84.4±3 79.5±3 77.4±4 84.4±3 89.5±4 88.0±3 
UR-144 124.2±5 126.3±5 120.4±3 50.9±7 51.5±5 48.9±6 
(B) Urine 
JWH-018 4-OH 
pentyl 
86.7±3 84.4±2 100.1±2 82.6±2 91.9±3 93.0±2 
JWH-073 3-OH 
butyl 
93.7±2 95.2±3 108.1±3 84.8±3 94.2±2 88.2±2 
AM-2201 4-OH 
pentyl 
89.5±2 80.6±2 100.7±2 81.9±3 83.4±2 90.1±3 
JWH-250 4-OH 
pentyl 
87.1±2 91.8±3 107.9±3 81.8±3 91.4±3 94.2±3 
JWH-122 5-OH 
pentyl 
81.2±4 96.7±5 100.4±3 81.2±3 86.8±3 84.0±4 
JWH-210 5-OH 
pentyl 
79.3±4 79.2±3 86.7±4 93.2±4 81.1±3 90.3±3 
5F-AKB-48 (N-4 
OH pentyl) 
89.1±3 80.8±2 93.1±4 89.7±2 93.1±2 84.5±2 
5F-PB-22 3-
carboxyindole 
77.4±4 83.1±4 82.3±3 87.7±3 108.0±4 89.7±3 
 
 
4.3.8.1 Benchtop Stability 
For the urine, the stability results were within the acceptance criteria of ±10%, 
which means that all metabolites of SCs investigated in this study are considered 
stable in urine at room temperature (18ºC) for up to 24 hours. For blood, all 
parent SCs were stable at room temperature for 24 hours except UR-144 and 5F-
PB-22, which showed degradation of 26.9 and 33.6% of their nominal 
concentration, respectively (Table 4.6).  
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UR-144 has a tetramethylcyclopropyl group containing ring strain, which is a kind 
of instability that occurs when bonds in a molecule form angles that are 
abnormal, and hence it is prone to ring-opening (i.e. degradation) [200]. 5F-PB-
22 was reported to degrade significantly due to the instability of the ester bond 
in its structure [88]. Ester groups are reactive and easily hydrolysed. Many 
parameters can contribute in this issue such as enzymatic processes in blood or 
reactions during sample preparation [88]. Peters et al. [288] reported that most 
drugs are probably stable in biological fluids when they are kept in appropriate 
storage conditions. However, some drugs which contain ester bonds are usually 
unstable in body fluids.  
4.3.8.2 Freeze-thaw Cycle Stability 
All parent SCs in blood and metabolites in urine were stable after being 
subjected to three freeze-thaw cycles (from -20C to room temperature) (Table 
4.6). 
4.3.8.3 In-Process Stability    
Analyte autosampler stability was assessed by re-injecting extracted low and 
high QC specimens in triplicate after 24 hours, and comparing with the time zero 
concentrations. Extracts of blood and urine samples were stored on the 
autosampler until the next analysis. In urine extracts, no significant degradation 
of the analytes was observed in the autosampler (at a room temperature of 
approximately 20ºC) for up to 24 hours. Although UR-144 and 5F-PB-22 were not 
stable in whole blood their stability was acceptable after extraction and 
reconstitution in 200 μL of 50:50 mobile phase mixture.  
Generally, the decrease in concentration is dependent on many factors including 
solvents, compounds, concentrations, the sample matrices and storage 
temperature.  
Table 4.6 summarises the stability results. 
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Table 4.6: Stability of Blood (A) and Urine (B) Analytes 
Analyte 
24 h Room 
Temperature (%) 
Freeze- Thaw 
Cycles (%) 
24 h Autosampler 
Stability (%) 
Low 
(n=3) 
Mean 
High 
(n=3) 
Mean 
Low 
(n=3) 
Mean 
High 
(n=3) 
Mean 
Low 
(n=3) 
Mean 
High 
(n=3) 
Mean 
(A) Blood 
JWH-018 92.3±4 91.5±3 95.5±4 93.7±2 91.2±4 93.1±2 
JWH-073 90.1±4 90.5±4 96.1±3 95.1±4 93.5±3 92.8±4 
JWH-250 90.9±3 91.1±4 97.8±3 94.6±3 95.2±4 96.0±3 
JWH-200 94.0±5 94.9±3 101.2±4 
105.1±
3 
96.1±4 92.1±3 
5F-AKB-48 93.2±2 91.4±2 94.8±3 95.4±3 92.2±4 91.5±3 
5F-PB-22 70.5±4 73.1±6 92.4±5 90.4±4 93.2±3 91.4±5 
AM-1248 92.4±3 92.0±4 93.2±4 97.8±5 91.2±5 94.7±5 
AB-FUBINACA 92.4±4 94.4±3 98.1±3 
100.5±
3 
92.4±6 95.1±4 
A-796260 95.5±6 93.5±5 97.9±5 96.4±3 92.2±7 91.9±4 
UR-144 68.4±5 66.4±3 92.4±3 91.7±3 91.6±4 90.4±5 
(B) Urine 
JWH-018 4-OH 
pentyl 
99.4±3 99.2±2 105.8±3 
100.4±
2 
98.2±2 103.9±2 
JWH-073 3-OH 
butyl 
96.2±4 89.8±2 96.3±3 93.6±3 97.6±4 96.6±4 
AM-2201 4-OH 
pentyl 
88.2±2 91.9±2 100.7±3 89.5±2 94.9±3 100.8±3 
JWH-250 4-OH 
pentyl 
100.8±3 94.5±3 93.6±4 90.8±3 101.0±2 99.1±3 
JWH-122 5-OH 
pentyl 
92.6±3 88.6±2 89.6±3 91.9±3 96.2±2 94.2±2 
JWH-210 5-OH 
pentyl 
94.6±4 88.3±5 94.5±4 90.3±3 95.8±5 95.0±3 
5F-AKB-48 (N-4 
OH pentyl) 
91.2±3 88.8±3 92.2±4 92.5±3 98.5±4 97.1±4 
5F-PB-22 3-
carboxyindole 
90.5±4 88.4±3 94.5±3 91.4±3 92.9±3 94.1±3 
 
4.3.8.4 Long Term Stability Study of 5F-AKB-48 (N-4 OH pentyl) and 5F-
PB-22 3-carboxyindole in Methanol/Acetonitrile Solutions for Up to 
3 Months  
This study showed good stability for 5F-AKB-48 (N-4 OH pentyl) in both 
acetonitrile and methanol stock solutions under three different conditions; at 
room temperature (18±1ºC), in the fridge at (4±1ºC), and in the freezer at -
20±1ºC for 3 months. 
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5F-PB-22 3-carboxyindole exhibited good stability in acetonitrile stock solutions 
under all storage conditions during the investigated time frame (Figure 4.6), 
whereas in methanol stock solutions lost 9% of its original concentration by the 
end of the 10th week at room temperature (Figure 4.7). 5F-PB-22 3-
carboxyindole may be more susceptible to instability than 5F-AKB-48 (N-4 OH 
pentyl) which can be improved by using acetonitrile as a solvent. 
 
Figure 4.6: Stability of 5F-PB-22 3-carboxyindole in ACN Stock Solution 
 
 
   Figure 4.7: Stability of 5F-PB-22 3-carboxyindole in MeOH Stock Solution 
124 
 
4.4 Conclusions  
The LC-MS/MS method developed has been validated according to SWGTOX 
Standard Practices for Method Validation in Forensic Toxicology [269] for the 
simultaneous determination of 10 SCs in whole blood and 8 corresponding 
metabolites in urine. All compounds were successfully extracted using LLE and 
achieved recoveries greater than 71.1% and 77.4% for all drugs in blood and 
urine respectively. The method was developed for a small sample volume (0.5 
mL) and achieved acceptable matrix effects (within ±25%) for all drugs (except 
UR-144 and JWH-200). Therefore, the method is invalid for the quantitation for 
these two drugs. The present study suggests that the difference in chemical 
structure of SCs produced the variation in recoveries with the LLE.   
Although a large number of analytes were included in the blood and urine 
methods, acceptance criteria for linearity, accuracy, precision, and recovery 
were achieved for all analytes. There were no endogenous or exogenous 
interferences which produced false-positive results for any of the analytes of 
interest. Since all analytes showed satisfactory stability at −20C, it is highly 
recommended to store samples in freezer as well as to transport samples frozen 
to avoid any significant decrease in concentration of analytes of interest during 
transportation. The influence of storage methods on the stability of 5F-AKB-48 
(N-4 OH pentyl) and 5F-PB-22 3-carboxyindole in methanol and acetonitrile stock 
solutions was evaluated and found 5F-PB-22 3-carboxyindole lost about 9% in 
methanol solution after 10 weeks at room temperature.  
Implementation of both methods can provide significant information for 
interpreting the forensic toxicological results for the toxicologist. The analytical 
results from urine can be used to indicate past exposure to SCs and may provide 
information concerning SCs consumed. In contrast, the blood results can identify 
the specific parent SCs used and blood concentrations are very useful in 
estimating the levels of impairment based on pharmacological activity. The 
analytical results from blood are critical in post-mortem investigations. 
Simultaneous methods can be a great advantage for forensic toxicology work 
where saving of effort, time and consumables are very important to obtain 
targets and meet deadlines.  
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Chapter 5 - Synthetic Cannabinoids: Case Samples 
Prevalence studies of illicit drug use are most often performed by collecting self-
reported data. However, these data usually suffer from several limitations. Use 
of self-reporting alone reduces the reliability of a prevalence study. In addition, 
the information obtained from a survey is usually insufficient to achieve all the 
aims of most studies. For example, it is very difficult to know the type of SCs 
that have been ingested. The type(s) of SCs and the concentration(s) in the body 
can be obtained by analysis of biological specimens. This information is very 
useful to the forensic community in different aspects. It may assist clinicians in 
Emergency Departments in toxidrome cases and evaluating their service. It also 
may help to understand the trend of SC use in order to address their sale and 
supply. In addition, it may help to order the priorities for national programmes 
concerning this issue. For these reasons the analysis of biological specimens in 
prevalence studies of illicit drug use has increased during the last decades, 
either replacing the use of questionnaires/interviews, or used as a supplement 
[289]. 
Analysis of biological matrices is a necessary part of forensic toxicology to 
decide whether an individual has been under the influence of any substance 
during a particular event that might have influenced his or her behaviour (e.g. 
medico–legal cases). In this project, blood and/or urine samples were used for 
the prevalence studies of SC use in Scotland and Saudi Arabia. 
5.1 Synthetic Cannabinoids in Scotland: Case Samples 
5.1.1 Introduction 
NPS including SCs are mainly produced in China and India and distributed to the 
European networks for ongoing supply to Scotland [290]. Measuring the scale of 
the drug market in Scotland is difficult due to its illicit nature. The evidence 
base on NPS including SCs, in respect of prevalence, is relatively scarce 
compared to well-established drugs (e.g heroin) in Scotland [291]. However, 
existing evidence suggests that use of NPS including SCs is relatively low among 
the general adult population in Scotland compared with use of traditional illicit 
drugs [291].   
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The prevalence of SCs in Scotland in earlier studies has been based on self-
report. Currently, there is limited epidemiological research on SC use in 
Scotland. The Scottish Schools Adolescent Lifestyle and Substance Use Survey 
(SALSUS) conducted a survey study targeting pupils in Secondary Schools, Years 2 
and 4, in 2011 and found approximately 1 and 2% of these 13- and 15-year-olds 
respectively, had used any NPS [292]. In the most recent SALSUS survey in 2013, 
4% of 15-year-olds reported having used one or more NPS at least once in their 
lifetime: the most commonly used NPS were mephedrone, SCs and salvia [165]. 
The prevalence of these new drugs among 15-year-olds seems to be an upward 
trend. Among 13-year-olds, less than 1% reported ever using one or more of the 
NPS, with the most commonly used NPS in this age group being SCs [165].   
According to the 2012/13 Scottish Crime and Justice Survey (SCJS), in 2013, 0.5% 
of all adults reported using any NPS in Scotland in the year prior to the survey 
(conducted between April 2012 and March 2013); NPS included in the survey 
were SCs, khat, salvia divinorum, benzylpiperazine (BZP) and gamma–
butyrolactone (GBL) [293]. This compares to 5.1% for cannabis, 1.7% for cocaine, 
and 1.3% for ecstasy. However, they found NPS use to be more prevalent in the 
16-24 age group than those aged 25-44 [291]. In 2015, Edinburgh was branded 
“legal high capital of the UK”, according to Members of the Scottish 
Parliament (MSPs), with approximately 15 head shops selling NPS including SC 
products across the city [294]. The above studies gave an indication of the 
prevalence of NPS-use including SCs in Scotland. However, beyond these 
statistics, we know very little about NPS and SCs. SALSUS is a survey of school 
pupils, while SCJS targets private households. Those with precarious living 
arrangements and/or chaotic drug use are likely to be under-represented in 
these figures [291]. In addition, the reliability of data is problematic due to the 
illicit nature of drug abuse. For these reasons, they are more an indication of 
scale rather than true prevalence.   
Although the scale of NPS-use in the general population in Scotland appears to 
be low, the picture is less clear within some subgroups of the general population 
(e.g. A&E patients prisoners) [290, 291]. In addition, the internet enables NPS 
distributors to reach new consumers directly, across borders. In 2013, the 
EMCDDA identified 651 online stores selling NPS including SC products across the 
EU [295]. The proliferation of online retailers and head shops has facilitated the 
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emergence of a range of SCs in Scotland. The diversity in the NPS market might 
cause variation between user groups along this variable. 
In response to the NPS ‘phenomenon’ and to tackle the sale and supply of NPS in 
Scotland, the Scottish Government established an Expert Review Group in order 
to review the powers which were currently available. In 2014, they also 
established an NPS Evidence Group to address existing gaps in knowledge 
relating to NPS, which included improving information sharing on NPS between 
different agencies and addressing the sale and supply of NPS [296].  
Police Scotland works with EU and UK partners in law enforcement to address 
the supply sources and transit countries of NPS [290]. Police Scotland also works 
in partnership with the local communities they serve to monitor and share 
information about NPS to restrict their supply. Police Scotland’s ‘day of action 
on NPS’ on 22 August 2014 identified 37 different chemical substances present 
across hundreds of NPS packets across the country, the majority of these being 
SCs [290]. On November 2015, Edinburgh City Council seized over £50,000 worth 
of NPS including SC products as part of a major crackdown on legal highs [297]. 
The Scottish Drug Forum in Glasgow and Crew in Edinburgh provide up-to-date 
information on drugs and aim to raise awareness and improve understanding of 
drug issues. They have raised concerns regarding NPS including SCs misused on 
the street [52]. Stakeholders across Scotland have raised concerns about the use 
of NPS and SCs, especially among injecting drug users, adults with mental health 
issues and vulnerable young people [291]. These groups are unlikely to be 
captured by targeted online surveys or by national household or school surveys.    
In order to evaluate the emerging drugs of SCs in Scotland, a study was carried 
out among 3 different subpopulations, A&E patients, prisoners and fatalities, to 
give a better picture of this new phenomenon. Analytical investigations of SCs 
within these ‘at-risk’ groups can help in outlining the scale of the problem that 
is critical to prioritising resources around harm treatment and prevention. 
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5.1.2 Accident and Emergency Samples, Spring 2014 
5.1.2.1 Introduction 
Many studies [298-304] have shown that illicit drugs are often found in injury 
patients in A&E, which makes problematic drug use a significant burden on 
health organisations. Few prevalence studies of illicit drug use either by blood 
and urine toxicology or by self-report have been carried out among A&E 
patients. These studies have also demonstrated large variations in prevalence 
rates that could be explained by the measures used, time lapse between A&E 
visits, period of data collection, age range, locale and/or country of research 
and types of drugs tested [298]. According to these studies, the most prevalent 
traditional illicit drugs in the USA, Norway and the UK were cannabis, cocaine, 
opiates and amphetamines. Some studies show a relationship between a positive 
screen for illicit drug use and demographic characteristics of emergency room 
patients. For example, Lindenbaum et al. [304] found that drug tests were most 
likely to be positive for males, and in persons aged 21–30 years.     
The prevalence of alcohol and drug use among A&E patients was well 
investigated by blood and urine toxicology and self-report studies. In contrast, 
NPS including SCs have been the subject of very limited studies. However, there 
is increasing evidence of the role that NPS play in hospital emergencies in 
Europe [295]. In July 2015, over 200 persons were hospitalised in Poland 
following use of “MOCARZ”. Some of these cases were in a very serious state of 
health and one fatal case has been reported [305]. The forensic examination of 
samples of MOCARZ revealed the presence of SC compounds (e.g. 5F-PB-22). 
Heath et al. [145] reported 2 cases of acute intoxication caused by a SCs in two 
adolescents presenting to the A&E.  
The prevalence of SC use among A&E patients based on self-reporting was 
evaluated by the Global Drug Survey (GDS). The annual GDS survey runs in 
November each year for approximately 6 weeks. GDS2014 [306] revealed that 
SCs were more likely to leave people needing Accident and Emergency Medical 
Treatment (A&E MT) than any other drug group explored in 2014. They found 
that compared to traditional cannabis, the use of SC products is associated with 
a 30 times higher risk of seeking A&E MT. The rates of seeking A&E MT for drugs 
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of abuse varied widely; in the recent survey GDS2015 [307] which was conducted 
during November/December 2015 with over 100,000 people, 3.5% of this world 
population had sought A&E MT following the use of SCs in the last 12 months 
(Figure 5.1). 
 
Figure 5.1: Global Percentage of Accident and Emergency Attendees who had 
Sought Medical Treatment Following the Use of Drugs/alcohol in 2014 (Source 
of Information: GDS) 
 
Very little medical literature currently exists studying the prevalence of SC use 
among A&E patients based on the analysis of biological samples. In a recent 
study, Helander et al. [308] monitored the occurrence and trends of NPS 
including SCs among emergency room patients in Sweden based on blood and 
urine toxicology. Besides traditional substances such as amphetamines, cannabis 
and ethanol, many NPS were detected including SCs, synthetic cathinones, 
ketamine and related substances, piperazines, GABA analogues, opioid-related 
substances, substituted phenethylamines and hallucinogenic tryptamines. They 
observed widespread use of many different NPS by mainly adolescents and young 
adults.    
In Scotland, there is lack of prevalence studies among these patients. In order to 
evaluate the prevalence of SCs among A&E patients in Scotland, a study was 
carried out in collaboration with Glasgow Royal Infirmary. The present study is 
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the first prevalence study to be carried out among emergency room patients in 
Scotland to assess the prevalence of SCs using urine analysis to confirm drug 
consumption.      
5.1.2.2 Aim 
The aim of this study was to assess the occurrence and trends of SCs in patients 
presenting to A&E with suspected acute intoxication. The study took place over 
a 3 month period (01/05/2014 to 29/07/2014). The prospective study was 
performed in collaboration with a large emergency department at Glasgow Royal 
Infirmary, which has approximately 86,000 attendances each year. 
5.1.2.3 Ethical Considerations 
Advice was obtained from the West of Scotland Research Ethics Committee who 
considered the study a “service evaluation” ” i.e. evaluating the A&E service. All 
results were reported to the A&E clinician so notes could be put on the patient’s 
record. Consent was waived as the study was considered a service development 
study and achievement of standard of care. Patients under 16 were excluded 
from the study.    
5.1.2.4 Study Design 
Participants were all A&E patients who were suspected of acute intoxication due 
to drugs either from the case history of the patient or from clinical observations. 
Urine samples were initially collected by Glasgow Royal Infirmary and stored in 
additive-free containers. Patient’s data and urine samples were encoded with a 
unique code number to protect the patient’s confidentiality. Data analysis was 
performed using Excel (Microsoft 2010). 
On receipt at Forensic Medicine and Science, urine samples were stored at -20°C 
until analysis. The samples were screened for NPS (SCs were not included) by 
Lowe et al. [309] using LC-HR/MS. The samples were then analysed for of the 
presence of SCs using the present method.   
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5.1.2.5 Results 
A total of 93 urine samples was collected from 80 patients presenting in the 
A&E. Case histories, which included gender, age, prescribed drugs, substance(s) 
used (self-report) and information on whether they were subsequently admitted 
to hospital or discharged from the A&E, were available for only 75 patients. 
Forty-nine per cent (37) of the patients were referred by ambulance, 32% (24) by 
police and 19% (14) by self-referral. 36% (27) of patients required hospital 
admission whereas 64% (48) were discharged from the emergency department. 
Seventy-two per cent (54) of the patients were male aged 17 to 55 (median 23) 
and (28%) 21 were female aged 16 to 47 (median 20). In only 5% (4) of these 
cases was there any evidence of SC use. They all tested positive for 5F-PB-22 3-
carboxyindole with concentrations of 7, 24, 60 and 268 ng/mL. Figure 5.2 shows 
the MRM ion chromatograms for an authentic urine specimen containing 60 
ng/mL 5F-PB-22 3-carboxyindole and its internal standard.  
 
Figure 5.2: LC-MS/MS MRM Chromatograms for 5F-PB-22 3-carboxyindole in an A&E Case 
Urine Sample (60 ng/mL), and its Internal Standard 
Quantitive 
Qualitative 
ISD 
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Three patients had reported consumption of an NPS (referred to as a legal high 
in their own terms). Table 5.1 demonstrates the demographic and toxicological 
data for these cases.  
Table 5.1: Demographic and Toxicological Data for 4 SC Metabolite Positive 
Cases 
Case Sex Age Positive SCs 
Other Confirmed 
Drugs* 
Conc. 
ng/mL 
1 F 20 5F-PB-22 3-carboxyindole 
Citalopram, 
Methedrone 
7 
2 F 29 5F-PB-22 3-carboxyindole - 24 
3 F 19 5F-PB-22 3-carboxyindole - 60 
4 M 40 5F-PB-22 3-carboxyindole 
Mirtazapine, 
Methadone, Diazepam, 
Amitripytline 
268 
* Tested by Lowe et al. [309]. 
 
5.1.2.6 Discussion 
Analysis and identification of SCs in biological specimens remains an ongoing 
challenge for forensic toxicologists. Reference standards for metabolites of SCs 
are not readily available. Therefore, urine screening methods have usually 
covered a limited panel of these analytes that can cause false negative results 
for SCs due to the illicit production of newer SCs. Implementing standard 
screening panels for SCs remains costly and time consuming. For these reasons, 
targeting the most appropriate substances is the key for the detection of SCs in 
biological specimens. The Scottish Police Authority kindly provided very useful 
information about the most significant SCs that are circulating and they are 
seeing in seizures in Scotland which helped target the analysis.  
In the present study, among those 80 patients who were suspected of being 
exposed to a recreational substance, 4 were confirmed positive for 5F-PB-22 3-
carboxyindole. One of these tested positive for another NPS (Methedrone). Two 
SCs samples were found in combination with other drugs. Diazepam and 
amitriptyline were illicit but methadone and mirtazapine were prescribed. Both 
of these cases were found positive for at least one antidepressant drug. Two 
samples tested positive for only SCs. 
In poly-drug intoxications, it is difficult to associate the clinical symptoms with 
one specific substance. Poly-drug use can be defined as the use of more than 
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one drug at the same time. Poly-drug detection may suggest the use of SCs for 
their affordability and availability and not necessarily to avoid the law due to 
their limited detection in common drug-screening tests.  
The presence of only one SC was detected in these cases. However it cannot be 
excluded that other SCs might have been present in the samples at either 
extremely low concentrations, or not included in the testing method. It is not 
surprising that most results of earlier studies vary from the present study 
regarding the type of SC compounds detected due to the variation in 
international SC drug scheduling, rapid production of newer SCs, and the 
targeting of newer 5F-AKB-48 and 5F-PB-22 metabolites.  
The results showed a higher SC detection rate in females than males although 
the data is limited. One patient reported using only ecstasy and it is unclear 
whether she was not aware she had ingested an SC or if there was deliberate 
misreporting by this patient. The rest of the cases reported using legal highs 
and/or SCs. Hospital admission was not required for any of these cases. 
The urine samples were screened in the Surveillance of Drugs of Abuse Study 
(SODAS) for a panel of NPS (SCs were not included) by Lowe et al. [309]. They 
found that a significant percentage (70%, n=56) of patients who were enrolled in 
the study had samples which were positive for more commonly encountered 
drugs of abuse, predominantly cocaine, whereas a small percentage (20%, n=16) 
tested positive for NPS, predominantly the ecstasy (MDMA) “mimics,” such as 
PMA/PMMA, TFMPP and MDAI, and 30% (n=24) tested negative. All NPS samples 
were found in combination with other drugs.  
Gaining insight into the prevalence of these drugs in clinical cases, particularly 
in patients who presented with a clinical toxidrome suggestive of acute drug 
intoxication or who reported drug consumption for recreational purposes, is 
important. The present study had some limitations. It was performed at a single 
hospital and involved a small number of cases, which may limit its 
representation of the whole population in Scotland. Due to a lack of reference 
standards some SCs may not have been detected. 
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5.1.3 Accident and Emergency Samples, June-December 2015 
5.1.3.1 Introduction 
This study was an extension to the previous study that targeted A&E patients and 
the second study was conducted around 1 year after the first over a longer 
period of time. It is clear that the analysis of biological samples from individuals 
suspected of using SC products in different periods can give a better picture of 
which chemicals are ingested in A&E cases. This study was carried out in 
collaboration with another project dealing with a new SC (MDMB-CHMICA). 
In the most recent report [310], during 2010–2015, a total of 42,138 cases of 
toxic exposure were recorded by 101 participating hospitals in the US. Among 
these, 456 cases involved SCs. 379 (83.1%) patients were male. 125 (27.4%) 
occurred in persons aged 13–18 years.   
5.1.3.2 Aim 
The aim of this study was to assess the trends of SCs in patients presenting to 
the A&E of Glasgow Royal Infirmary with suspected toxicological ingestion, using 
the analysis of their blood and/or urine samples. The study took place over a 6-
months period in 2015 and compared analysis of their blood and urine samples 
with collected information about their clinical toxicity, symptoms and associated 
health hazards.  
5.1.3.3 Study Design 
Participants were A&E patients who were suspected of acute intoxication due to 
SCs either from the case history of the patient or based on clinical observations. 
Unpreserved blood and urine samples were obtained during the clinical 
management of these A&E patients. Blood and urine samples were transferred to 
Forensic Medicine and Science (FMS), University of Glasgow, and stored between 
2 and 8°C prior to analysis. Case histories including gender, age and 
circumstances were included with each sample.   
The specimens were analysed for SCs using the method detailed in Chapter 4.  
Due to further intelligence on a new drug, MDMB-CHMICA, they were further 
analysed as reported by Seywright et al. [311].  
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5.1.3.4 Results 
Blood and/or urine samples were analysed from 34 patients out of a total of 98 
patients presenting in the A&E of Glasgow Royal Infirmary in the UK, between 
the 3 June and the 9 December 2015 with suspected toxicological ingestion due 
to SCs. It was not possible to analyse all the samples for SCs because of the 
limited sample volume and the need to test them for other drugs. There was no 
information about the way of referral. 19 cases were confirmed positive for at 
least one SC. MDMB-CHMICA results are quoted from the paper by Seywright et 
al. [311]. These cases are detailed in Table 5.2.  
Only 2 cases out of the 19 cases positive for SCs were female, aged 16 and 20. 
The majority of positive cases for SCs (17) were males aged 15 to 55 (median 
20). The most prevalent substance found in combination with SCs in the samples 
tested was alcohol (26.3%). 
5.1.3.5 Discussion 
19 cases out of 34 were found positive for at least one SC. 5F-AKB-48, 5F-PB-22 
and MDMB-CHMICA were detected in 9, 3 and 9 cases respectively. Patients 
reported using several Spice products including “Damnation”, “Black Mamba”, 
“Sweet Leaf” and “Vertex”. At that time, some of these products were freely 
available in Scotland in local shops (e.g. newsagents, e-cigarette shops) as well 
as online [47]. “Damnation”, also known as “Exodus Damnation” and “Black 
Mamba”, contained a blend of more than one cannabinoid [52]. During the 
period (21/06/2014 to 31/03/2015), Crew [52] collected 337 NPS packets, of 
which 93.8% were picked up from the streets surrounding Crew (in Edinburgh). 
They found 155 (46%) of the packets were SC compounds, mostly 5F-AKB-48 and 
5F-PB-22. According to the listed ingredients, both “Exodus Damnation” and 
“Black Mamba” contained 5F-AKB-48 and 5F-PB-22. “Vertex” is one of the Spice 
products family. Online stores sold various “Vertex” brands such as “Space Cadet 
Edition” and “Pirate Edition”. Media and online stores indicated that “Vertex” 
products contained 5F-AKB-48 and/or AB–CHMINACA. However, the packet list of 
ingredients in Spice products should not be relied on because their chemical 
constituents may change over time (See Chapter 2.3.1).  
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Table 5.2: Details of A&E Cases Positive for SCs 
Case 
Date 
Collected 
Gender 
Age 
(years) 
Sample SCs detected* 
Conc. 
ng/mL 
Circumstances/ 
Other Substances Present 
1 
03/06/15 
M 25 
Blood 5F-AKB-48 2 
Ingestion of “Vertex” product. 
04/06/15 Urine 5F-PB-22 3-carboxyindole 20 
2 
05/06/15 
M 15 
Blood 5F-AKB-48 1 
Ingestion of “Damnation” product. 
06/06/15 Urine 
5F-AKB-48 (N-4 OH 
pentyl), 
5F-PB-22 3-carboxyindole 
<1, 
5 
3 07/06/15 M 20 Blood 5F-AKB-48 1 Ingestion of “Damnation” product. 
4 15/06/15 M 23 Blood 5F-AKB-48 3 
Ingestion of “Black Mamba” 
product. 
Ethanol 
5 30/06/15 M 18 Urine 5F-PB-22 3-carboxyindole <1 
Ingestion of “Exodus” product. 
Ethanol 
6 30/06/15 M 55 
Blood 5F-PB-22 3-carboxyindole Present 
Ingestion of “Exodus Damnation” 
product. Urine 
5F-AKB-48 (N-4 OH 
pentyl), 
5F-PB-22 3-carboxyindole 
<1, 
<1 
7 20/08/15 F 20 Blood MDMB-CHMICA 5 
Ingestion of “Sweet Leaf” product. 
Ethanol and Diazepam 
8 28/08/15 M 18 Blood 5F-AKB-48 <0.5 
Ingestion of “Exodus Damnation” 
and “anniliation” products. 
9 29/08/15 M 41 Blood 
5F-PB-22, 
5F-AKB-48 
<0.5, 
<0.5 
Ingestion of “Black Mamba” 
product. 
* MDMB-CHMICA tested by Seywright et al. [311].  
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Table 5.2: Details of A&E Cases Positive for SCs (Continued…)  
Case 
Date 
Collected 
Gender 
Age 
(years) 
Sample Positive SCs* 
Conc 
ng/mL 
Circumstances/ 
Other Substances Present 
10 01/09/15 M 41 Blood 
MDMB-CHMICA, 
5F-AKB-48, 
5F-PB22 3-carboxyindole, 
5F-PB-22 
22, 
<0.5, 
Present, 
<0.5 
Ingestion of “Black Mamba” 
product. 
11 01/09/15 M 25 Blood 
5F-AKB-48, 
MDMB-CHMICA 
<0.5, 
<5 
Ingestion of “Sweet Leaf” and 
“Saint Row” products. 
Ethanol and cannabis 
12 22/09/15 M 15 Blood MDMB-CHMICA <2 Ingestion of “Red Exodus” product. 
13 23/09/15 M 43 Blood 5F-AKB-48 <0.5 
Mixed cannabinoid use suggested at 
ED 
14 15/10/15 M 18 Blood 
AKB-48 metabolite, 
5F-PB-22 
<0.5, 
<0.5 
Ingestion of “Exodus Damnation” 
product. 
15 16/10/15 M 15 Blood MDMB-CHMICA <2 Ingestion of “Red Exodus” product. 
16 18/10/15 M 18 Blood MDMB-CHMICA 2 
Ingestion of “Damnation” product. 
Ethanol 
17 18/10/15 F 16 Blood MDMB-CHMICA <1 
Ingestion of “Red Exodus” product. 
Ethanol and cannabis 
18 12/11/15 M 24 Blood MDMB-CHMICA 1 
Ingestion of “Obliteration” product. 
Cannabis, diazepam, 
desmethyldiazepam, morphine 
19 19/11/15 M 20 Blood MDMB-CHMICA 4 
Ingestion of K2 product. 
Cannabis, diazepam, 
desmethyldiazepam 
 * MDMB-CHMICA tested by Seywright et al. [311].  
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The absence of the parent 5F-PB-22 in blood samples in cases 1 and 2 despite 
the presence of its major metabolite 5F-PB-22 3-carboxyindole in urine, 
highlights the rapid metabolism of 5F-PB-22 [88] and/or may be due to the 
instability of the ester bond. The stability of 5F-PB-22 in blood samples was 
reported in this work in Chapter 4 and the same finding was observed the 
current study. The elevated temperatures during smoking of products containing 
5F-PB-22 might lead to pyrolysis of some percentage of the parent compound 
[88]. Decomposition as a result of incorrect storage conditions may lead to false 
negatives as well. This may lead to misinterpretation in forensic settings, when 
proof of compound intake is required. 
The metabolism of 5F-AKB-48 has been identified using human liver microsomal 
incubation, and found the major metabolites were mono, di and tri-hydroxylated 
[58]. Only one MRM transition (384.2 > 135.0) was found for the identification 
and quantification of 5F-AKB-48 as a unique indicator of the parent drug. Figure 
5.3 shows an example of 5F-AKB-48 detected in A&E blood case samples. Holm 
et al. [58] and Vikingsson et al. [312] also used only one product ion for 5F-AKB-
48. In this case, strict identification criteria should be used to avoid 
misidentification. This is very important in forensic toxicology, particularly for 
clinicians in the A&E that often needs reliable results to treat patients who have 
taken these new drugs safely. In addition, law courts rely on toxicological 
analytical results, therefore the confirmation of identity of a particular drug in a 
given matrix should be reliable and objective [313]. The following paragraphs 
discuss the identification criteria which have been used.     
Interference occurring from endogenous components or from another drug that 
shares the same molecular mass is the most undesired problem. Although the 
presence of interference is rare in LC-MS/MS, which is highly recommended as a 
confirmatory technique, wherever practical [248], decreasing the HPLC run time 
to increase the throughput can lead to an increase in the possibility of matrix 
effects from co-eluting endogenous components. The method has to be able to 
discriminate between the analytes of interest and all interfering components 
that could possibly occur in the biological sample. 
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Figure 5.3: LC-MS/MS MRM Chromatograms for 5F-AKB-48 in an A&E Case 
Blood Sample (1 ng/mL) and its Internal Standard 
 
LC-MS/MS libraries created in-house in most forensic laboratories depend on 
known certified standards and real cases results [314]. Manual optimisation of 
LC-MS/MS parameters for an individual analyte is available using an infusion 
pump. The identification of analytes of interest can be achieved with a certified 
standard and/or published mass spectra. However, the latter is not 
recommended since it is possible that the published data is incorrect or that 
there are differences caused by the type of instrumentation and assay method 
[314]. It would appear that the creation of a universal LC-MS and LC-MS/MS 
library of analytes remains a problem because of the differences in mass 
fragmentation patterns between instruments and also because the spectrum 
changes according to the parameters used even in the same instrument [315]. 
Potential reasons for this might because the availability of many types of 
interface (e.g. ESI, APCI) and mass analyser (e.g. TQ-MS, IT-MS, Q-TOF), and 
some factors that influence the performance of instruments such as ionisation 
and retention of analytes due to the use of different columns and mobile phases, 
leading to differences in fragmentation and spectra as well [315]. Some forensic 
laboratories have established their own library using in-house LC-MS/MS 
methods. For example, Dresen et al. [316] developed an ESI MS/MS library of 800 
compounds including illegal drugs. However, it seems to be very difficult to 
 5F-AKB-48 
ISD 
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continuously involve SCs because of the rapid proliferation of new SCs on the 
world market.  
In forensic and clinical toxicology, the risk of false positives always needs to be 
considered. Identification criteria proposed by the EU [317] can be used to 
minimize the risk of errors. The recommendation is that a minimum of three 
identification points (IPs) should be used in forensic analysis as identification 
criteria for drug of abuse confirmation using LC-MS/(MS) [317]. IPs are a criterion 
that can be used to ensure objective and reliable identification of the particular 
substance [313]. Specifically, they are accumulation points depending on the MS 
attached to HPLC, whether it is single or tandem mass spectrometry and high or 
low resolution. In the case of LC-MS/MS, four IPs can be achieved by determining 
one parent drug with two of its product ions. If the points required cannot be 
met, a second fragmentation or ionisation technique should be used. However, 
WADA and SOFT accepted that the identification of analytes can be obtained 
using only single product ions subject to the uniqueness and resolution of the ion 
[252, 279].  
In the current method, good chromatographic separation was satisfactorily 
achieved for all compounds (except JWH-250 4-OH pentyl, JWH-250 and AB-
FUBINACA which have retention time of 3.5 min, and JWH-073 and JWH-250 
which have retention times of 7.0 and 6.9 min respectively) that may provide an 
additional identification point according to the analyte retention time and the 
presence of internal standards.  
The findings generated from this study suggest that 5F-AKB-48, 5F-PB-22 and 
MDMB-CHMICA were more toxic and therefore more likely to result in attendance 
at the A&E in Scotland at that time. It was found that no correlation was 
detected between the concentration of MDMB-CHMICA in blood and the clinical 
presentation in these cases [311]. The inclusion of metabolites of MDMB-CHMICA 
in the analysis can increase the window of detection for the drug that may result 
in additional positive cases being detected [311].   
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5.1.4 Scottish Prison Service Samples 
5.1.4.1 Introduction 
Drugs of abuse are a serious threat to prison security, the safety of prisoners and 
staff and the health of individual prisoners [318]. Information available from 
many previous studies is based on self-reported drug use among prisoners, which 
has a number of methodological limitations due to the nature of the subject 
(drug use and prison). The prevalence of substance abuse use in prisons in a 
number of countries has been widely reported and is highly variable [319]. The 
drugs available in prison can be traditional illegal drugs, NPS or prescription 
drugs.  
For traditional illegal drugs, there are many studies and reports of their 
prevalence in prison. According to EMCDDA, illegal drug users represent a large 
proportion of the prison populations in Europe [320]. In Scotland, an alarming 
amount of illegal drugs permeates prisons. All prisons in Scotland conduct drug 
testing known Addiction Prevalence Testing (APT) during one month per year, 
where prisoners released from and admitted to prisons are tested to assess the 
levels coming into and leaving the institution. The data shows that illegal drugs 
are still a significant issue in prisons in Scotland. The Scottish Prison Service 
(SPS) which is an agency of the Scottish Government (established in 1993) carries 
out an annual APT study in Scottish prisons in November of each year. They 
tested 1934 samples among the prison population (at reception and liberation) in 
November 2013 and found 77 and 25% of reception and liberation tests 
respectively, were positive for traditional illegal drugs (NPS were not included) 
(See Figure 5.4) [321]. 
For SCs, the picture of the prevalence among prison populations is still unclear. 
It seems difficult to determine precisely the prevalence of prisoners using SC 
products because they are often not tested in the prison programs in most 
countries like Scotland and Saudi Arabia [322]. 
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Figure 5.4: SPS Addiction Prevalence Testing Statistics, November 2013 
* These are based on unconfirmed immunoassay screening results for urine 
samples, which excludes drugs prescribed as part of a treatment programme but 
include illicit use of prescribed drugs. 
 
In England and Wales, the number of seizures of Spice products in prisons sharply 
increased from 15 seizures in 2010 to 430 seizures in the first seven months of 
2014 [322]. The Prisons and Probation Ombudsmen for England and Wales [323] 
released a ‘learning lessons’ bulletin in 2015 and looked at 19 deaths in prisoners 
where the use of NPS including SCs was suspected between April 2012 and 
September 2014. The report focused on SCs and related aspects. 
In Scotland, the picture of SCs in prisons is unclear. However, there are several 
media reports suggesting that Spice products are being used by prisoners [324]. 
It is clear that media reports are frequently inaccurate therefore it needs more 
scientific work on the prevalence of these new compounds among prisoners using 
biological toxicology testing and/or self-report.       
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5.1.4.2 Aims 
This study aimed to assess the occurrence of SCs among a prisoner population in 
Scotland. It also attempted to provide more information on the extent of SCs use 
in Scotland. This is the first study of the prevalence of SCs to be carried out on a 
large proportion of prisoners in Scotland using urine analysis to confirm the drug 
consumption.    
5.1.4.3 Study Design 
Ethical approval from the West of Scotland Research Ethics Service (WoSRES) 
was obtained. SPS suggested participating in their annual APT in November of 
each year when they collect urine samples routinely from all prisoners leaving 
and arriving in custody. Each prisoner’s data and urine sample were completely 
anonymised using a unique code number to protect the prisoner’s 
confidentiality.  
5.1.4.4 Results 
Eight out of the 16 prisons in Scotland participated in this study: Edinburgh, 
Corton Vale, Low Moss, Perth, Barlinnie, Addiwell, Polmont and Greenock and 
urine samples from newly-admitted and prisoners about to be released were 
collected over a one month period. It was not possible to include all prisons in 
Scotland due to logistical reasons of sample transport. Figure 5.5 shows the 
location of Scotland’s prisons and number of collected samples from participating 
prisons. Participants were all prisoners, male and female, admitted to and 
released from the selected prisons over a one-month period (November 2013). 
Urine samples were initially collected in additive-free containers by the SPS to 
assess the APT of traditional illicit drugs. After the samples had been analysed 
using an ELISA technique by the SPS, the samples were transferred to FMS and 
stored at -20°C until analysed. 
Demographic Descriptive 
A total of 904 urine samples were obtained from SPS. Only the sample numbers 
and whether they were admission or liberation samples were provided with the 
samples. The available demographic data on selected prisons is shown in Table 
5.3.
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Figure 5.5: Regional Distribution and Number of Collected Samples from Scottish Participating Prisons [306] 
 
Prison (on 
the map) 
Scotland’s 
Prisons 
No. of Collected 
Samples 
1 Addiwell 63 
2 Barlinnie 172 
3 Castle Huntly - 
4 Cornton Vale 101 
5 Dumfries - 
6 Edinburgh 85 
7 Glenochil - 
8 Grampian - 
9 Greenock 27 
10 Headquarters - 
11 Inverness - 
12 Kilmarnock - 
13 Low Moss 118 
14 Perth 187 
15 Polmont 151 
16 Shotts - 
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Table 5.3: Demographic Data on Selected Prison. Prison Population Numbers Obtained from SPS [306]  
Prison 
 
 
Average Daily 
Population 
Maximum No. 
Age 
No. of 
Collected 
Samples 
Aa Lb Facility Area served 
Men Women Men Women 
Addiwell 700 - 700 - >21 63 33 30 Local 
Lanarkshire, West 
Lothian 
Barlinnie 1,303 - 1,433 - >21 172 106 66 Local West of Scotland 
Cornton Vale 
Adult - 213 - 264 >21 
101* 99 11 National Whole of Scotland 
Young - 20 - 29 16-21 
Edinburgh 775 89 829 107 >21 85 25 60 Local 
Edinburgh, Lothian, 
Borders, Kirkcaldy, 
Fife 
Greenock 183 52 195 56 >21 27 11 16 Local West of Scotland 
Low Moss 737 - 764 - >21 118 100 18 Local North Strathclyde 
Perth 643 - 689 - >21 187 123 64 Local 
Angus, Dundee, 
Perth, Kinross, Fife 
Polmont 501 - 546 - 16-21 151 ? ? National Whole of Scotland 
Total 4,842 374 5,156 456  904     
a A=Admission. b  L=Liberation. 
*  There is no information if this number includes any young subjects 
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The Use of Synthetic Cannabinoids among Prisoner Population in Scotland 
904 urine samples from individuals admitted to/liberated from Scottish prisons 
over a 1 month period (November 2013) were tested for the presence of SCs. 5F-
AKB-48 (N-4 OH pentyl) was detected in 10 cases and the concentration ranged 
between <1 and 4 ng/mL. Figures 5.6 below shows an example of 5F-AKB-48 (N-4 
OH pentyl) detected in a prison case sample and its internal standard. Three 
samples were found positive for 5F-PB-22 3-carboxyindole with concentrations of 
5, 7 and 9 ng/mL. All analytes were found alone, except in one case. 
  
 
 
Figure 5.6: LC-MS/MS MRM Chromatograms of 5F-AKB-48 (N-4 OH pentyl) 
Detected in a Prison Case Samples (4 ng/mL), and its Internal Standard 
 
 
 
Quantitive 
Qualitative 
ISD 
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7 samples from Polmont prison were found positive for at least one SC. There is 
a lack of Admission/liberation information for Polmont samples but all other 
positive cases were from admission prisoners. The details of the results are 
found below in Table 5.4. 
Table 5.4: Toxicological Data for 12 SC Metabolite Positive Cases 
Case Prison Positive SCs 
Other Screened Drugs* 
 
Conc. 
ng/mL 
1 Polmont 
5F-PB-22 3-
carboxyindole 
- 9 
2 Polmont 
5F-AKB-48 (N-4 OH 
pentyl) 
- 2 
3 Polmont 
5F-AKB-48 (N-4 OH 
pentyl) 
- 2 
4 Polmont 
5F-AKB-48 (N-4 OH 
pentyl) 
- 3 
5 Polmont 
5F-AKB-48 (N-4 OH 
pentyl) 
Buprenorphine, 
Cannabis 
4 
6 Polmont 
5F-AKB-48 (N-4 OH 
pentyl), 
5F-PB-22 3-
carboxyindole 
Cannabis 
2, 
 
7 
7 Polmont 
5F-PB-22 3-
carboxyindole 
Benzodiazapines, 
Cannabis 
5 
8 Low Moss 
5F-AKB-48 (N-4 OH 
pentyl) 
Opiates, 
Benzodiazapines 
1 
9 Low Moss 
5F-AKB-48 (N-4 OH 
pentyl) 
Benzodiazapines, 
Cannabis, Methadone 
1 
10 Edinburgh 
5F-AKB-48 (N-4 OH 
pentyl) 
Opiates, 
Benzodiazapines, 
Cocaine, Methadone 
2 
11 Perth 
5F-AKB-48 (N-4 OH 
pentyl) 
- 2 
12 Greenock 
5F-AKB-48 (N-4 OH 
pentyl) 
Opiates, 
Benzodiazapines, 
Cocaine 
< 1 
 * Tested by SPS by ELISA, but not subject to confirmatory analysis. 
 
Illicit Drug Prevalence in Synthetic Cannabinoid Positive Samples 
The urine samples were initially tested by the SPS for drugs of abuse including 
amphetamines, methamphetamines, benzodiazepines, barbiturates, opiates, 
cannabis, cocaine, buprenorphine and methadone using a dip-stick test. SPS 
provided the screening results and whether the drug was prescribed or not. All 
nonprescribed drugs were considered abused by SPS. 
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SC positive samples were compared with SPS findings to investigate other illicit 
drugs associated with SCs. Figure 5.7 shows the percentages of illicit drug 
prevalence in positive SCs samples; details of drugs detected along with SCs are 
presented in Table 5.4.  
 
Figure 5.7: Illicit Drug Prevalence Based on an ELISA Test in SC Positive 
Samples 
 
5.1.4.5 Discussion 
The results of the analyses found 12 of the 904 samples to be positive for at 
least one SC (1.3%). 5F-AKB-48 (N-4 OH pentyl) was the most abundant analyte 
detected in these case samples. It was identified in 10 samples with 
concentrations ranging between <1 and 4 ng/mL (Figure 5.8). 
As mentioned previously, there are many various packets with different brand 
names which have different SCs. Some packets listed both 5F-AKB-48 and 5F-PB-
22 as ingredients (e.g. “Spunout” and “Psyclone clown”) but forensic 
examination of these products by TICTAC confirmed that they contained only 5F-
AKB48 [52]. TICTAC is a leading provider of drug information and drug 
identification to the healthcare and criminal justice sectors located at St. 
George’s University of London.  
5F-PB-22 3-carboxyindole was detected in 3 urine samples with concentrations of 
5, 7 and 9 ng/mL, respectively.  
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Figure 5.8: The Percentages Prison Case Samples Found to Contain SC 
Metabolites 
 
 
Polmont is Scotland's prison for young offenders aged between 16 and 21 years 
and had the highest proportion of SC positive samples (58.3%) detected in this 
study. This can be seen as a sign of the high popularity of SCs among adolescents 
and again supports the previous studies that suggest young people are the 
primary users of these new substances. A potential reason for this might be 
because these products are easier for young people to buy than alcohol.   
Two (16.7%) of samples positive for SCs were from prisoners at Low Moss Prison. 
Edinburgh, Perth and Greenock prisons each had one  SC-positive sample (8.3%). 
Edinburgh is a large prison serving Edinburgh, Lothians, Borders and Fife 
area. Perth is prison receiving offenders predominantly from courts in Perth and 
Kinross, Fife, Angus and Dundee. Greenock is essentially a male prison but at the 
time of the study it held a number of female prisoners due to Corton Vale 
establishment renovation. Greenock prison has been included in the study in 
spite of its small population as they specifically requested to participate. 
Barlinnie is the largest prison establishment in Scotland with a capacity of 1,433 
prisoners and holds all categories of prisoners. However, no samples tested 
positive for the selected SCs in this study. Corton Vale is Scotland's only all-
female prison and also no SCs were detected in this group.  
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There is no information on whether Polmont samples were admission or 
liberation, making the assessment of use of SCs among prisoners at Polmont 
prison impossible. Although some people believe in tackling the drug problem 
from the user side, rather than from the supply side, creating a new approach to 
prevent drugs being smuggled into prisons can help to rid the prison population 
the scourge of drug addiction.  
At the time of this study, some SCs were legal in the community but all forms 
are banned in prisons. This may increase the price of these products in prison 
compared to traditional drugs such as cannabis or opiates, which are illegal in 
both settings. However, these products are still relatively cheap in prisons. 
The present study is important to understand the range of drugs that are 
affecting the prison population. Although the current testing method included 
only a small panel of SCs, the results reflected the presence of the problem in 
prisons in Scotland, particularly among young people. Suitable methods for the 
detection of SC compounds should be added to the Annual Prevalence Testing 
carried out by SPS. This can elevate the testing capabilities and provide benefits 
to the prison population and the entire society as well. Clearly there is an 
increased cost and this needs to be considered.    
The present study had several limitations. The major one is that the analytical 
method was only looking for a limited number of SCs. In addition, there was a 
lack of information regarding age, sex and medical history provided along with 
each sample. 
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5.1.5  Post-mortem Samples 
5.1.5.1 Introduction 
In post-mortem toxicology, forensic toxicologists assist procurators fiscal, 
coroners, pathologists, and medical examiners in evaluating contributory aspects 
in the cause of death. They provide consultations on drug kinetics and 
interactions, pharmacology, metabolism, drug stability, drug tolerance, and 
other information supporting the pathologist [12, 13].  
Drug-related deaths (DRD) are a complex concept and hence countries have 
different definitions for DRD cases that may lead to variations in the quality and 
quantity of mortality data. The following definition is used by the EMCDDA 
“deaths caused directly by the consumption of one or more drugs and, 
generally, occurring shortly after the consumption of the substance(s)” [326]. 
At present, national statistics are improving in most European countries and 
their definitions are becoming relatively similar to the EMCDDA definition.  
The latest figures, according to EMCDDA [295], show that the UK had the seventh 
highest DRD rate in Europe. In 2014, there were 3,346 drug poisoning deaths 
(involving both legal and illegal drugs) registered in England and Wales [327]. In 
Northern Ireland, there were 115 DRD in 2013 (the latest figures available) 
[327].  
In Scotland, National Records of Scotland (NRS) produce an annual report on 
DRD. According to NRS, there were 613 DRD registered in 2014, 86 (16%) more 
than in 2013 [328]. This is the largest number ever recorded since 1996 when the 
current series began. Figure 5.9 shows the number of drug-related deaths in 
Scotland from 1996 to 2014.  
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Figure 5.9: Drug-Related Deaths in Scotland 1996–2014 (Source of 
Information: NRS [328]) 
 
The statistics show that males accounted for 74% of DRD in 2014. However, the 
percentage increase in the number of DRD was greater for females (141%) than 
for males (50%). They also show that the numbers have fluctuated in the last 5 
years before the sharp rise in 2014. However, NRS suggested that the sudden rise 
may be because the changes in the classification of some drugs in 2014 such as 
zopiclone and tramadol that would not have been included in previous years. 
However, direct comparisons between countries in the numbers of DRD should 
be made with caution due to differences in data collection methods, definition 
for DRD cases and in the death registration system [295, 326]. 
NRS uses two terms in their statistics to describe the death associated with NPS; 
“NPS-related deaths” and “deaths involving NPS”. In the case of a death due 
solely to one of the uncontrolled NPS at the time of death, NRS would not count 
this as NPS-related deaths. However, it would be counted in the figures for 
deaths involving NPS. The first Scottish deaths involving NPS were registered in 
2009. The number of NPS-related deaths and deaths involving NPS increased 
rapidly between 2009 and 2014 (Figure 5.10).    
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Figure 5.10: NPS-Related Deaths and Deaths Involving NPS in Scotland 2009–
2014 (Source of Information: NRS [328]) 
 
In 2014, NPS were implicated in 10.1% (62) of DRD registered in Scotland, or 
potentially contributed to the cause of death. In 40 of the 62 deaths, the only 
NPS present were benzodiazepine-type NPS (usually phenazepam or etizolam). In 
17 cases, other types of NPS were present (e.g. mephedrone, methiopropamine). 
There were 5 deaths for which both benzodiazepine-type NPS and other types of 
NPS were present. Only a small proportion of cases (7 out of 62) were believed 
to have been caused by NPS alone. There were also 52 cases for which NPS were 
present but were not decided to have contributed to the death.  
For SCs, the general feeling was that if they act like cannabis they would not 
lead to fatalities. However after a string of deaths apparently due to SCs and 
many reports of serious side effects, more consideration needs to be given to 
each SC. Some pharmacologic and pharmacokinetic data on earlier generations 
of SCs are available. However, more recent compounds often have unknown 
receptor-binding affinity and selectivity that might cause unexpectedly severe 
toxicity [91].  
Recently, a number of cases of SC-related deaths, either on their own or in 
combination with other drugs, have been reported in publications [3, 110, 146, 
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148, 154, 329, 330]. In one case [329], a 36 year-old male collapsed at home 
who was known to have taken “Mary Joy Annihilation”. The toxicology report 
confirmed the presence of 5 different SCs in peripheral blood in addition to 250 
ng/mL amphetamine. SCs were considered as a contributory factor in his death 
due to drug intoxication. Another case [110] describes a 59 year-old male 
decedent who was found with 3 herbal mixture sachets at his residence. The 
toxicology analysis showed the presence of MAM-2201 in several of his biological 
samples and, as no evidence of external injuries or endogenous disease was 
noted, the use of this drug was determined to have caused his death. In 
Scotland, only one case of SC-related death has been reported in 2014 by NRS. In 
this case 5-F-PB-22 was determined to have potentially contributed to the 
death. 
SCs are increasingly tested in post-mortem cases when reported in the case 
history but some cases do not clearly involve SCs in the case history making the 
toxicological analysis the only information to confirm if it is a SC-related death.  
Many forms of biological matrices are available for drug analysis in post-mortem 
cases such as blood, urine, hair, bone marrow, stomach contents, liver and many 
others. Selection of the appropriate specimen is an important step in post-
mortem toxicology and often dictated by the case being investigated [331], 
however the most commonly-used matrices are blood, urine and vitreous humour 
[331]. Blood can give an indication of levels of impairment in a user and is very 
useful for indicating most recent use. Blood can provide information about 
distribution, metabolism, and pharmacokinetics of drugs.  Urine samples are less 
important in interpretation of abused drugs, particularly in post-mortem 
toxicology. However, they can be useful because drugs can be detected for days, 
depending on the drug. 
5.1.5.2 Aims 
This study aimed to better understand the presence of SC in fatalities by 
comparing the blood concentrations found of these drugs and the symptoms 
and/or pathological findings.     
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5.1.5.3 Ethical Approval 
Ethics approval was given by the College of Medical, Veterinary and Life Sciences 
Ethics Committee for Non-Clinical Research Involving Human Subjects at 
University of Glasgow (See Appendix 5). They reviewed the research proposal 
and agreed that there was no objection on ethical grounds. 
5.1.5.4 Results 
4 Samples of blood and urine collected at post-mortem during summer 2015 
were analysed for a panel of SCs using the present method as part of the 
investigation of medico-legal cases involving DRD submitted to FMS, University of 
Glasgow. Samples were for two post-mortem cases with suspected ingestion of 
NPS. A case history was obtained with each case.   
Case 1 
The deceased was a 26 year-old man and had a history of drug abuse which 
included intravenous heroin and cannabis. He was prescribed methadone. He had 
started experimenting with legal highs and this had led to erratic behaviour. The 
day before his death, he presented to A&E with hallucinations, and stated he 
had been unwell and had taken several legal highs including "Sweet leaf", "Grape 
Shoot", "Purple G Punch" and "Dark Obsession" and had also taken cannabis. The 
following afternoon, he was detained under the Mental Health Act and 
deteriorated before subsequently dying. Only a blood sample (preserved) was 
available. The blood sample tested positive for 5F-AKB-48 with a concentration 
of 1 ng/mL. 
Case 2  
The deceased was a 34 year-old man with a history of heavy cannabis use. As a 
result of his drug abuse, he started to suffer from mental health problems 
including schizophrenia, bipolar disorder and depression for the past 16 years. 
He was prescribed citalopram and risperidone. In the recent past police 
witnessed him in possession of a bag containing green herbal material believed 
to be an NPS. In his medical history, he had admitted to taking NPS and it is 
believed that he had been taking them for some time. Concerns had been raised 
by his parents regarding his use of SCs known as “Diesel”, bath salts known as 
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“Monkey Dust” and tablets known as “Pink Panthers”. He was found lying on his 
back within the living room evidently dead on arrival of the police. There was 
evidence of drug use including cigarette papers, overflowing ashtrays with roll 
up cigarette butts and remnants of a large amount of green herbal products on 
the ground. Toxicology confirmed the presence of alcohol at concentrations of 
11 and 17 mg/dl in preserved blood and urine respectively, in addition to 0.62 
and 0.36 ng/mL citalopram and methylthienylpropamine (MPA) respectively in 
the blood sample (unpreserved). The urine sample tested positive for 5F-AKB-48 
(N-4 OH pentyl) with a concentration of 18 ng/mL.  
5.1.5.5 Discussion 
The number of NPS-related deaths is low compared with the number of heroin- 
and/or morphine-related deaths in Scotland [328]. However, over the past four 
years there has been an increase in the number of NPS-related deaths, 
particularly the new benzodiazepines in combination with other respiratory 
depressants e.g. heroin/methadone. In 2014, NRS reported that 5F-PB-22 was 
implicated in, or potentially contributed to the one cause of death. However, 
there are possibly additional deaths related to other SCs which are not recorded 
due to the difficulties of their detection. 
Both cases involved poly-drug use that was compatible with the DRD figures in 
Scotland in 2014, in which 553 out of 613 involved more than one substance. 
There are several confounding elements in the interpretation of results of post-
mortem toxicology including individual variation, the lack of data examining 
influences of post-mortem redistribution, the lack of information regarding to a 
fatal dose of the drug and in cases in which the person had also taken other 
substances.  
The differences in individual pharmacogenetics and drug behaviour of users 
(including frequency and dose) may affect the length of time that the drug 
remains in the body and at what concentration, resulting in a wide range of 
concentrations in fatalities [91, 330]. The redistribution phenomenon refers to 
the changes in drug concentrations according to the interval and sampling site 
between death and sample collection [332]. Different pathologists could have 
different views on whether a specific drug would cause or potentially contribute 
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to a death. For instance, views can differ on the fatal dose of the drug for the 
person concerned, or in a case where the person had a poly-drug condition, on 
the level of impairment that may be caused by the combination of the drugs. 
Therefore, therapeutic, toxic and lethal concentrations of drugs in biological 
specimens have been compiled into various books in order to aid interpretation 
of the result [333].  
In contrast, the literature reveals major deficiencies regarding toxic and/or 
lethal concentrations of most of the SCs. A study by Kronstrand et al. [90] 
presented toxicological findings of some SCs including JWH-018, JWH-250, JWH-
201, JWH-203, JWH-210, JWH-122, JWH-081, JWH-019, AM-2201, AM-2233, AM-
694, MAM-2201, AB-001, UR-144 and RCS-4 in whole blood from recreational 
users and from a fatal intoxication. The authors indicated that the median 
concentrations of the selected SCs were < 0.5 ng/g in whole blood. Recently, 
Labay et al. [153] reported a collection of data for SCs-related death from 25 
medical examiner and coroner cases where their presence was analytically 
determined. They found that some deaths were linked to SCs, either as 
contributing factors in subjects with pre-existing cardiopulmonary disease or as 
a cause of death as behavioural toxicity resulting in excited delirium, trauma or 
accidents. They found that blood concentrations for all the SCs varied widely, 
ranging from 0.11 to 105 ng/mL, and the manner of death included accident, 
natural, accident/toxicity and unknown. These findings can be useful to forensic 
pathologists for comparison purposes to accurately determine cause and manner 
of death. However, due to the rapid proliferation of SCs on the world market, 
the data must be updated with the emerging of any new compound. 
In this study, in case 1, the blood concentration of 5F-AKB-48 was 1 ng/mL. 
There is no information regarding the relationship between blood concentrations 
of 5F-AKB-48 and life-threatening (toxic) and/or lethal case outcomes, making 
the interpretation of toxicological results for deciding the extent of the 
contribution of death more challenging. To the author’s knowledge, the only 
publication concerning blood concentrations of 5F-AKB-48 toxicity in 
recreational users was conducted by the Norwegian Institute of Public Health 
[316]. The authors found that the concentrations of 5F-AKB-48 in whole blood 
from 4 DUID cases ranged from 0.9 to 6.5 ng/mL.  
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In case 2, the urine concentration of AKB-48 (N-4 OH pentyl) was 18 ng/mL. 
Although urine is the most commonly used matrix for toxicological analysis, as it 
provides evidence of previous drug consumption and parent drugs and/or 
metabolites are present mostly in higher concentrations than other specimens, 
the interpretation of drug concentrations detected in urine is usually complex. 
Importantly, drug concentrations detected in urine cannot reliably determine 
the amount of drug used, how it was administered, or infer impairment at the 
time the urine was collected. However, useful findings and indications can be 
obtained. For instance, a positive result indicates that the specific drug(s) is 
present and these findings might be correlated to the patient’s history and 
symptom presentation. Individuals who take drugs more regularly will typically 
have higher concentrations of drugs in their urine [335]. This possibly can lead to 
longer windows of detection. The nature of the drugs can also play an important 
role in this issue. Cannabinoid metabolites can persist for extended periods of 
time due to their high lipophilicity and urine tests can remain positive after 
discontinuation of use for up to 7 to 10 days in a casual user, 2 to 4 weeks in a 
heavy user, and months in a chronic heavy user [336].   
The causes of death are not available for either case. However, the association 
of 5F-AKB-48 and deaths seems very challenges because the toxic concentration 
of 5F-AKB-48 in blood is not yet known, especially in the presence of other 
substances “poly-drugs”.     
In comparison with cannabis, SCs seem to exhibit more toxicity due to their 
increased potency and dose that might cause overdose and serious clinical 
consequences [37, 337]. Illicit manufacturing of Spice products may lead to the 
presence of contaminants, impurities, or variability in SC [91] that can cause 
varying degrees of effect depending on the batch [338]. Unlike opioid drugs, SCs 
have no available antidote, and treatment of severe adverse effects is largely 
supportive [153]. In addition, there are no clear symptoms that signal exposure 
to SCs in someone without a history of SC-product use [153], which might lead to 
misreporting of the cause of death. 
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5.2 Synthetic Cannabinoids in Saudi Arabia: Case 
Samples 
5.2.1 Introduction 
Despite the suggestion from different sources [61] that the use of NPS including 
SCs is widespread around the world, there is currently no data on their use in 
Saudi Arabia. Legislation controlling SCs has been put in place in many countries 
in a bid to stem the flow. In Saudi Arabia, the Saudi Food and Drug Authority 
(SFDA) is responsible for the regulation of drugs and medical devices and of 
chemical and biological substances. The majority of controlled illicit drugs in 
Saudi Arabia depend on the United Nations Conventions on drugs of 1961, 1971 
and 1988. As with most countries, legislation in Saudi Arabia tends to be one 
step behind the manufacturers of SCs and the only controlled SCs are the first 
generation compounds including HU-210, JWH-015, oleamide and CP 47,497. 
Therefore, many SCs still remain legal in Saudi Arabia.  
It is necessary to understand the prevalence of illicit drug use and dependence 
in Saudi Arabia. The true prevalence of illicit drug use in Saudi Arabia is 
unknown due to the absence of epidemiological population-based studies [9, 
339]. Nevertheless, it can be estimated indirectly through indicators like official 
statistics of illicit drug seizures, illicit drug-related crime statistics, illicit drug-
related deaths and treatment data. 
According to UNODC [340], in 2012, over 12 tons of amphetamine seizures were 
reported in the Near and Middle East/South-West Asia, representing 56 per cent 
of global seizures. The largest seizures were reported in Saudi Arabia, Jordan 
and the Syrian Arab Republic, in that order. The Saudi Ministry of Interior (MOI) 
announced the arrest of 17 tons of hashish in 2012 [341]. Illicit drug-related 
crime includes crimes to obtain money to buy illicit drugs, possession or sale of 
drugs, driving under the influence of illicit drugs and crimes such as child abuse 
resulting from illicit drugs [342]. Between 2010 and 2012, 119,000 people have 
been arrested for illicit drug offences which represent 60% of all crimes in Saudi 
Arabia [6]. Figures from psychiatric clinics or hospitals show increases in the 
number of patients seeking treatment for alcohol and drug use disorders in Saudi 
Arabia [343]. All these indicators clarify the increasing trend of problem drug use 
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in Saudi Arabia. Social and economic development in Saudi Arabia in the last 
years might contribute to the increase in drug abusers. 
Although there is a lack of official statistics related to drug abuse rates in Saudi 
Arabia, the prevalence of drug abuse and clinical characteristics and associated 
socio-demographic among drug abusers in treatment settings have been 
investigated in several survey studies [343-352]. Conducted over different time 
periods and regions of Saudi Arabia, these papers provide a useful insight into 
the prevalence of drug use (Table 5.5). By contrast, the Saudi picture of NPS 
including SCs is still unclear.   
Table 5.5: Prevalence of Drug Abuse among Saudi Patients in Addiction 
Treatment Settings (Percentage) 
No of 
drug 
abusers 
Year 
of 
study 
Region Al Am Ca He Co Ba Be Ref 
485 1992 Jeddah 16.1 5.2 - 43.5 - 8.0 8.7 [324] 
116 1995 Dammam 31.2 - 26.0 83.6 - 0.9 0.9 [329] 
160 1999 Riyadh 23.8 - 10.6 18.8 - - - [326] 
799 2000 Jeddah 18.0 4.0 1.0 70.0 0.1 - 0.5 [325] 
423 2000 Al-Qassim 52.0 25.3 4.1 6.7 - - - [327] 
302 2001 Jeddah 21.5 - - 68.2 - - - [330] 
101 2008 Jeddah 56.0 70.7 60.0 25.0 2.3 - 8.0 [331] 
Al= Alcohol, Am=Amphetamine, Ca=Cannabis, He=Heroin, Co=Cocaine, 
Ba=Barbiturate, Be=Benzodiazepine 
 
In many countries, when people are applying for employment, especially for 
safety-sensitive positions (e.g. transport, medicine or armed forces), they have 
to undergo regular laboratory tests for the detection of illicit substances, known 
as Workplace Drug Testing (WDT) [353]. Random drug testing could be enforced 
as well. Forensic toxicologists perform drug screening of human samples (mostly 
urine) in a programme managed by the guidelines such as EWDTS [354]. The 
procedures for specimen collection, analysis and interpretation are well‐defined 
to minimise the risk of errors. Current WDT in Saudi Arabia only covers illicit 
traditional drugs including alcohol, amphetamines, cannabis, cocaine, opiates, 
benzodiazepines, barbiturates and methadone. 
In order to evaluate the prevalence of SCs within WDT in Saudi Arabia, a study 
was carried out in collaboration with the Security Forces Hospital (SFH), (Riyadh, 
Saudi Arabia). This study is unique in that no previous publications have studied 
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SCs among Saudi society to assess their occurrence. Urine samples from workers 
or people applying for employment over a one-month period were collected. 
Urine was chosen because it can provide evidence of previous drug consumption 
and metabolites are present mostly in high concentrations, as well as for its easy 
sampling compared to blood. Some drugs also remain in the urine for days or 
longer following their use.        
5.2.2 Aim 
It is important to understand the range of drugs that are affecting a particular 
population. The aim of this study was to evaluate the scale of use of SCs in Saudi 
individuals in WDT during a one-month period (July 2014) using analysis of their 
urine samples. This study also provided unique information on SCs in Saudi 
Arabia and this can help for sharing information on the prevalence of SCs in new 
regions leading to the development of a better understanding of this issue. The 
prospective study was performed in the Saudi Security Forces Hospital (SFH) 
which is one of the leading Health Care Providers in Saudi Arabia, founded in 
1975.  
5.2.3 Ethical Approval 
All procedures in this study were conducted according to the guidelines laid 
down in the College of MVLS Ethics Committee for Non-Clinical Research 
Involving Human Subjects at the University of Glasgow (See Appendix 6) and they 
were also approved by the Research Committee at SFH, (Riyadh, Saudi Arabia) 
(See Appendix 7). Both committees reviewed the research proposal and agreed 
that there was no objection on ethical grounds.    
During the processing of ethical approval, three documents were prepared 
including the application form for ethical approval, participant information 
sheet (Appendix 8) and consent form (Appendix 9). The patient information 
sheet was provided in lay terms (in English and Arabic languages) and in the style 
of questions and answers. The consent form was also in English and Arabic 
languages. 
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5.2.4 Study Design 
Participants were Saudi individuals, male and female, presenting at SFH to 
provide urine samples for WDT as a requirement of their job during a one-month 
period (July 2014). SFH advised that the urine sampling for both WDT and the 
research would be at the same time due to the high work load at the hospital 
site. 
The researcher met donors at the toxicology lab in SFH and asked them if they 
would like to take part in the study and gave them the information sheet to 
read. Participants were recruited voluntarily and were selected from personnel 
who already had to undergo regular urine drug screening. Participants were fully 
briefed regarding the purpose of the study and were allowed to opt out of the 
study at any time. After a potential participant read the information sheet and 
agreed to participate they were given the consent form to sign and a plastic 
container to donate a urine sample. They were asked their age prior to 
completing the consent form and those under the age of 18 were excluded from 
this project. Collection of samples was carried out by the researcher under 
supervision from the hospital administration.    
Consent and the urine samples were taken at the same time. The consent form 
was physically separated from the urine sample in the presence of the subject to 
maintain the anonymity. The consent forms did not have any number on it which 
would link it to a number on the sample. The consent forms were stored 
securely with the researcher until travelling back to the UK where they have 
been kept with the researcher in a secure cabinet in FMS.  
All samples were labelled with a unique number assigned to the individuals at 
the time consent was given and did not have any dates at all. This made the 
urine samples completely anonymous, and at no point would they be identified 
to individuals. Every participant attended on only one occasion and was asked to 
provide only one urine sample. The urine samples were collected in completely 
clean containers with pre-prepared serial numbers starting from 1 to 500. These 
serial numbers were different from the hospital numbers to protect the person’s 
confidentiality. Each sample contained less than 10 mL of human urine. The 
samples were kept secure in Saudi Arabia by storing in a special freezer at -20°C 
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in Toxicology lab until the sample shipment. The participant took approximately 
3 to 5 minutes to give the sample. The urine collection area was completely 
suitable for the collection of urine samples and the procedure followed SAMHSA 
guidelines. The toxicology lab at SFH has accreditation by the Standards Council 
of Canada, which is a mark of competence and reliability recognised throughout 
the world.  
Urine samples  were chilled throughout the transit with dry ice and delivered to 
FMS, University of Glasgow by CitySprint. The samples were received in an 
acceptable condition and stored at -20°C until analysis. The packaging process 
took place in the SFH toxicology lab under supervision of the researcher and lab 
staff. These measures helped maintain both security and integrity of the 
samples. Urine samples were stored within the secure unit of FMS in a freezer at 
-20°C until they were analysed. Only the researcher had access to the data. 
Figure 5.11 below summarises the study design. 
 
Figure 5.11: Summary of Study Design 
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5.2.5 Analysis of Urine Samples 
Because the picture of use of SCs in Saudi Arabia is largely unknown, it was 
decided to select as target analytes some of the most prevalent SCs from 
different generations as follows: 
 JWH-018 4-OH pentyl, JWH-073 3-OH butyl and JWH-250 4-OH 
pentyl (first generation 2008-2009).   
 JWH-122 5-OH pentyl, JWH-210 5-OH pentyl and AM-2201 4-OH 
pentyl (second generation 2010-2011).  
 5F-AKB-48 (N-4 OH pentyl) and 5F-PB-22 3-carboxyindole (third 
generation 2013-2014).     
Chemical structures of these compounds can be seen in Figure 2.7.  The urine 
samples were analysed using the method described in Chapter 3.  
5.2.6 Results and Discussion 
A total of 463 urine samples were collected from personnel who presented to 
SFH for WDT as a requirement for their job during the period of one month (July 
2014). The results of the analysis found 2 of 463 samples to be positive for SCs 
(0.4%). 5F-PB-22 3-carboxyindole was detected in both of these casas with 
concentrations of 11 and 51 ng/mL respectively. No other SC drugs or 
metabolites were found. However it cannot be excluded that other SCs might 
have been present in the samples at either extremely low concentrations, or not 
included in the testing method due to a lack of reference standards, which may 
have caused false negatives. For these reasons, this data should be interpreted 
with caution.  
Although only a few invited participants 2 (4.5%) refused to take part in this 
study, they may represent a significant number due to the sensitivity of the 
topic. It was not possible to analyse all WDT samples because the toxicology 
report that generates by SFH includes alcohol and specific drugs (amphetamine, 
cannabis, cocaine, barbiturate, benzodiazepine, opiates and methadone) and 
analyse any further drug needs acceptance from person who is applying for 
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employment, Moreover, the study was performed at a single institution in one 
city that may limit how representative it is. The overseas transport of urine 
samples may also have affected the results with respect to stability of the 
analytes, although this was mitigated by freezing the samples.  
However, these results do indicate the presence of SC use in Saudi Arabia. The 
findings showed that SCs are a worldwide problem and the Kingdom of Saudi 
Arabia is no exception. 5F-PB-22 was detected in Scotland and Saudi Arabia. This 
may be the result of the proliferation of online retailers that enables NPS and SC 
distributors to reach new consumers across borders. In addition, Saudi Arabia is a 
big country and its many borders with other countries makes the control of 
smuggling difficult [339]. Unfortunately, there has been no other study 
measuring SCs in Saudi Arabia in order to compare with the present one and see 
the trends of SC use.   
Drug misuse and trafficking have been recently recognised and acknowledged by 
the Saudi government as both a social and law enforcement problem. The GDNC 
in the Ministry of Interior, the National Committee for Combating Drugs (NCCD) 
and the Saudi Customs are the principal Saudi authorities dealing with this issue. 
The Saudi GDNC has 105 branches distributed in all the 13 governorates of Saudi 
Arabia. In April 2009, the NCCD was founded to coordinate the actions all 
related agencies. Official responses have become more comprehensive in the 
country, providing a three-pronged strategy which includes prevention, 
suppression and rehabilitation strategies to address illicit drug use [6]. However, 
the emergence of NPS including SCs does not get as much attention from the 
official authorities in Saudi Arabia as traditional illicit drugs.  
Emergency scheduling of SC compounds must be undertaken and updated in 
Saudi Arabia by SFDA. Nevertheless, SCs could continue to be consumed, as the 
bans in some countries have proven ineffective in addressing their growing use 
as has been the case for traditional illicit drugs. The concerned authorities in 
Saudi Arabia should develop a programme of analytic work to address some of 
the key knowledge gaps. Awareness campaigns including television programmes, 
exhibitions and the launching of a website to illustrate the harmful effects of 
using NPS and SCs, for those who do not yet use NPS and also for those who 
already use NPS, should be launched as a prevention strategy. Cooperation with 
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international organisations regarding the tackling of NPS should be improved as a 
suppression strategy. Suitable methods for the detection of SC compounds 
should be added to the drug testing policy within Saudi Arabia. It is 
recommended that a new “Early Warning System” is created in the Arab Gulf in 
order to mimic the EU (EWS). This can improve the work on the fight against 
illicit drugs, especially NPS, through sharing information on the trends and 
appearance of NPS, along with reported harms, from Arab Gulf countries.  
Before this is set-up, all countries would benefit from accessing information 
already collated from other countries around the world including those in Europe 
and the USA.  
The present study had some limitations. The major one was the lack of 
information regarding age, sex and screening results provided along with each 
sample due to the requirements of ethical approval that not have been given if 
age and sex were known. 
5.3 Conclusions 
5F-AKB-48, 5F-PB-22 and MDMB-CHMICA have been identified in Scotland in 
several cases among 3 subpopulations; A&E patients, prisoners and fatalities 
during a period from November 2013 to November 2015. 5F-PB-22 3-
carboxyindole has been identified in 2 WDT urine samples in Saudi Arabia during 
the period of one month (July 2014).  
The findings give an idea of the extent of use of SCs in Scotland and provide 
valuable information to the forensic community. They reflect the presence of 
the problem in Scotland’s prisons, particularly among young people, as well as 
among A&E patients. It seems that 5F-AKB-48 and 5F-PB-22 are most popular in 
Scotland, or at least during the study period. This was also observed in Wales; 
according to WEDINOS [44, 338], 5F-PB-22 and 5F-AKB-48 were the most 
commonly identified of SCs between April 2014 and 31th March 2015. The 
findings described in this chapter reflect the range and extent of use of SCs in 
Saudi Arabia and shared an identical trend with Scotland. This is the first study 
that reports the detection of SCs using human urine toxicology in Saudi Arabia. 
More information regarding 5F-PB-22, 5F-AKB-48 and MDMB-CHMICA can be found 
in [56, 58, 59, 88]. The extent of poly-drug ingestion has significant implications 
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for management of A&E patients as well as for complicated decision-making 
within DRD.  
Forensic communities must monitor the world drug market to ensure that 
clinical and forensic laboratories are keeping up with the illegal drug suppliers. 
When new compounds appear in the drug-user marketplace, toxicologists need 
to respond quickly and identify suitable biomarkers via in vitro studies to detect 
intake. Certified Reference Material suppliers and toxicologists need also to 
address the synthesis of reference standards for these new compounds. 
Nowadays, laboratories have gained more experience with these drugs. 
Therefore, toxicologists should collect larger databases of searchable mass 
spectra of many SCs and their metabolites and biomarkers that can indicate SC 
use. However the problem of LC-MS/MS spectra being different between labs and 
instruments remains. 
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Chapter 6 - Synthetic Cannabinoids in Saudi 
Arabia – Survey Study 
6.1 Introduction 
A survey is defined as a series of questions used to gather information from a 
sample of a population [355]. The primary purpose of a survey study is to 
describe characteristics of the population [356]. The description of the whole 
population is inferred by the findings and interpretations obtained from the 
sample. In survey studies, researchers ask questions about peoples’ 
characteristics, behaviour and beliefs. Researchers can investigate the 
associations between different respondents’ characteristics and their current 
attitudes toward some issue. Survey studies typically describe the distributions 
of variables in a target population but do not make causal inferences [355].          
The types of surveys depend on the time frame for data collection and are 
longitudinal or cross-sectional surveys [355]. A longitudinal survey involves the 
collection of information at different points in time in order to study changes 
that occur over a time whereas; a cross-sectional survey involves the collection 
of information from participants at just one point in time or over a short time 
period [355].  
There are several techniques to obtain information in survey research such as 
interviews, questionnaires and data mining (e.g. interrogating a database for 
causes of death). Interviews can be conducted in person (face–to-face) or by 
telephone. Questionnaires can be handed directly to the participants, completed 
on the Web, or sent and returned by email or post. Choosing between interviews 
and questionnaires is an important decision in survey research and it depends on 
several research aspects. For sensitive topics a questionnaire is generally a 
better choice because it is more anonymous. It is a type of self-report method 
which involves questions often in a structured written form. Self-reports have 
been widely used in forensic toxicology (See Section 2.3.8). For complex topics, 
interviews are usually preferred because the researcher can explain questions 
that the participants may not understand. 
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According to the EMCDDA [295], a number of surveys based on a questionnaire 
have studied the prevalence of Spice use but their coverage and 
representativeness is still limited (See Section 2.3.3 for details).        
6.2 Aim 
The aim of this study was to determine the extent of awareness and usage of 
Spice products in 3 subpopulations of Saudi Arabia (known drug users, medical 
professionals and members of the public in and around smoking cafes). 
6.3 Ethical Approval 
Ethics approval was given by the College of Medical, Veterinary and Life Sciences 
(MVLS) Ethics Committee for Non-Clinical Research Involving Human Subjects at 
the University of Glasgow (See Appendix 6) and they were also approved by the 
General Administration for Research and Studies at the Ministry of Health of 
Saudi Arabia (See Appendix 10). The letter of approval obtained from the Saudi 
Ministry of Health was sent to the Al-amal Complex for Mental Health in Riyadh 
to get permission for this study.  
Three documents were prepared during the processing of ethical approval 
including the application form, a participant information sheet (See Appendix 
11) which contains basic information regarding the purpose of the research in lay 
terms for all participants to read, and a consent form (Appendix 9). The patient 
information sheet and consent form were in English and Arabic languages.   
6.4 Methodology 
Survey studies allow the collection of information from a large sample of 
individuals relatively inexpensively and quickly. However, it is not an easy 
process. In order to yield valid and reliable information, planning, 
implementation, and analysis should be conducted carefully. Figure 6.1 shows 
the process that has been conducted in this study.  The cyclical design reflects 
the use of a pilot survey prior to the main survey. 
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Figure 6.1: The Basic Process of the Study [355] 
 
6.4.1 Planning  
The purpose of the study was to explore the knowledge and usage of Spice 
among three different populations in Saudi Arabia including known drug users, 
medical professionals and members of the public in and around smoking cafes. A 
cross-sectional design with self-administered questionnaire was used to collect 
data. A questionnaire has been chosen because the topic is quite sensitive and 
the questionnaire can provide more anonymity than other techniques.   
6.4.2 Identifying the Population and Sample Size  
A population is defined as all individuals of the group that meet the selection 
criteria to be studied, whereas a sample is a portion of a population [355]. A 
common goal in choosing the sample is whether the individuals selected are 
representative of the population. Both the number and ‘type’ of respondents are 
important. The two main types of sampling procedures include nonprobability 
and probability sampling. Nonprobability sampling contains non-random 
procedures for selecting the subjects of the sample. In this type of sampling, 
there is no assurance that every member in the population has a chance of being 
included [355]. Probability sampling is the type of sampling in which every 
subject has an equal chance of being selected [355]. It includes simple random, 
stratified, cluster and systematic sampling [355]. Random sampling technique 
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was applied in the present study to select participants in each group. In this 
method, individuals of the population were selected in a manner such that 
everyone had an equal chance of being selected.   
In general, the sample size required will be determined by many factors 
including willingness of people to participate, the budget of the project and the 
importance of the research. The determination of sample size is an important 
step of survey study design because inadequate, excessive or inappropriate 
sample sizes might influence the accuracy and quality of research [357]. 
Inadequate sample size will not allow reliable insights and excessive sample size 
will lead to a waste of money and time.  
To determine the appropriate sample size, the confidence level and confidence 
intervals (the level of precision) should be specified dependent on the required 
accuracy. The level of confidence or risk is the percentage of all probable 
samples that can be distributed normally about the true value [358]. A 
confidence level of 95% means that 95 out of 100 samples will be representative 
of the true population value. A confidence interval or margin of error refers to 
the positive and negative deviation allowed on survey results for the sample. It 
is often expressed as: estimate ± margin of error. 
After deciding the desired accuracy for the sample data (e.g. 1%, 5%, 10% …), 
the sample size can be calculated by several methods. A first approach to 
determine the sample size is to rely on published tables. The second way is to 
use the same sample size as in similar studies. This approach should review the 
procedures employed in these studies to avoid repeating any errors. Another 
approach to calculate the sample size is to use one of several formulas.            
6.4.2.1 Medical Professionals  
The first target population was Saudi medical professionals including physicians, 
pharmacists, nurses and medical technologists. This population was selected 
because of the nature of their work to examine the awareness and use of SCs. 
According to the Saudi Commission for Health Specialties, there were a total of 
139,309 medical professionals in SA in 2014 [359]. The sample size has been 
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calculated according to the simplified formula provided by Yamane [341]. A 95% 
confidence level has been decided. The margin of error on either side of the 
proportion was estimated to be 5%. The equation is below [341]:    
                                              
2)(1 eN
N
n

                                     Equation 11                               
Where N is the population size, n is the sample size and e is the level of 
precision (confidence intervals).  
399
)05.0(309,1391
309,139
2


n  
The target sample size for the medical professionals group was 399 individuals.   
6.4.2.2 Members of the Public in and around Smoking Cafes  
The second population of interest for the current study were members of the 
public in and around smoking cafes or shisha smokers in Saudi Arabia. Shisha 
smoking is very popular in Saudi Arabia. There are many shisha smoking cafes in 
Saudi Arabia particularly in the larger cities. Shisha smokers usually spend one to 
three hours in these cafes mostly in groups. Several articles showed that there is 
an association between smoking and using illicit drugs [361, 362]. NPS such as 
SCs are likely to be used by smokers; this project was specifically aimed at 
reaching this target population. In addition, the majority of shisha smokers in 
these places are adolescents and this age group has been strongly associated 
with SC use (See Chapter 2.3.3).   
There is no data about Saudi shisha smokers in 2014. However, it was estimated 
indirectly through the available data. According to the report in 2005 of Saudi 
Ministry of Health (MOH) in collaboration with the World Health Organization, 
the prevalence of shisha smoking among the Saudi population is 4.2% [363]. 
According to the Saudi Central Department of Statistics and Information, Saudi 
Arabia’s population stood at 22.7 million at the end of 2004, of which 16.5 
million were Saudis, making up 72.9 percent of the population [364]. Therefore 
the number of Saudi shisha smokers in 2004/2005 was around 693,000. Using 
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Equation 11, the target sample size for shisha smokers group was 400 
individuals.    
6.4.2.3 Known Drug Users  
The third target population was known illicit drug users in Saudi Arabia. SCs are 
likely to be used by illicit drug users for several reasons including trying to evade 
detection, due to the misconception they are safer, availability, low cost or to 
experiment with new effects.  
As mentioned previously, the number of known drug users in Saudi Arabia is not 
clear. It is impossible to estimate the size of the population and consequently to 
calculate the sample size. Therefore, it was considered that the target 
population was all known drug users in Al-amal hospital in Riyadh giving a sample 
size of 200 individuals.    
6.4.3 Constructing the Questionnaire  
6.4.3.1 Preparing the Questionnaire 
After planning (defining the problem) and determining the sample group sizes, 
the next step was the preparation of a questionnaire. Cross-sectional designs 
usually take less time to complete and require less dedication from research 
participants compared to longitudinal designs [355]. In order to prepare the 
questionnaire, an account was created with SurveyMonkey. The questionnaire 
was in English and Arabic languages and involved an introductory message and 
the questions. The introductory message was located on the top of the 
questionnaire form and explained briefly the importance of the respondents’ 
participation and gave a statement guaranteeing confidentiality to encourage 
people to take part (See Appendix 12).  
Four processes were conducted to prepare the questions including deciding, 
wording, ordering and formatting. These steps might help to maximise the 
response rate and obtain accurate relevant information for the study.   
Several questions that have a key link with the research aims were generated. 
Depending on the information type, the questions were grouped into 3 sections. 
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A question to explore whether or not the respondents worked in medical fields 
was added to confirm that all the participants were relevant to this group (See 
question 5 in Appendix 12). Three core questions were compiled to obtain 
primary information. For ethics issues and because of the sensitivity of the 
topic, the question “Have you ever smoked synthetic cannabis, Spice or k2?” was 
deleted and replaced by the question “Do any of your friends smoke these 
drugs?”. This question aimed to investigate the general prevalence of Spice 
usage. However, this limited the information that could be generated from the 
survey. 
General rules for wording the questions have been followed to construct good 
questions and minimise bias in the questionnaire. Short and simple sentences 
were generally used. Ambiguous, leading and negative questions were avoided to 
reduce confusion amongst participants. Closed, multiple choice and open 
questions were used. A suitable order for the questions was very important to 
reduce missing data. The particularly sensitive questions were left to the end of 
the questionnaire to give the participant a chance to feel relaxed. The layout 
and formatting of the questions and answer choices was important to make it as 
easy and quick as possible to complete a questionnaire. The questionnaire was 
fitted on to two pages: the first contained only the demographic section, 
whereas the second involved the behaviour and the core sections. Plenty of grey 
space between these three sections and enough room to answer questions were 
provided. The headings and questions were in bold.     
6.4.3.2 Piloting and Evaluating Questionnaire   
It is very useful to test the questionnaire and survey methodology on a few 
participants prior to conducting the main survey. This pilot study is used to 
detect any flaws in the questionnaire. The questionnaire was piloted with 12 
friends and colleagues from the UK and Saudi Arabia.. 
During the pilot study, three questions were asked to every participant: “Were 
any questions ambiguous?”, “How long did it take to complete?” and “Are there 
any suggestions?”. The feedback from the pilot sample was useful. Based on the 
results of the pilot study, participants were generally happy inputting their 
responses. However, the pilot indicated wording in Arabic language of some 
175 
 
questions in the behaviour section could be improved by using common words. 
Changes in the translation of that question were made to accommodate this 
situation.  
The participants of the pilot sample took approximately 2 to 5 minutes to 
complete the questionnaire. The general view was that it was feasible to 
continue the survey. The questionnaire was finalised and printed in two versions; 
(with page numbers) for the shisha smokers group and (without page numbers) 
for known drug users group to make the process of data transfer from 
questionnaire papers to an Excel file easier to organise.  
6.4.4 Conducting the Survey  
The questionnaires were distributed to participants in Saudi Arabia in two ways, 
both online and by paper, but they contained the same questions. All the 
questionnaires were conducted over a 2 month period during December 2014 and 
January 2015. Any information produced by these individuals was completely 
anonymous.   
6.4.4.1 Online Questionnaire 
An online questionnaire (self-administered) was used specifically for the medical 
professional population. This method was deemed most appropriate for this 
group for several reasons. Firstly, members of this group were literate and could 
interpret questions without assistance, secondly, it was relatively easy to 
identify and access the sample population through the Saudi medical group’s 
emails and finally, self-administered questionnaires can be completed at the 
respondent’s convenience. 
The target sample size of the medical professional population was 399 
individuals (See Section 6.4.2.1). However, the response rate must be taken into 
account, particularly for online and postal surveys. Approximately 550 emails 
were sent to those individuals.  
The email included a welcoming message for medical professionals and offered 
them to partake in the research project by filling out a questionnaire. The email 
was attached with the web link for the questionnaire (generated by 
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SurveyMonkey) and also involved information about the purpose of the research 
project.  
6.4.4.2 Paper Questionnaire  
The paper survey was aimed at two Saudi populations: shisha smokers and known 
drug users. Participants in these two groups were identified from engagement 
with people in public spaces (smoking cafes) and participants at Al-amal hospital 
in Riyadh (for known drug users). Permission was obtained from cafes and 
hospital.  
The target sample size of the Saudi shisha smoker population was 400 individuals 
(See 6.4.2.2). Assuming a non-response rate of 20%, 480 questionnaires were 
distributed to members of the public in and around smoking cafes in Riyadh. The 
target sample size of the Saudi known drug users was 200 individuals (See 
6.4.2.3). However, only 90 questionnaires were distributed to this group due to 
the restricted facilities of some departments at Al-amal hospital including 
female and children departments.     
Participants were asked if they would like to take part in the study and given the 
information sheet to read. After a potential participant completed reading the 
information sheet and agreed to participate, the consent form was supplied for 
them to sign and the questionnaire was completed. The consent forms were kept 
separately from the questionnaires to maintain anonymity and kept in a secure 
place by the researcher. All participants were allowed to opt out of the study at 
any time. Each participant completed only one questionnaire.   
6.4.5 Data Analysis 
This part presents different statistical techniques that were used for editing, 
coding and analysing the data. The choosing of statistical software is very 
important at the questionnaire design stage. The data was transferred from an 
Excel file to the Statistical Package for the Social Sciences (SPSS) for analysis. 
SPSS is a software package used for statistical analysis. In the present study, IBM 
SPSS Statistic 21 was provided through the University of Glasgow and used to 
produce statistics of descriptive and frequency for all variables as well as to 
perform chi-square tests. 
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Chi-square test (also called х2) was used to explore relationships between 
variables. It compares observed frequencies and expected frequencies for 
categorical variables. Chi-square tests determine whether different kinds of 
respondents (e.g., male and female) gave significantly different survey 
responses. A p-value will be significant if less than 0.05.  
6.4.5.1 Response Rates  
In total, 391 questionnaires were returned: 184 questionnaires were completed 
by medical professionals, 170 by shisha smokers and 37 by known drug users. 
After collecting all the questionnaires of the three groups, the data was ready to 
process.  
The response rate in survey research is the number of responses divided by the 
number of people invited to take part in the survey. It is usually expressed in the 
percentage form. The response rate for self-administered questionnaires is 
usually low. However, the overall response rates were 33.5%, 35.4% and 41.1% 
for the medical professionals, shisha smokers and known drug users, respectively 
and these are considered acceptable rates.  
Four of the medical professionals who participated in the survey did not answer 
more than three-quarters of the questions. It was appropriate to remove those 
four participants. Subsequently the sample size of medical professional group 
became 180 participants. The missing data for the rest of all other participants 
in the three groups was tiny and randomly scattered through the data field 
accounting for only 1.1%. The sample size of the three groups was sufficient to 
achieve the aims of the project. The missing data was coded by (999).                                    
6.4.5.2 Editing and Cleaning  
Socio-demographic, behaviour and core data from the questionnaire were 
initially collected and coded. Independent and dependent variables have been 
used in the present study. Independent variables consist of socio-demographic 
and behaviour variables. Dependent variables include the data related to the 
legal highs and Spice knowledge and usage of participants. Coding of the 
variables and comments is shown in Table 6.1. 
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Table 6.1: Variables and Coding 
Variable Definition / Question Coding 
Sex Gender of respondent Female = 0, Male = 1 
Home Where does the respondent live? 
Riyadh = 1, Jeddah = 2, Dammam = 3 
Other = 4 
Age Age of respondent 18 – 25 = 1, 26 – 40 = 2, 41 – or over = 3 
Education Educational level of respondent 
High school or less = 1, Undergraduate 
level = 2, Postgraduate level = 3 
Behaviour 1 I feel my life is very stressful Agree = 1, Disagree = 0 
Behaviour 2 When I feel upset or down, I am likely looking for medication Agree = 1, Disagree = 0 
Behaviour 3 When I feel upset or down, I am likely looking for a herb Agree = 1, Disagree = 0 
Behaviour 4 I like to try new herb products Agree = 1, Disagree = 0 
Behaviour 5 
When I feel upset, I usually ask my friends to give me something could be 
help 
Agree = 1, Disagree = 0 
Behaviour 6 I usually buy the herb products that I have seen advertised Agree = 1, Disagree = 0 
Behaviour 7 I usually buy the herb products that my friends recommended to me Agree = 1, Disagree = 0 
Behaviour 8 I like to access the internet Agree = 1, Disagree = 0 
Knowledge 1 Have you heard of new psychoactive substances or legal highs? Yes = 1, No = 0 
Knowledge 2 Have you heard of synthetic cannabis, Spice or K2? Yes = 1, No = 0 
Comments Where did you hear about “legal highs”/“Spice”? 
No comment = 1, On internet = 2, Social 
media and TV = 3, Lectures = 4, Friends 
= 5, Literatures = 6 
Use Do any of your friends smoke “Spice” or K2? Yes = 1, No = 0 
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6.5 Results and Discussion  
6.5.1 General Descriptive 
General descriptive statistics were used to describe the data. The study sample 
included males and females aged 18 years or over. No expatriates were included 
in this study. The participants were randomly selected from three target 
populations including medical professionals, members of the public in and 
around smoking cafes and known drug users in Saudi Arabia, during December 
2014 and January 2015. Figure 6.2 below illustrates study sample derivation. 
 
Figure 6.2: Study Sample Derivation 
 
6.5.1.1 Socio-demographic Data  
1) Medical Professional Population:   
Details of these participants are shown in Table 6.2. The analysis of the 
population of Saudi medical professionals was based upon a sample of 180 (71 
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(39%) females, 109 (61%) males). Nearly half (52%) of female participants were 
between 18-25 years whereas only (5%) of male participants belonged to this age 
group. This is potentially due to the increased attention of the Saudi government 
to encourage education for women and open many new medical and health 
colleges for them in recent years. There were significant differences between 
the percent of men and women in each age group (Chi-square= 55.7, p <0.0001).  
Forty four percent of male participants had postgrad degrees, while only 14% of 
female participants have this level of education. There were significant 
differences between the percent of men and women in each education level 
(Chi-square= 18.6, p <0.0001).  
It was shown that almost a third (29%) of male participants was living in Riyadh, 
whereas approximately 41% of female participants lived in Dammam. About 37% 
of participants lived outside the main cities of Riyadh, Jeddah and Dammam. 
Table 6.2: Socio-demographic Characteristics of Medical Professional 
Participants (n=180) 
Characteristic 
All 
(n=180) (%) 
Female 
(n=71) (%) 
Male 
(n=109) (%) 
P * 
Age groups <0.0001 
18-25 years 42 (23) 37 (52) 5 (5)  
26-40 years 106 (59) 29 (41) 77 (71)  
41 - or over 32 (18) 5 (7) 27 (25)  
Total 180 71 (39) 109 (61)  
Education <0.0001 
High school or less 11 (6) 4 (6) 7 (6)  
Undergraduate level 111 (62) 57 (80) 54 (50)  
Postgraduate level 58 (32) 10 (14) 48 (44)  
Total 180 71 (39) 109 (61)  
Location 0.021 
Riyadh 38 (12) 7 (10) 31 (29)  
Jeddah 22 (12) 9 (13) 13 (12)  
Dammam 53 (30) 26 (37) 27 (25)  
Other 65 (37) 29 (41) 36 (34)  
Total 178 71 (40) 107 (60)  
* Value was significantly different between males and females (P <0.05) based 
on chi square analysis 
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2) Members of the Public in and around Smoking Cafes Population: 
Details of these participants are shown in Table 6.3. A total of 170 participants 
were recruited. The majority were men, 146 (86%), reflecting that the 
prevalence rate of shisha smoking is generally higher in men in Saudi Arabia 
[363]. The majority of participants (77%) were between 18 and 25 years. There 
are no significant differences between the percent of men and women in each 
age group (Chi-square= 4.8, p =0.092).  
The majority of male participants (77%) were educated to high school or less. 
There were significant differences between the percent of men and women in 
each education level (Chi-square= 10.5, p =0.005). Most of the participants (68%) 
were living in Riyadh as this study was carried out in cafes in Riyadh. There were 
no significant differences between the percent of men and women at each 
location item (Chi-square= 4.4, p =0.226). 
Table 6.3: Socio-demographic Characteristics of Shisha Smoker 
Participants (n=170) 
Characteristics 
All (170) 
(%) 
Female (n=24) 
(%) 
Male (n=146) 
(%) 
P * 
Age groups 0.092 
18-25 years 131 (77) 15 (63) 116 (80)  
26-40 years 36 (21) 9 (38) 27 (2)  
41 - or over 3 (2) 0 3 (2)  
Total 170 24 (14) 146 (86)  
Education 0.005 
High school or less 123 (73) 12 (50) 111 (77)  
Undergraduate level 41 (24) 12 (50) 29 (20)  
Postgraduate level 5 (3) 0 5 (3.4)  
Total 169 24 (14) 145 (86)  
Location 0.226 
Riyadh 115 (68) 19 (79) 96 (66)  
Jeddah 10 (6) 1 (4.2) 9 (6)  
Dammam 7 (4) 2 (8.3) 5 (3)  
Other 38 (22) 2 (8.3) 36 (25)  
Total 170 24 (14) 146 (86)  
* Value was significantly different between males and females (P <0.05) based 
on chi square analysis  
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3) Known Drug User Population:  
 
Details of these participants are shown in Table 6.4. A total of 37 male 
participants were recruited. On the basis of the instructions given by the Al-amal 
hospital, female participants were excluded. Nearly half (49%) of participants 
were aged between 26-40 years. The majority of participants (92%) were 
educated to only high school. Seventy three percent of those participants lived 
in Riyadh as the study was conducted in a hospital in Riyadh. 
Table 6.4: Socio-demographic Characteristics of Known Drug User 
Participants (n=37) 
Characteristics Male (n=37) (%) 
Age groups 
18-25 years 14 (38) 
26-40 years 18 (49) 
41 - or over 5 (14) 
Total 37 
Education 
High school or less 34 (92) 
Undergraduate level 3 (8) 
Postgraduate level 0 
Total 37 
Location 
Riyadh 27 (73) 
Jeddah 4 (11) 
Dammam 2 (5) 
Other 4 (11) 
Total 37 
 
 
6.5.1.2 Behaviour Data 
Detailed in Table 6.5 are the behaviour characteristics of all 3 groups. Nearly 
half of those participants of medical professional (53%) and known drug user 
(57%) think their life is very stressful, while only (34%) of those participants of 
shisha smokers have this feeling. About 40% of medical professional participants 
were looking for an herb when they are feeling upset, whereas 17% of them are 
looking for a medication. The same trend can be observed in the other two 
populations. These findings were expected and compatible with a number of 
studies that reported a significant percentage of Saudi people using herbs for 
different reasons [365, 366]. Overall 86%, 76% and 62% of participants of medical 
professionals, shisha smokers and known drug users, respectively, reported they 
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liked to access the internet for general use. These results were also expected. A 
study [367] conducted during 2009 in several areas of Saudi Arabia showed that 
84% of Saudi people were found to be internet users. 
Table 6.5: Behaviour Characteristics of All 3 Groups (n=387) 
Characteristics * 
Medical 
professionals 
All (N=180) 
(%) 
Shisha 
smokers 
All(N=170) 
(%) 
Known 
drug users 
All (N=37) 
(%) 
I feel my life is very stressful 95 (53) 56 (34) 21 (57) 
Total 179 167 37 
When I feel upset or down, I am 
likely looking for medication 
30 (17) 60 (36) 12 (33) 
Total 178 166 36 
When I feel upset or down, I am 
likely looking for a herb 
71 (40) 71 (42) 16 (44) 
Total 179 169 36 
I like to try new herb products 23 (13) 31 (19) 15 (42) 
Total 178 168 36 
When I feel upset, I usually ask my 
friends to give me something could 
be help 
36 (20) 46 (28) 18 (50) 
Total 178 163 36 
I usually buy the herb products that 
I have seen advertised 
30 (17) 31 (18) 6 (17) 
Total 178 169 36 
I usually buy the herb products that 
my friends recommended to me 
49 (28) 46 (27) 10 (27) 
Total 178 169 37 
I like to access the internet 153 (86) 128 (76) 23 (62) 
Total 178 169 37 
* The analysis based on AGREE answer 
   
6.5.2 The Knowledge and Sources of Information of Legal Highs 
and Spice in Saudi Arabia  
With regards to a Saudi’s general awareness of legal highs, 19%, 19% and 22% of 
those participants of medical professionals, shisha smokers and known drug 
users, respectively, were aware of the existence of new psychoactive substances 
or legal high drugs. The awareness of Spice products is slightly less than that of 
legal highs, with 16%, 11% and 22% of those surveyed of medical professionals, 
shisha smokers and known drug users, respectively. Figures 6.3 and 6.4 show the 
results of the knowledge of legal highs and Spice respectively among all three 
groups. There were no significant differences between women and men 
184 
 
participants in their knowledge of Spice in medical professional and shisha 
smoker participants (Chi-square= 0.94, p = 0.333) and (Chi-square= 1.3, p = 
0.263), respectively.  
 
Figure 6.3: The Knowledge of Legal highs (Q7) among All 3 Groups 
 
 
Figure 6.4: The Knowledge of Spice (Q8) among All 3 Groups 
 
Internet, social media and TV, lectures, friends, literatures and at work were 
the reported means by which respondents became aware of these products. The 
results are shown in Figure 6.5. 
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Legal highs                                                                          Spice 
 
 
Figure 6.5: Sources of Information Regarding Legal highs (Q 7) and Spice (Q 8) in All 3 Groups  
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6.5.3 The Socio-demographic and Behaviour Characteristics of 
those having Knowledge of Legal Highs and Spice in Saudi 
Arabia  
Table 6.6 summarises the main findings for the socio-demographic and behaviour 
characteristics that were found among participants having knowledge of legal 
highs and Spice in all populations. Among the respondents that reported having 
knowledge of legal highs and Spice, 82% and 83%, respectively, were men. It is 
not clear which factors might play a role in this result. About 50% and 42% of 
participants reported having knowledge of legal highs and Spice, respectively, 
were between 18 and 25 years. 79% and 85% self-reported having knowledge of 
legal highs and Spice, respectively, like to access the internet.   
Table 6.6: Socio-demographic and Behaviour Characteristics Associated with 
Knowledge of Legal highs and Spice in All Populations 
 
Characteristics * 
Legal highs 
All gender 
(n=70)(%) 
Spice 
All gender 
(n=52)(%) 
Socio-demographic characteristics 
Gender 
Female 12 (17) 9 (17) 
Male 58 (82) 43 (83) 
Age groups 
18-25 years 35 (50) 22 (42) 
26-40 years 27 (39) 24 (46) 
41 - or over 8 (11) 6 (12) 
Education 
High school or less 32 (46) 20 (39) 
Undergraduate level 25 (36) 22 (42) 
Postgraduate level 13 (19) 10 (19) 
Location 
Riyadh 32 (46) 24 (47) 
Jeddah 7 (10) 8 (15) 
Dammam 14 (20) 7 (14) 
Other 17 (24) 13 (25) 
Behaviour characteristics ** 
I feel my life is very stressful 21 (30) 22 (42) 
I like to access the internet 55 (79) 44 (85) 
When I feel upset or down, I am 
likely looking for a herb 
22 (31) 13 (25) 
I like to try new herb products 16 (23) 9 (17) 
I usually buy the herb products that 
my friends recommended to me 
20 (29) 15 (29) 
* The analysis is based on AGREE answers 
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6.5.4 The Use of Spice Products in Saudi Arabia  
In sensitive questions, it is usually difficult to obtain truthful answers which may 
lead to negative responses or even no response. In the present study, the “other 
people approach” was used to estimate the prevalence of Spice usage in Saudi 
Arabia. 3.0%, 2.4% and 8.1% of those participants of medical professionals, 
shisha smokers and known drug users, respectively, reported having friends that 
have smoked Spice or K2 products in their lifetime (Figure 6.6). 
It has been difficult to compare the results obtained from the present survey 
with other surveys (See 2.3.8) because each researcher or team has used 
different methods (e.g. definitions, terminologies) and age ranges. However, the 
present survey can be used to give indications, particularly in the case of lack of 
prevalence studies of SCs among Saudi people. 
In the present study, the overall percentage of usage of Spice products in Saudi 
Arabia was 4.5%, compared with the most recent findings from the SALSUS 
survey (4% of 15-year-olds having used one or more NPS and most commonly SC) 
in 2013; it seems there is no big difference in the prevalence of SC use between 
Scotland and Saudi Arabia.  
  
 
Figure 6.6: Percentage of Respondents who Reported Having Friends that 
Have Smoked “Spice” 
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6.5.5 Limitations of the Study 
Although great care was taken to ensure that the present study was as accurate 
as possible, several limitations might have impacted on the results of the study. 
Firstly, the sample size may not have been fully representative of the whole 
population. Various factors have affected the achieved sample size including 
time limitations, willingness of people to participate and the sensitivity of the 
topic. Furthermore, known drug user population contained only male 
participants that may also limit the present survey. The elimination of a direct 
use question prevented examining whether the prevalence of SC use among 
these groups partly depends on their socio-demographic variables. These 
limitations could limit the overall generalisability of the results; however, it is 
sufficient to be statistically viable.   
Many aspects should be considered in this situation. These types of surveys are 
usually conducted by national committees and research centres because they 
plan the national strategies and have the facilities and resources. As there are 
no national surveys studying these types of drugs among Saudi society, the 
present study remains very useful in taking a snapshot of these emerging drugs in 
the Saudi population.   
6.6 Conclusions  
The questionnaire prepared was easy to comprehend, complete and return. 
Participation was not time consuming, taking less than 5 minutes. Associations 
were analysed in Chi-square statistics to assess statistical significance. The study 
population consisted primarily of three different populations in Saudi Arabia 
including known drug users, medical professionals and in members of the public 
in and around smoking cafes. 
This study attempted to understand the significance of SC use among Saudi 
society. Overall, data obtained from the current study suggests that a significant 
percentage of the population under examination is not cognisant of the 
existence of legal highs and/or Spice products. It also suggests that usage of 
these products among Saudi individuals may be similar to the usage in Scotland. 
The findings of this study highlight the need to educate potential users of these 
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drugs and that the internet would provide an effective way of doing this. Whilst 
the numbers found are low it is important to realise that this is an ever-changing 
landscape and therefore it would be useful to carry out the same survey on a 
regular basis (e.g. annually) to see if there is a rising trend of use. Really this 
study gives baseline knowledge and further studies should build on this.  
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Chapter 7 - Conclusions  
The consumption of NPS, particularly SCs, is a matter of rising concern to 
society. SCs and their potential role in forensic cases have been investigated in 
this project. It would appear that the major motivations for SC use are the legal 
status of these drugs, their lack of detection in common drug-screening tests and 
their low price level as well as the widespread marketing. Their rapid 
proliferation on the world market and absence of certified reference materials 
might resulted in several analytical challenges. It was found that SCs are not 
ideal compounds for GC-MS analysis in biological samples. LC–MS/MS is the 
preferred instrument for the detection of SCs in biological samples because it 
provides better sensitivity.  
A simple, cost-effective and accurate LC-MS/MS method for the simultaneous 
quantification of 10 parent SCs in whole blood and 8 corresponding metabolites 
in urine has been developed and validated. LLE was an important part of both 
methods and provided clean extracts and high recoveries of SCs from both blood 
and urine samples. Moreover, LLE was time-saving and little solvent was 
required. In addition, using MTBE as solvent and 1 M sodium acetate buffer (pH 
5.0) improved the recoveries. Stability studies are a crucial issue in forensic 
toxicology where loss of analyte from samples could adversely affect the quality 
of test results. The stability of 5F-AKB-48 (N-4 OH pentyl) and 5F-PB-22 3-
carboxyindole in methanol/acetonitrile solutions were studied for up to 3 
months and were found to be relatively stable, with only the 5F-PB-22 
metabolite degrading at room temperature in methanol. Due to the stability 
issues of SCs in biological samples, it is recommended to keep samples frozen 
whenever possible and sample extracts should be analysed shortly after 
extraction. 
Selection of the appropriate specimen is an important step in forensic 
toxicology. In blood, parent compounds of SCs are found at extremely low 
concentrations therefore methods for analysis of SCs in blood must be very 
sensitive. Urine is the most commonly collected sample for monitoring recent 
exposure. SCs have an extensive metabolism, therefore the main target 
compounds in urine specimens are their hydroxyl- and carboxy-metabolites. 
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However, the analysis of drugs in urine is complex because it requires knowledge 
and understanding of the drug’s metabolism. 
Due to the recurring threat of SCs to public health and their rapidly increasing 
usage worldwide, the occurrence of SCs in Scotland and Saudi Arabia were 
evaluated. The prevalence of use of SCs is hard to ascertain because the drug-
using population is hidden. 
In Scotland, a study using blood and urine analysis was carried out among 3 
different subpopulations; A&E patients, prisoners and fatalities. The findings 
reflected the presence of the problem in A&E patients and prisons in Scotland, 
particularly among young people. It was noticeable in this research that 
regulation of SCs does not necessarily reduce DRD or drug related harm. Several 
cases exhibit poly-drug use that may suggest the use of SCs for their affordability 
and/or availability and not necessarily to bypass the common drug-screening 
tests. The deficiencies regarding information on the toxic and/or lethal 
concentrations of most SCs with/without the presence of poly-ingestion make 
the interpretation of the cause of death more complicated.   
Because the picture of use of SCs in Saudi Arabia is unclear, the most prevalent 
SCs from different generations have been selected. A study using self-report was 
conducted among 3 subpopulations in Saudi Arabia (medical professionals, 
members of the public in and around smoking cafes and known drug users). The 
study showed a small number of participants are cognisant of the existence of 
Spice products. A low number of the population under examination has reported 
they know a friend using Spice products. The results of the analysis found only 2 
of 463 samples to be positive for 5F-PB-22 3-carboxyindole.   
This project showed a wide range in urine concentrations of SCs (1 – 268 ng/mL) 
and can be explained by the timing of sample collection, storage, precision of 
the method, or variability in SC content of Spice products.  
Understanding the range and extent of use of SCs that are affecting the 
populations in Scotland and Saudi Arabia can provide valuable information to the 
forensic community. The study was carried out over a short period and showed 
that more recently produced SCs are used.  
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To address this new phenomenon, drug addiction services, education and police 
organisations should be proactive in raising awareness around SCs. They should 
also effectively respond to, engage and treat people using SCs. Suitable urine 
drug tests for SCs present in Spice need to become more widely available within 
Scotland and Saudi Arabia, although this will likely always require some kind of 
mass spectrometric technique as it would be difficult to develop a dip-stick 
urine assay which would remain current for any length of time.  
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Chapter 8 – Further Work 
Whilst the numbers found in the self-report study are low it is important to 
realise that this is an ever-changing landscape and therefore it is important to 
carry out the same survey on a regular basis (e.g. annually) to evaluate the 
scene with respect to trends of SC use. It would be an advantage to incorporate 
questions about use of SCs in national surveys in Saudi Arabia like those in 
Scotland. It would be very useful to introduce a common methodology that 
enables the data to be comparable between countries. 
The present prevalence studies of SCs among A&E patients in Scotland and WDT 
in Saudi Arabia were conducted at a single institution which limits the 
representativeness. To obtain more representative figures of the prevalence of 
SC use, future studies should include a larger sample size from all parts of the 
country and should be conducted in Scotland and Saudi Arabia. Accurate data 
regarding sex, age and other drug positives should be collected with each  
biological sample to generate a better understanding of the users of SC. It is also 
very useful to combine use of drug testing and questionnaires to obtain more 
accurate data. 
The current method tested only a small panel of SCs due to lack of reference 
standards which may have caused false negatives. SCs are constantly being 
modified and rapidly becoming widely available; therefore forensic laboratories 
should update their scope for detecting the most prevalent compounds at a 
specific time and/or use HRMS to look for unknowns. Stability of SCs, especially 
UR-144 and 5F-PB-22 in blood, requires further investigation using different 
methods of preservation under different storage conditions.  
Studying the relationship between drug effects and the blood concentrations of 
SCs may shed further light on the association between cannabinoids and DRD 
although this is clearly difficult with poly-drug use. Publishing of blood 
concentrations found and their clinical effects should be encouraged in order to 
aid interpretation of positive results in any setting.  
Awareness among health organisations should be raised regarding these drugs 
and their risk to individuals, especially young people. With more research and 
194 
 
better understanding of the problem and its extent, the response can be 
improved and be more effective.  
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Appendix 1: Bioanalytical Procedures for Determination of SCs and Metabolites in  
Blood, Serum or Plasma Samples 
SCs Matrix 
Sample 
Prep 
Detection 
Mode 
LOD (ng/mL) ; 
LOQ (ng/mL) 
Ref 
(25 SCs): JWH-018, JWH-073, JWH-081, JWH-203, JWH-210, JWH-250, 
JWH-251, JWH-007, JWH-015, JWH-019, JWH-030, JWH-302, JWH-398, 
CP47, 497, CP47, 497 C8-homolog, HU-210, AM-694, AM-1241, RCS-4, RCS-
4 2- and 3-methoxy homolog, RCS-8, RCS-4-C-4-homolog, WIN48 098, 
WIN55 212-2 mesylate 
Whole 
blood 
LLE 
LC-MS/MS-
ESI+/- 
LOQ = 0.5 and 5 [190] 
(29 SCs): JWH-018, JWH-019, JWH-020, JWH-073, JWH-122, JWH-147, 
JWH-200, JWH-210, JWH-250, JWH-251, JWH-398, JWH-007, JWH-203, 
JWH-015, JWH-073-methyl, JWH-081, JWH-098, AM-1220, AM-1241, AM-
2201, AM-2233, MAM-2201, AB-001, AM-694, RCS-4, RCS-4 ortho, RCS-8, 
UR-144, WIN55 212-2 
Whole 
blood 
LLE 
LC-MS/MS-
ESI+ 
Not specified [90] 
(2 SCs): JWH-018, JWH-073 
Whole 
blood 
LLE 
LC-MS/MS-
ESI+ 
0.01 ; 0.05 [154] 
(4 SCs): JWH-018, JWH-073, JWH-019, JWH-250 
Whole 
blood 
LLE 
LC-MS/MS-
ESI+ 
0.006 ; 0.016 [191] 
(20 SCs and 7 metabolites):  AM-2201, AM-2201-N-4-OH-pentyl, JWH-018, 
JWH-210, JWH-203, JWH-250, JWH-251, JWH-081, JWH-122, JWH-122-N-
5-OHpentyl, JWH-018-N-4- and 5-OH-pentyl, JWH-147, JWH-200,JWH-200-
4-OHindole, JWH-201, JWH-302, JWH-398, JWH-412, MAM-2201, RCS-4, 
RCS-4 ortho isomer, RCS-4-N-5- OH-pentyl, RCS-4- N-COOH, RCS-8, WIN48 
098, WIN55 212 
Whole 
blood 
 
PPT 
 
LC-MS/MS-
ESI+ 
Not specified 
[146] 
 
(18 SCs): 5F-PB-22, JWH-018, JWH-073, JWH-019, JWH-122, JWH-210, 
JWH-250, JWH-015, JWH-081, AM-2201, Cl-2201, MAM-2201, UR-144, XLR-
11, BB-22, PB-22, AB-PINACA, ADB-PINACA, 
Whole 
blood 
LLE LC-MS/MS Not specified [3] 
(13 SCs): JWH-018, JWH-073, JWH-081, JWH-019, JWH-122, JWH-200, 
JWH-210, JWH-250, JWH-175, AM-2201, AM-694, RCS-4, RCS-8 
Whole 
blood 
LLE 
LC-MS/MS-
ESI+ 
Not specified 
[253] 
 
(18 SCs): JWH-018, JWH-073, JWH-081, JWH-250, JWH-251, JWH-122, 
JWH-200, JWH-210, JWH-015, JWH-019, JWH-020, CP47, 497, HU-210, AM-
694, AM-2201, RCS-4, RCS-4-C4, RCS-8, WIN55,212-2 
Whole 
blood 
LLE 
LC-MS/MS-
ESI+ 
Not specified [167] 
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SCs Matrix 
Sample 
Prep 
Detection 
Mode 
LOD (ng/mL) ; 
LOQ (ng/mL) 
Ref 
UR-144 and pyrolysis product [1- (1-pentyl-1H-indol-3-yl)-3-methyl-2- 
(propan-2yl)but-3-en-1-one] 
Whole 
Blood 
LLE 
LC-MS/MS-
ESI+ 
0.15 ; 0.5 [200] 
(10 SCs): JWH-018, JWH-073, JWH-081, JWH-250, JWH-015, JWH-200, 
JWH-019, JWH-020, WIN55 212-2, methanandamide 
Serum LLE 
LC-MS/MS-
ESI 
0.1 ; 0.1 - 0.6 
[192] 
 
(15 SCs): JWH-018, JWH-073, JWH-081, JWH-019, JWH-122, JWH-200, 
JWH-210, JWH-250, JWH-251, JWH-203, JWH-307, JWH-015, AM-1220, AM-
2201, AM-694 
Serum LLE 
LC-MS/MS-
ESI+/- 
0.02 - 0.4 ; 0.05 
- 0.5 
[193] 
JWH-018 Serum LLE 
LC-MS/MS-
ESI+ 
0.07 ; 0.21 [149] 
(30 SCs): JWH-018, JWH-018 adamantyl derivative, JWH-073, JWH-081, 
JWH-122, JWH-122 5-fluoropentyl derivative, JWH-200, JWH-210, JWH-
250, JWH-251, JWH-015, JWH-019, JWH-020, JWH-203, JWH-307, JWH-
387, JWH-398, JWH-007, AM-694, AM-1220, AM-2201, AM-2233, MAM-2201, 
methanandamide, CRA-13, RCS-4, RCS-4 ortho isomer, RCS-8, WIN 48 098, 
WIN 55 212-2 
Serum LLE 
LC-MS/MS-
ESI+ 
0.01 - 2.0 ; 0.1 - 
2.0 
[152] 
 
(46 SCs): JWH-018, JWH-073, JWH-081, JWH-122, JWH-182, JWH-200, 
JWH-007, JWH-015, JWH-019, JWH-210, JWH-250, JWH-251, JWH-020, 
JWH-022, JWH-203, JWH-307, JWH-370, JWH-387, JWH-398, JWH-412, 
AM-694, AM-1220, AM-1220 azepane isomer, AM-2201, APICA, AM-1248, 
AM-2232, AM-2233, MAM-2201, Methanandamide, AB-001, 
Cannabipiperidie- thanone, CRA-13, RCS-4, RCS-4-C4, RCS-4 ortho isomer, 
RCS-8, STS-135, UR- 144, UR-144 isomer, XLR-11, XLR-11 isomer, WIN48 
098, WIN55 212-2, AKB48, 5F-AKB-48 
Serum LLE 
LC-TOF/MS-
ESI+ 
LOD = 0.1 - 0.5 
[194] 
 
(5 SCs): JWH-122, PB-22, AM-2233, BB-22, 5-F PB-22 Plasma LLE LC-HR-MS Not specified [195] 
(20 SCs): JWH-018, JWH-073, JWH-081, JWH-122, JWH-200, JWH-007, 
JWH-015, JWH-016, JWH-018-6-MeO, JWH-098, JWH-210, JWH-250, JWH-
022, JWH-203, AM-694, AM-2201, AM-1241, RCS-4, RCS-8, WIN 48 098 
Blood, 
serum 
SPE 
LC-TOF/MS-
ESI+ 
Not specified [210] 
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Appendix 2: Bioanalytical Procedures for Determination of SCs and Metabolites in 
Urine Samples 
SCs 
Sample 
Prep 
Detection Mode 
LOD (ng/mL) ; 
LOQ (ng/mL) 
Ref 
(5 metabolites of JWH-018): JWH-018 N-5-OH-pentyl, 5-OHindole, N-COOH, N-
dealkylated-5-OH-indole and 2-OH-naphthoyl 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ 
0.1 ; 0.5 Only 
JWH-018-N-OH-
pentyl & COOH 
[129] 
Metabolites of JWH-018 and AM-2201 
Hydrolysis, 
LLE 
LC-HR/MS Not specified [82] 
(3 metabolites of JWH-018): N-5-OH-pentyl, N-COOH, 6-OH-indole 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ 0.01 - 0.1 ; 1 [130] 
(10 metabolites of 7 SCs): JWH-018 N-5-OH-pentyl, -COOH, JWH-073 N-4-OH-
butyl, -COOH, JWH-250 5-OH-indole, N-COOH, JWH-122 N-5-OH-pentyl, JWH-200 
5-OH-indole, JWH-019 5-OH-indole, RCS-4 N-5- OH-pentyl 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ LOQ = 0.1 [151] 
JWH-018 and its metabolites 
Hydrolysis, 
LLE 
LC-MS/MS 
heated- 
ESI 
Not specified [79] 
(JWH-018 and 7 metabolites): JWH-018 N-5-OH-pentyl, N-COOH, 2-, 4-,5-,6- and 
-7-OH-indole 
(JWH-073 and 6 metabolites): JWH-073 N-4-OHbutyl, N-COOH, 4-, 5-, 6- and -7-
OH-indole 
LLE/SPE LC-MS/MS-ESI+ LOD = 1 [166] 
Metabolites of UR-144 Hydrolysis 
GC-MS, LC-
MS/MS 
Not specified [236] 
CP47, 497 Dilution LC-MS/MS-ESI- 10 ; 20 [187] 
(JWH-018 and 6 metabolites): JWH-018 N-5-OH-pentyl, –COOH and 4-, 5-, 6-, 7-
OH-indole (JWH-073 and 6 metabolites): JWH-073 N-4-OH-butyl, -COOH and 4-
,5-,6-,7-OH-indole 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ < 2 ; 1.8- 10.8 [131] 
(3 metabolites of JWH-018): JWH-018 N-4- and 5-OH-pentyl and COOH 
(3 metabolites of JWH-073): JWH-073 N-3- and 4-OH-butyl and COOH. 
Hydrolysis, 
SPE 
LC-MS/MS-ESI+ 0.1 ; 0.1 [262] 
JWH-018 and 19 metabolites (mainly hydroxylated and N-
dealkylatedmetabolites) 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ LOD = 0.1 [120] 
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SCs 
Sample 
Prep 
Detection Mode 
LOD (ng/mL) ; 
LOQ (ng/mL) 
Ref 
AB-001 and 7 metabolites LLE GC-MS Not specified [196] 
(4 metabolites of JWH-018): JWH-018 N-COOH,  6-OH-indole,  N-4- and 5 OH-
pentyl 
(4 metabolites of JWH-073):  JWH-073 N-COOH, 6-OH-indole,  N-3- and 4-OH-
butyl 
Dilution, 
Hydrolysis, 
SPE 
ELISA, LC-
MS/MS-ESI+ 
0.025 – 0.1 ; 2.5 [211] 
(UR-144 and 5 metabolites): despentyl-OH-UR-144, di- OH-UR-144, despentyl-
UR-144, dehydrated OH-UR-144, OH-UR-144 
(AM2201 and 7 metabolites): JWH-018 N-(5-OH-pentyl), N-(5-OH-pentyl) 
dihydrodiol-JWH-018, di-OH-AM-2201, dihydrodiol-AM-2201, OH-AM-
2201,despentyl-AM-2201, JWH-018 N-COOH 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ Not specified [127] 
RCS-4 and its metabolites 
Hydrolysis, 
LLE, 
GC-MS Not specified [197] 
(8 metabolites of 5 SCs): JWH-018 N-4- and 5-OH-pentyl, JWH-073 N-3- and 4-
OH-butyl, JWH-250 N-4-OHpentyl, JWH-019 N-5- and 6-OH-hexyl, AM-2201 N-4-
OH-pentyl 
Hydrolysis, 
LLE 
ELISA, LC-
MS/MS-ESI+ 
Not specified [198] 
5F-AKB-48 and its metabolites 
Hydrolysis, 
LLE 
LC-HR-MS Not specified [58] 
(37 metabolites of 17 SCs): JWH-018 N-COOH, -6-OH-indole, N-4- and 5 OH-
pentyl, JWH-073 N-COOH, 6-OH-indole,  N-3- and 4-OH-butyl, JWH-250 N-COOH,  
N-4- and 5 OH-pentyl,  JWH-122 N-4- and 5 OH-pentyl, JWH-019 N-6 OH-pentyl, 
JWH-210 N-4- and 5 OH-pentyl, JWH-081 N-5 OH-pentyl , JWH-398 N-4- and 5 OH-
pentyl, JWH-203 N-COOH,  N-4- and 5 OH-pentyl, AM-2201-6-OH-indole, N-4 OH-
pentyl, MAM-2201 N-COOH, N-4 OH-pentyl, UR-144 N-COOH,  N-4- and 5 OH-
pentyl, XLR-11 N-4 OH-pentyl, AB-PINACA N-COOH, N-4 OH-pentyl, 5F-AB-PINACA 
N-4 OH-pentyl, AKB48 N-COOH,  N-4- and 5 OH-pentyl, 5F-AKB48 N-4 OH-pentyl 
Hydrolysis, 
SPE 
LC-MS/MS-ESI+ LOD = 0.1 - 1 [256] 
Major metabolites of JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, 
JWH-250, RCS-4 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+, 
LC-TOF/MS-ESI+ 
Not specified [114] 
(UR-144 and 7 metabolites): UR-144 N-COOH, di-OH-UR-144, UR-144 N-5-OH-
pentyl- β-Gluc, despentyl-UR-144, despentyl-OH-UR-144, dehydrated-OH-UR-144, 
OH-UR-144 
Hydrolysis, 
LLE 
LC-TOF-MS-ESI+ 0.15 ; 0.5 [200] 
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SCs 
Sample 
Prep 
Detection Mode 
LOD (ng/mL) ; 
LOQ (ng/mL) 
Ref 
(4 metabolites of JWH-018): JWH-018 N-4- and 5- OH-pentyl, N-COOH, methyl 
ester 
(2 metabolites of JWH-073): JWH-073 N-3-OH-butyl, N-COOH 
JWH-072 N-COOH 
Hydrolysis 
 
LC-MS/MS-ESI+ LOQ = 4 [257] 
(47 metabolites of 21 SCs): JWH-018 N-OH-pentyl, N-COOH, 5- and 6-OH-indole, 
JWH-073 N-OH-butyl, 5- and 6-OH-indole, NCOOH, JWH-122 N-OHpentyl, N-
COOH, JWH-250 5-OH-indole, N-OH-pentyl, N-COOH, JWH-210 N-COOH, N-OH-
pentyl, JWH-200 5- and 6-OH-indole, JWH-398 N-OH-pentyl, N-COOH, JWH-019 5-
OH-indole, -OH-hexyl, JWH-081 N OH-pentyl, AM-2201 6-OH-indole, N-OH-pentyl, 
MAM-2201 N-OH-pentyl, RCS-4 N-OH-pentyl, N-COOH,  M9, UR-144 N-OH-pentyl, 
N-COOH, degradant-COOH, XLR-11 N-OH-pentyl, 6-OH-indole, ADB-PINACA N-OH-
pentyl, AKB48 N-OH-pentyl, N-COOH, 5F-AKB48 N-OH-pentyl, 5F-AB-PINACA N-
OH-pentyl, AB-PINACA N-OH-pentyl, -COOH, PB-22 N-OH-pentyl, N-COOH, N-OH-
pentyl-3-COOH-indole, N-COOH-3-COOHindole, 3-COOH-indole, 5F-PB-22 3-COOH 
indole 
Dilution, 
Hydrolysis, 
SLE+ 
LC-TOF/MS-ESI+ LOD = 0.25 - 20 [245] 
(35 SCs and 19 metabolites): JWH-018, JWH-018 N-4- and 5-OH-pentyl, N-COOH, 
-4-, 5-, 6- and 7-OH-indole, 6-methoxy-indole, -1-methyl-hexyl, JWH-073, JWH-
073 N-3- and 4-OH-butyl, -4-, 5-, 6-, and 7-OH-indole, N-COOH, 2- and 3-methyl 
homology, JWH-122, JWH-122 N-5-OH-pentyl, JWH-200, JWH-200 4-OH-indole, 
JWH-250, JWH-251, JWH-081, JWH-147, JWH-007, JWH-015, JWH-019, JWH-201, 
JWH-210, JWH-203, JWH-302, JWH-398, JWH-412, CP47, 497,CP47, 497-C8, 
CP55,940, HU-210, AM-694, AM-1220, AM-1220 azepane isomer, AM-2201, MAM-
2201, RCS-4, RCS-4 ortho isomer,  N-5-OH-pentyl,  N-COOH, RCS-8, AB-0101, 
WIN48 098, WIN55 212 
Hydrolysis, 
SPE 
LC-TOF-MS-ESI+ Not specified [212] 
22 SC and 37 metabolites 
No sample 
preparation 
Biochip array 
technology 
immunoassay 
Not specified [285] 
JWH-018 N-COOH (calibrator) 
No sample 
preparation 
ELISA Not specified [220] 
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SCs 
Sample 
Prep 
Detection Mode 
LOD (ng/mL) ; 
LOQ (ng/mL) 
Ref 
(9 SC and 20 metabolites):  JWH-018, JWH-018 N-5-OH-pentyl, 5- and 6-OH-
indole, N-COOH, JWH-073, JWH-073 N-4-OH-butyl, N-COOH, 5- and 6-OH-indole, 
JWH-250 N-4- and 5-OH-pentyl, 5-OH-indole, JWH-200 5- and 6-OH-indole, JWH-
081, JWH-081 N-5-OH-pentyl, JWH-210, JWH-210 N-4- and 5-OH-pentyl, N-COOH, 
JWH-122, JWH-122 N-5-OH-pentyl, AM-2201, AM-2201 6-OH-indole, N-4-OH-
pentyl, MAM2201, RCS-4, RCS-4 N-5-OH-pentyl, N-COOH 
PPT, 
Hydrolysis 
LC-MS/MS-ESI+ LOD = 0.5 - 10 [259] 
(5 SC and 6 metabolites): JWH-018, JWH-018 N-4- and 5-OHpentyl, 4- and 5-OH-
indole, JWH-073, JWH-073 N-3- and 4-OH-butyl, JWH-250, HU-210, AM-2201 
Hydrolysis, 
SPE 
LC-MS/MS-ESI+ 
0.01 - 0.5 ; 0.05 
- 5 
[213] 
(20 SC and 33 metabolites): JWH-018, JWH-018 N-OH-pentyl, N-COOH, 5- and 6-
OH-indole, JWH-073, JWH-073 N- OH-butyl, N-COOH, 5- and 6-OH-indole, JWH-
019, JWH-019 5-OH-indole, -N-OH-hexyl, JWH-250 N-OH-pentyl, N-COOH, -5-OH-
indole, JWH-081, JWH-081 N-OH-pentyl, JWH-210, JWH-210 N-OH-pentyl, N-
COOH, 5-OH-indole, JWH-200 5- and 6-OH-indole, JWH-122, JWH-122 N-OH-
pentyl, JWH-398, JWH-398 N-OH-pentyl, N-COOH, JWH-203, CP47, 497-C7, CP47, 
497-C7-OH, CP47, 497-C8, CP47, 497-C8-OH dimethyloctyl, HU-210, AM-694, AM-
2201, AM-2201 6-OH-indole, N-OH-pentyl, MAM-2201, MAM-2201 N-OH-pentyl, N-
COOH, UR-144 N-OH-pentyl, N-COOH, RCS-4, RCS-4 N-OH-pentyl, M9, M10, N-
COOH 
Dilution, 
Hydrolysis, 
SLE 
LC-MS/MS-
ESI+/- 
0.05 - 1 ; 0.1 - 1 [260] 
(38 metabolites of 12 SCs): JWH-018 N-4- and 5-OH-pentyl, N-COOH, 5-, 6- and 
7-OH-indole, JWH-073 N-3- and 4-OH-butyl, N-COOH, 5-, 6- and 7-OH-indole, 
JWH-250 N-4- and 5-OH-pentyl, N-COOH, JWH-019 N-5- and 6-OH-hexyl, JWH-210 
N-4- and 5-OH-pentyl, N-COOH, JWH-122 N-4-OH-pentyl, N-5-OH-pentyl, JWH-081 
N-5-OH-pentyl, N-COOH, JWH-398 N-4- and 5-OH-pentyl, N-COOH, AM-2201 N-4-
OHpentyl, 6- and 7-OH-indole, MAM-2201 N-4-OHpentyl, N-COOH, UR-144 4- and 
5-OH-pentyl, N-COOH, RCS-4 4- and 5-OH-pentyl, N-COOH 
SALLE 
HEIA, 
LC-TOF/MS-ESI+ 
Not specified [222] 
(8 metabolites of 3 SCs): JWH-018 N-4 and 5-OH-pentyl, N-COOH, N-5-OH-pentyl  
β-Gluc, 6-OH-indole, JWH-073 N-COOH, AM-2201 N-4-OH-pentyl, 6-OH-indole 
Hydrolysis, 
SPE 
LC-MS/MS-ESI+ 0.1 ; 2.5 [83] 
(2 metabolites of JWH-018): JWH-018 N-4-OH-pentyl, N-COOH, 
(2 metabolites of JWH-073): JWH-073 N-3-OH-butyl, N-COOH 
Hydrolysis, 
LLE 
LC-MS/MS-ESI+ LOQ = 4 [199] 
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Appendix 3: Bioanalytical Procedures for Determination of SCs and Metabolites in 
Oral Fluid Samples 
SCs 
Sample 
Prep 
Detection 
Mode 
LOD (ng/mL); 
LOQ (ng/mL) 
Ref 
(10 SCs): JWH-018, JWH-073, JWH-250, JWH-122, JWH-019, JWH-200, HU-210, 
CP47,497, nabilone, AM-694 
Dilution 
LC-MS/MS-
ESI+ 
LOD = 1 - 20 [267] 
(10 SCs): JWH-018, JWH-073, JWH-250, JWH-200, JWH-081, HU-210, CP47,497, 
CP47,497 (C8), AM-2201, RCS-4 
Dilution 
ELISA, LC-
MS/MS-ESI+ 
0.1 ; 0.25 [218] 
(28 SCs): JWH-018, JWH-073, JWH-250, JWH-200, JWH-122, JWH-019, JWH-210, 
JWH-007, JWH-015, JWH-387, JWH-398, JWH-251, JWH-307, JWH-081, JWH-203, 
JWH-020, JWH-412,  AM-694, AM-1220, AM-2233, AM-2201, MAM-2201, 
methanandamide, RCS-4, RCS-8, RCS-4 ortho isomer, WIN48, 098, WIN55 212-2 
PPT 
LC-MS/MS-
ESI+ 
0.015 - 0.9 ; 
0.15 - 3 
[189] 
(30 SCs): JWH-018, JWH-018 adamantyl derivative,  JWH-073, JWH-250, JWH-081, 
JWH-122, JWH-007, JWH-015, JWH-387, JWH-398, JWH-251, JWH-307, JWH-210, 
JWH-200, JWH-203, JWH-019, JWH-020, AM-2201, AM-2233, AM-694, AM-1220, CRA-
13, AB-001, MAM-2201, methanandamide, RCS-8, RCS-4, RCS-4 ortho isomer, WIN48 
098, WIN55 212-2 
LLE 
LC-MS/MS-
ESI+ 
 
0.015 - 0.9 ; 
0.15 - 30 
[201] 
(18 SCs): JWH-018, JWH-073, JWH-250, JWH-122, JWH-019, JWH-200, JWH-015, 
JWH-020, JWH-210, JWH-081, JWH-251, HU-210, AM-2201, AM-694, RCS- 4, RCS-4-C4, 
RCS-8, WIN55 212-2 
LLE 
LC-MS/MS-
ESI+ 
LOD = 0.05 - 1.2 [202] 
(UR-144 and 2 metabolites): UR-144 4-OH-pentyl, pyrolysis product of UR-144 
(XLR-11 and 2 metabolites): XLR-11 4-OHpentyl and pyrolysis product of XLR-11 
SPE 
LC-MS/MS-
ESI+ 
0.35 - 1.93 ; 5 [126] 
(6 SCs): JWH-018, JWH-073, JWH-250, HU-210, CP47,497, CP47,497 (C8) SPE 
LC-MS/MS-
ESI+/- 
LOQ = 0.5 [214] 
(7 SCs): JWH-018, JWH-073, JWH-250, JWH-200, HU-211, CP47,497, CP47,497 (C8) SPE 
LC-MS/MS-
ESI+/- 
0.025 - 1.0 ; 0.1 
- 2.5 
[215] 
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Appendix 4: Bioanalytical Procedures for Determination of SCs and Metabolites in 
Hair Samples  
SCs 
Sample 
Prep 
Detection 
Mode 
LOD (pg/mg); 
LOQ (pg/mg) 
Ref 
(18 SCs): JWH-018, JWH-073, JWH-018-N-NCOOH, JWH-250, JWH-200, JWH-122, 
JWH-210, JWH-081, JWH-015, JWH-020, JWH-019, JWH-203, JWH-007, HU-210, 
CP47,497, AM-2201, AM-694,WIN55 212-2 
Washing, 
Digestion 
LC-MS/MS-
ESI+ 
LOQ = 500 [268] 
(JWH-018 and 3 metabolites): JWH-018 N-4- and 5-OH-pentyl, N-NCOOH 
(JWH-073 and 3 metabolites): JWH-073 N-3- and -4-OHbutyl, N-COOH 
Washing, 
LLE 
LC-MS/MS-
ESI+ 
LOD = 0.05 [203] 
(5 SC and 11 metabolites):  JWH-018, JWH-073, JWH-122, AM2201, MAM2201, JWH-
018 N-4- and 5-OH-pentyl, N-NCOOH, JWH-073 N-3- and -4-OHbutyl, N-COOH, JWH-
122 N-5-OH-pentyl, N-COOH, AM-2201 N-4-OH-pentyl, 6-OH-indole, MAM-2201 N-4-
OHpentyl 
Washing, 
LLE 
LC-MS/MS-
ESI+ 
0.05 ; 0.1 [204] 
(23 SCs): JWH-018, JWH-073, JWH-250, JWH-122, JWH-019, JWH-200, JWH-015, 
JWH-020, JWH-210, JWH-081, JWH-251, JWH-307, JWH-007, JWH-398, JWH-203, HU-
210, AM-694, AM-2201, AM-1220, RCS- 4, RCS-8, WIN55 212-2, WIN48 098 
Washing, 
Digestion, 
LLE 
LC-MS/MS-
ESI+ 
0.2 – 1.3 ; 0.7 – 
4.3 except (HU-
210 = 80 LOQ) 
[205] 
(8 SCs): JWH-018, JWH-073, JWH-250, JWH-200, JWH-122, JWH-210, JWH-081, AM-
694 
Base 
hydrolysis, 
LLE 
LC-TOF-MS-
ESI+ 
LOD = 10 [206] 
(5 SCs): JWH-018, JWH-073, JWH-250, JWH-200, HU-210 
Washing, 
digestion, 
LLE 
LC-MS/MS-
ESI+ 
0.02 – 0.18 ; 
0.07 - 18 
[207] 
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Appendix 5: Ethical Approval for Post-mortem 
Samples 
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Appendix 6: Ethical Approval (from University of 
Glasgow) to Collect Urine Samples and 
Questionnaires from Saudi People  
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Appendix 7: Ethical Approval (from SFH) to Collect 
Urine Samples from Saudi People  
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Appendix 8: Participant Information Sheet for Urine 
Samples Study in Saudi Arabia 
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Appendix 9: Consent Form for Survey and Urine 
Samples Studies in Saudi Arabia 
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Appendix 10: Ethical Approval to Collect 
Questionnaires from Saudi Known Drug Users 
 
 
 
  
 
 
237 
 
Appendix 11: Participant Information Sheet for 
Survey Study 
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Appendix 12: Questionnaire Form 
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Validation of a Liquid Chromatography—Tandem Mass Spectrometry 
method for the Detection and Quantitation of 9 Synthetic Cannabinoid 
Metabolites in Urine 
 
Abdulaziz A. Aldlgan and Hazel J. Torrance 
Forensic Medicine and Science, University of Glasgow, Glasgow, UK 
 
Abstract 
 
      Synthetic cannabinoids (SCs) are one of the new groups of drugs, “Legal highs”, 
which are substances created and used to avoid the law and mimic the effect of traditional 
drugs. Recently the use of SCs has increased at an unprecedented pace around the world. 
Several methods have been published recently for the analysis of SCs in different 
biological matrices. However, comprehensive methods for urine analysis covering the most 
recent substances 5-F-AKB48 (N-4 OH pentyl) and 5-F-PB-22 3-carboxyindole are 
lacking. SCs have an extensive metabolism, therefore the unchanged compounds usually 
are not found in urine after consumption. A simple, cost-effective and accurate liquid 
chromatography tandem mass spectrometric (LC-MS/MS) method for the simultaneous 
quantification of JWH-018 5-OH pentyl, JWH-018 4-OH pentyl, JWH-073 3-OH butyl, 
AM-2201 4-OH pentyl, JWH-250 4-OH pentyl, JWH-122 5-OH pentyl, JWH-210 5-OH 
pentyl, 5-F-AKB48(N-4 OH pentyl) and 5-F-PB-22 3-carboxyindole in urine has been 
developed and validated. Drug-free urine samples spiked with various SC metabolites were 
buffered, hydrolyzed, and extracted with a liquid-liquid extraction technique and separated 
on a Phenomenex Gemini C18 (150 x 2.0 mm, 5µm) column. Gradient elution was 
employed using a mobile phase consisting of A: 2M ammonium acetate and formic acid 
0.1% in deionised water and B: 2M ammonium acetate and formic acid 0.1% in methanol. 
All SCs were detected and quantified within 11.5 min without endogenous interferences. 
The correlation coefficient (R
2
) was > 0.996 for all SCs with precision < 14 and accuracy 
ranging from 87 to 110% for all analytes at concentrations of 5, 40 and 75 ng/mL. The 
limit of detection ranged between 0.01 and 0.25 ng/mL and, the lower limit of 
quantification for each compound was determined to be 1.0 ng/mL. The recovery ranged 
from 77 to 108 % and the matrix effect was acceptable and ranged from 81 to 108 % for all 
analytes at concentrations of 5, 50 and 100 ng/mL. 
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Application of a Validated LC-MS/MS Method for the Simultaneous 
Analysis of 9 Synthetic Cannabinoid Metabolites to Hospital 
Admission Urine Samples  
 
1Abdulaziz A. Aldlgan, 2Richard Stevenson, 2David Lowe and 1Hazel J. Torrance 
1 Forensic Medicine and Science, University of Glasgow, Glasgow, UK 
2 Glasgow Royal Infirmary, Glasgow, UK 
 
Introduction 
Recently the use of cannabimimetics (more commonly known as synthetic 
cannabinoids) has increased at an unprecedented rate around the world. As a 
result the importance for the analysis of synthetic cannabinoids in human 
matrices is evident and continues to be increasingly challenging since these 
compounds are constantly being modified and are rapidly becoming available. 
They have extensive metabolism pathways; therefore the main target 
compounds in urine specimens are their hydroxyl and carboxy metabolites, 
which is important to recognise when establishing clinical and forensic 
toxicology screening and confirmatory methods. 
Aims 
The aim of the study was to apply a validated liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method for the detection and quantitation of 
JWH-018 5-OH pentyl, JWH-018 4-OH pentyl, JWH-073 3-OH butyl, AM-2201 4-OH 
pentyl, JWH-250 4-OH pentyl, JWH-122 5-OH pentyl and JWH-210 5-OH pentyl, 
and the most recent substances 5-F-AKB48 (N-4 OH pentyl) and 5-F-PB-22 3-
carboxyindole in urine samples from individuals admitted to Accident and 
Emergency, Glasgow Royal Infirmary, UK. 
Methods 
The urine samples were buffered with 1M sodium acetate (pH 5.5) before being 
hydrolysed with β-glucuronidase. Liquid-liquid extraction (methyl-tert-butyl-
ether) was used to isolate and concentrate 9 synthetic cannabinoid metabolites 
from urine. Chromatographic separation (run-time 11.5 mins) was achieved using 
a Phenomenex Gemini C18 (150 x 2.0 mm, 5µm) column and a gradient elution 
system consisting of two mobile phases; 2mM ammonium acetate and 0.1% 
formic acid in de-ionised water and in methanol. Agilent LC-MS/MS equipped 
with an electrospray ionisation interface, operated in positive polarity, was used 
for analysis. Multiple Reaction Monitoring (MRM) mode was used to monitor 2 ion 
transitions (quantifier and qualifier) for each analyte and 1 transition was used 
for the internal standard.  
Results 
All synthetic cannabinoids were detected and quantified without endogenous 
interferences. The correlation coefficient (R2) was ≥ 0.996 for all analytes, with 
precision < 14% and accuracy ranging from 87 to 110% for all analytes at 
concentrations of 5, 40 and 75 ng/mL. The limit of detection ranged between 
0.01 and 0.25 ng/mL and, the lower limit of quantification for each compound 
was determined to be 1.0 ng/mL. The recovery ranged from 77 to 108 % and the 
matrix effects were acceptable, ranging from 81 to 108 % for all analytes at 
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concentrations of 5, 50 and 100 ng/mL. The presented method was successfully 
applied to 93 authentic urine admission samples collected at Glasgow Royal 
Infirmary, UK. Four (4.3%) samples were found positive for 5-F-PB-22 3-
carboxyindole with concentrations of 6.6, 23.7, 60.3 and 267.7 ng/mL. 
Conclusions 
A simple, cost-effective and accurate LC-MS/MS method for the simultaneous 
quantification of 9 synthetic cannabinoid metabolites in urine has been 
developed and validated. The method has been successfully verified using 93 
authentic hospital case samples.  
 
Synthetic Cannabinoids, Urine, LC/MS-MS 
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